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ABSTRACT 
Humans carry two near identical copies of Survival Motor Neuron gene: SMN1 
and SMN2. Deletion or a mutation(s) of SMN1 coupled with the predominant skipping of 
SMN2 exon 7 causes SMA, the most frequent genetic cause of infant mortality. 
Correction of SMN2 exon 7 splicing holds the promise for cure. Hence it is crucial to 
understand the regulation of SMN2 splicing and function of SMN isoforms. We employ a 
multiple-exon-skipping detection assay (MESDA) to capture the relative abundance of all 
major transcripts in one reaction. Our results show surprising diversity of splice isoforms 
and reveal novel splicing events that include skipping of exon 4, co-skipping of three 
adjacent exons of SMN and exonization of a portion of intron 6. In cell-based studies, our 
results reveal oxidative stress (OS) induced skipping of SMN1 exon 5 in several cell 
types, including non-neuronal cells. In in vivo study, we observed that unique tissue-
specific signature of SMN2 splice isoforms generated under OS. We also show profound 
differences between male and female reproductive organs with respect to the SMN2 
splice isoforms produced under normal and OS conditions. Employing a super minigene 
harboring SMN2 promoter, all internal exons and flanking intronic sequences, we 
demonstrate transcription-coupled splicing regulation of various SMN2 exons under 
normal and OS conditions. Our results of proteome analysis of mouse brain revealed OS-
induced downregulation of hnRNP H, a multifunctional proteins, involved in pre-mRNA 
splicing and 3ʹ′-end processing. We confirm hnRNP H as a positive regulator of SMN 
levels and likely serves as a disease-modifying factor for SMA. Taken together, a number 
of important observations expand the diversity of splice isoforms generated by SMN and 
bring new insight into our understanding of splicing regulation of SMN. 
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CHAPTER 1. GENERAL INTRODUCTION 
Human has two copies of survival motor neuron gene: SMN1 and SMN2 (Figure 
1) (Lefebvre et al., 1995). Loss of Smn in mouse is embryonic lethal (Schrank et al., 
1997). Homozygous loss and mutation of the SMN1 causes Spinal Muscular Atrophy 
(SMA). Two nearly identical (>99%) copies of SMN genes (the telomeric SMN1 and 
centromeric SMN2) are ubiquitously expressed in all tissues (Lefebvre et al., 1995) and 
are abundant in motor neurons (Battaglia et al., 1997; La Bella et al., 1998; Tizzano et al., 
1998; Williams et al., 1999). SMN genes are located within an inverted duplication of 500 
kb on chromosome 5q13 (Lefebvre et al., 1995). These genes are 35 kb including 9 exons 
encoding a 294-amino acid localized in the cytoplasm and the nucleus, where it is 
structures called ‘gems’ (Figure 2) (Coovert et al., 1997; Liu and Dreyfuss, 1996). The 
predicted mass of SMN protein is 32 kDa. However, due to post-translational 
modifications, the molecular mass of cellular SMN is between 38 and 42 kDa (Battaglia 
et al., 1997; DiDonato et al., 1997). While SMN2 mainly generates a short transcript, 
which is translated into a truncated, unstable protein (SMNΔ7) due to skipping of exon 7, 
SMN1 almost exclusively generates full-length transcript, producing SMN protein (Figure 
2) (Cho and Dreyfuss, 2010; Lorson et al., 1999; Monani et al., 1999a; Vitte et al., 2007).  
 
Spinal Muscular Atrophy 
SMA is a genetic disorder characterized by weakness and muscle wasting, which 
is the results of selective loss of lower motor neurons in the anterior horn of the spinal 
cord. The incidence of SMA is estimated at about one in 10,000 live births (Prior, 2007). 
Different clinical presentations have been described on the basis of age at the onset and 
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degree of motor disability: severe (type I), intermediate (type II), mild (type III), and 
adult-onset (type IV). Low levels of SMN protein primarily due to deletion or mutation 
of SMN1 cause SMA (Lefebvre et al., 1995; McAndrew et al., 1997; Wirth et al., 2006a). 
More than 95% of SMA patients have an SMN1-null genotype due to homozygous SMN1 
deletions or spontaneous SMN1-to-SMN2 conversion, yet have normal or extra copies of 
the SMN2 gene (Wirth et al., 2006b). The remaining 3-5% of patients are compound 
heterozygous, with one deleted SMN1 allele and a small mutation in the other (He et al., 
2013). Because majority of SMN2 transcripts have deleted exon 7, coding for SMNΔ7 
that is less stable (Figure 2) (Kashima et al., 2007a; Lefebvre et al., 1995), severity of 
SMA is correlates with the copy number of SMN2 (Coovert et al., 1997; Feldkötter et al., 
2002; Lefebvre et al., 1997; Wirth et al., 2006c). However, despite low stability, high-
level expression of SMNΔ7 has been shown to increase the survival of mouse model of 
SMA (Monani et al., 2000). Therefore, spare SMN2 copies have potential correct defects 
associated with SMA. It is unclear why deficiency in SMN, a ubiquitously expressed 
gene, specifically affects degeneration of motor neuron. Although there is no cure for 
SMA, there are many SMA therapies including means to correct aberrant SMN2 exon 7 
splicing, enhance SMN2 transcription, stabilize SMN mRNA, SMN and SMNΔ7 protein, 
manipulate SMN-regulated pathways and delivery SMN1 gene using viral vectors 
(Howell et al., 2014).  
 
SMN Structure 
Both SMN genes have nine exons (exons 1, 2A, 2B, 3, 4, 5, 6, 7 and 8) and the 
stop codon is located within exon 7 (Figure 1). A critical cytosine (C) to thymidine (T) 
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mutation at the 6th position of exon 7 and an adenosine (A) to guanosine (G) transition at 
the 100th position (A100G) of intron 7 cause SMN2 exon 7 skipping (Kashima et al., 
2007b; Lorson et al., 1999). A G to A mutation at the 236th position (G236A) of exon 8 
creates a SMN2 specific signature motif (CTGAG), DdeI enzyme site (Figure 1) (Lorson 
et al., 1999). The last six residues of exon 7 and the entire exon 8 of the SMN transcript 
serve as the 3ʹ′untranslated region (3ʹ′UTR) of mRNA. Both SMN promoters are almost 
identical in sequence and activity (Boda et al., 2004; Echaniz-Laguna et al., 1999; 
Monani et al., 1999a; Monani et al., 1999b). Four transcriptional start sites (TSS) have 
been mapped upstream of the translation initiation site (Figure 3) (Echaniz-Laguna et al., 
1999; Germain-Desprez et al., 2001; Monani et al., 1999b). The principal TSS (+1) is 
located 163 base pairs (bp) upstream of translation start site, and TSS (-79) appears to be 
used during fetal development (Figure 3) (Germain-Desprez et al., 2001). Sequences up 
to 4.6 kb upstream of the TSS have putative bindings sites of transcription factors 
including cAMP response element-binding protein and ETS domain-containing protein 
Elk-1 (Figure 3) (Branchu et al., 2013). 
 
SMN Function and Domain Organization 
Among known functions of SMN, small nuclear ribonucleoprotein (snRNP) 
biogenesis is well characterized. (Battle et al., 2006; Massenet et al., 2002; Meister et al., 
2001; Meister et al., 2002; Pellizzoni et al., 2002; Winkler et al., 2005; Yong et al., 
2002). The depletion of SMN protein is linked to defective snRNP assembly and function 
(Kolb et al., 2007). SMN also modulates axon outgrowth. The SMN depletion exhibited 
reduced growth cone seize and shorter axons in primary neural culture from SMA 
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animals (Rossoll et al., 2003). A-SMN, including a portion of SMN intron 3, was shown 
to stimulate cell motility, promote axon growth, and regulate expression of chemokines 
(CCL2, CCL7) and Insulin-like growth factor-1 (Figure 2) (Locatelli et al., 2012). Other 
studied SMN functions include transcription (Strasswimmer et al., 1999), 
macromolecular trafficking (Peter et al., 2011; Rossoll et al., 2002), signal transduction 
(Bowerman et al., 2007), neuromuscular junction regulation (Kariya et al., 2008), DNA 
recombination (Takaku et al., 2011), detection of specific chromatin modifications (Sabra 
et al., 2013), stress granule formation (Zou et al., 2011), signal recognition particle (SRP) 
biogenesis (Piazzon et al., 2013), and translation (Sanchez et al., 2013).  
The SMN protein contains multiple domains including Gemin2 binding, nucleic 
acid binding, Tudor, Calpain cleavage regions, proline-rich, Gemin3 and ZPR1 binding, 
YG-box and self-association (Figures 2 and 4) (Cauchi, 2010; Fuentes et al., 2010; 
Gangwani et al., 2001; Liu et al., 1997; Lorson and Androphy, 2000; Pellizzoni et al., 
2002; Renvoisé et al., 2006; Todd et al., 2010; Young et al., 2000). Loss of SMN 
function associated with deletions or missense mutations throughout every SMN 
functional domain is considered to be the major cause of SMA (reviewed by (Howell et 
al., 2014)). When SMN protein is depleted, the level of Gemin2 significantly decrease 
(Wang and Dreyfuss, 2001). The interaction between SMN and Gemin2 involves several 
SMN functions including snRNP biogenesis (Zhang et al., 2011), signal recognition 
particle biogenesis (Piazzon et al., 2013), DNA recombination (Takaku et al., 2011), 
motor neuron trafficking of mRNAs (Fallini et al., 2011), and translation regulation 
(Sanchez et al., 2013). Nucleic acid binding domains binding to guanosine residues are 
linked to stress granule formation (Hua and Zhou, 2004b; Lorson and Androphy, 1998). 
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Tudor domain in exon 3 is associated with interaction with Sm protein (Bühler et al., 
1999; Selenko et al., 2001) and nucleocytoplasmic trafficking of SMN (Renvoisé et al., 
2006). The carboxy-terminal domain of SMN, spanning exons 6 and 7, is required for 
binding to Gemin3, the Sm proteins, zinc finger protein ZPR1 (Gangwani et al., 2001) 
and for its oligomerization (Charroux et al., 1999; Gangwani et al., 2001; Lorson et al., 
1998; Pellizzoni et al., 1999). The YG box in exon 6 and EMLA in exon 8 are major 
contributors to SMNΔ7’s instability that has oligomerization defect and is unstable and 
rapidly degraded by proteasome (Burnett et al., 2009; Cho and Dreyfuss, 2010; Lorson et 
al., 1998; Vitte et al., 2007). Exon 7 spans 54 nucleotide that harbor the translation 
termination codon and contains a cytoplasmic targeting signal, QNQKE (Zhang et al., 
2003), hnRNP Q binding (Mourelatos et al., 2001) and inhibition of nuclear aggregation 
(Hua and Zhou, 2004a).  
 
Alternative Splicing 
Majority of human genes with two or more exons are alternatively spliced (Nilsen 
and Graveley, 2010). Consequences of alternative splicing are insertion/delition of 
protien domains and alteration of transcript/protein acitivity/stability (Black, 2003; 
Garcia et al., 2004; Resch et al., 2004; Xing and Lee, 2007; Xing et al., 2003). Many 
human genetic disorders are caused by aberrant pre-mRNA splicing (Faustino and 
Cooper, 2003; Garcia-Blanco et al., 2004; Mills and Janitz, 2012; Pagani and Baralle, 
2004). Regulation of alternative splicing of an exon is dependent upon arrangement of 
cis-elements within exonic and flanking intronic sequences (Wang and Burge, 2008; Yu 
et al., 2008), and the relative concentrations of spliceosomal and nonspliceosomal protein 
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(Jurica and Moore, 2003). Nonspliceosomal proteins including serine-arginine-rich 
proteins (SR proteins), SR-like proteins, and heterogeneous nuclear ribonucleoproteins 
(hnRNPs), bind to pre-mRNA sequences, exonic or intronic splicing enhancers and 
silencers (Cartegni et al., 2002; Dreyfuss et al., 2002; Graveley, 2000; Hastings and 
Krainer, 2001; Maniatis and Tasic, 2002; Nilsen, 2003; Smith and Valcárcel, 2000; Tacke 
and Manley, 1999). Moreover, RNA secondary structure affect modulatory activity by 
providing accessibility to the splice sites and/or constituting binding sites for interacting 
proteins (Buratti and Baralle, 2004; Damgaard et al., 2002; Grover et al., 1999; Tu et al., 
2000).  
 
Splicing Regulation of SMN 
Due to a direct connection to SMA pathogenesis, mechanism of SMN2 exon 7 
splicing has been intensively studied. Loss of an enhancer, gain of a silencer, 
strengthening of a stem-loop structure (TSL1) at the 3ʹ′ splice site (ss) of exon 7, and 
creation of extended inhibitory context (EXINCT) have been proposed (Figure 5) 
(Cartegni et al., 2006; Cartegni and Krainer, 2002; Kashima and Manley, 2003; Kashima 
et al., 2007a; Singh et al., 2004a, b). SMN2 exon 7 has a weak 5ʹ′ ss (Singh et al., 2004b) 
and a weak 3ʹ′ ss (Lim and Hertel, 2001). The 5ʹ′ ss of SMN2 exon 7 was a critical 
determinant of exon inclusion (Jodelka et al., 2010). Among SMN2-specific mutations, a 
C to T substitution at the 6th position (C6U in transcript) of exon 7 and an A to G 
mutation at the 100th position (A100G) of intron 7 have been linked to skipping of SMN2 
exon 7 (Kashima et al., 2007a; Lorson et al., 1999; Monani et al., 1999a). Both C6U and 
A100G substitutions create inhibitory cis-elements associated with hnRNP A1 (Kashima 
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and Manley, 2003; Kashima et al., 2007b). Additional hnRNP A1 motifs are located 
within intronic splicing silencer N1 (ISS-N1). Reduction of hnRNP A1 in HeLa cells 
promoted exon 7 inclusion in SMN2 (Kashima and Manley, 2003). Several inhibitory cis-
elements are in the vicinity of the 5ʹ′ ss of exon 7 including TSL2, an 8-nt long GC-rich 
sequence (GCRS), ISS-N1 and ISS-N2 (Figure 5) (Singh et al., 2006; Singh et al., 2013; 
Singh et al., 2009; Singh et al., 2007). ASO-mediated sequestration of GCRS, ISS-N1 
and ISS-N2 promoted SMN2 exon 7 inclusion (Hua et al., 2008; Keil et al., 2014; Singh 
et al., 2006; Singh et al., 2013; Singh et al., 2009). 
Multiple factors including SF2/ASF (+, positive), Tra2-β1 (+), SRp30c (+), 
hnRNP G (+), hnRNP Q (+), TDP-43 (+), TIA1 (+), Sam68 (-, negative) and hnRNP A1 
(-), have been implicated in regulation of SMN2 exon 7 (Figure 5) (Hofmann and Wirth, 
2002; Singh and Singh, 2011; Young et al., 2002). Tra2-β1 directly interacts with exon 7 
and recruits SRp30c, hnRNP G and TDP-43 to exon 7 (Bose et al., 2008; Hofmann et al., 
2000; Hofmann and Wirth, 2002; Young et al., 2002). However, Tra2-β1 knockout 
mouse demonstrate that Tra2-β1 is dispensable for SMN exon 7 splicing (Mende et al., 
2010). TIA1 is known to recruit U1 snRNP at the 5ʹ′ ss of exons (Förch et al., 2002) and 
stimulated SMN2 exon 7 inclusion by binding to intronic U-rich clusters downstream of 
ISS-N1 (Figure 5) (Singh et al., 2011). A recent report showed that Welander distal 
myopathy patients carrying TIA1 mutations increased SMN exon 7 skipping (Klar et al., 
2013).  
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Oxidative Stress 
Oxidative stress (OS) is the condition arising from the imbalance between the 
physiological production of toxic reactive oxygen species (ROS) and reactive nitrogen 
species and the physiological scavenging activities. OS has been implicated in the 
initiation and progression of human diseases, including cancer, neurodegenerative 
diseases and cardiovascular disease (Benz and Yau, 2008; Potashkin and Meredith, 
2006). Paraquat (PQ) is an environmental toxin and belongs to the class of redox cycling 
compounds capable of generating ROS, inducing OS and interfering with the function of 
complex I of the mitochondrial respiratory chain (Castello et al., 2007; Cochemé and 
Murphy, 2008; Fukushima et al., 1994; Jenner, 2003; Maher et al., 2014; McCormack et 
al., 2005; Sharp et al., 1972; Sherer et al., 2002). PQ is commonly used in cell and 
animal-based models to understand the pathogenesis of Parkinson’s disease and to study 
the mechanism by which OS impacts various pathways in cells and tissues (Kamel, 2013; 
Le et al., 2014; Ryan et al., 2013). PQ induced neurodegeneration (Dinis-Oliveira et al., 
2006), neuronal apoptosis (Peng et al., 2004), lipid peroxidation (Bus et al., 1976), DNA 
Double strand breaks (Vivarelli et al., 2013), dopaminergic neuronal loss (Kuter et al., 
2007), proteasome dysfunction (Yang et al., 2007), mitochondrial dysfunction and 
apoptosis (Castello et al., 2007; McCarthy et al., 2004). In several cell-based studies PQ 
has been shown to trigger aberrant splicing (Lenzken et al., 2011; Maracchioni et al., 
2007). In neuronal SH-SY5Y cells, PQ leads to re-localization of SRPK2 to the cell 
nucleus, where it phosphorylates SR proteins, leading to their accumulation in nuclear 
speckles (Vivarelli et al., 2013).  
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Dissertation Organization 
This dissertation begins with a general introduction (in Chapter 1). The body of 
this dissertation is composed of three manuscripts published or in preparation to be 
submitted to peer-reviewed international journals  (Chapter 2, 3 and 4).  
Chapter 2 describes a multiple-exon-skipping detection assay (MESDA). The 
basis of this assay and application to diversity of SMN splicing isoforms identification in 
non-neuronal and neuronal cells is described. My contribution included developing 
MESDA, testing effect of an 8-mer antisense oligonucleotide on SMN2 exon 7 splicing 
under the conditions of OS, and examining levels of SMN isoforms under the conditions 
of OS.   
Chapter 3 describes in vivo study to understand the OS-induced aberrant splicing 
regulation of SMN2. Also, transcription-coupled splicing regulation of various SMN2 
exons under normal and OS conditions was studied using a super minigene harboring 
SMN2 promoter, all internal exons and flanking intronic sequences. Proteome analysis of 
mouse brain under normal and OS conditions is described. My contribution included 
testing OS-induced aberrant splicing of various SMN2 exons using transgenic mouse 
models, generating the minigene harboring all SMN2 exons and conducting proteome 
analysis. 
Chapter 4 describes SMN6B, a novel splice variant generated by exonization of a 
portion of intron 6. We analyzed various tissues from humans and mouse model of SMA 
to confirm the universal expression of SMN6B. My contribution included conducting the 
experiments and writing the manuscript. 
The final chapter (Chapter 5) of this dissertation contains general conclusion. 
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Figure Legends 
Figure 1. Organization of human SMN1. Number starts with translation start site. Amino 
acids indicated on the top of DNA sequences. Exons are indicated with different colors. 
Sequences difference between SMN1 and SMN2 are indicated (exons 7 and 8). 
 
Figure 2. Description of transcripts and protein encoded SMN (The figure is adapted 
from (Howell et al., 2014)). (A) Diagrammatic representation of the major transcript and 
the full-length protein derived from SMN1. Exons are presented as colored boxes with the 
number of amino acids noted within each box. Arrows indicate locations of the start and 
stop codons. Corresponding protein domains and their functions are indicated. (B) 
Diagrammatic representation of the major transcript and the truncated protein derived 
from SMN2. Arrows indicate locations of the start and stop codons as well as EMLA 
degron that renders that protein unstable. (C) Diagrammatic representation of a-SMN 
transcript and protein. Presence of an extra exon due to inclusion of a portion of intron 3 
(3x) is shown as white box.  
 
Figure 3. Organization of SMN2 promoter. The arrow corresponds to the transcription 
start sites (TSS). Location numbers are relative to TSS of adult (+1). Blue color indicates 
differences between SMN1 and SMN2 promoters. Exon 1 is uppercase. Red color 
indicates polyA run. Putative cis-elements are underlined.  
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Figure 4. Amino acids sequences from the start and stop codons. Sequences were aligned 
by ClustalW using MacVector software. Human SMN2 exons are presented on the top of 
human sequences. Corresponding protein domains are indicated.  
 
Figure 5. Regulators of SMN exon 7 splicing. (The figure is adapted from (Howell et al., 
2014)). Diagrammatic representation of cis-elements and transacting factors that affect 
splicing of exon 7. Exon 7 sequence is shown in capital letters, while adjacent intronic 
sequences, including the first 104 nucleotides of intron 7, are shown in lower-case letters. 
The ss of exon 7 are indicated by arrows; in addition, the 5ʹ′ ss is highlighted with a blue 
arrow. Nucleotide numbering starts from the first position of intron 7. Cis-
elements/transacting factors that promote exon 7 inclusion are indicated by (+), while cis-
elements/transacting factors that promote exon 7 skipping are indicated by (−). GCRS: 
GC-rich sequence; ISS-N1: Intronic splicing silencer N1; LDI: Long-distance interaction; 
ss: Splice site; URC: U-rich cluster. 
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Figure 1. Organization of human SMN1.  
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Figure 2. Description of transcripts and protein encoded SMN (The figure is adapted 
from (Howell et al., 2014)). 
 
 
 
Figure 3. Organization of SMN2 promoter. 
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Figure 4. Amino acids sequences from the start and stop codons. 
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Figure 5. Regulators of SMN exon 7 splicing. (The figure is adapted from (Howell et al., 
2014)). 
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Abstract 
Humans have two near identical copies of Survival Motor Neuron gene: SMN1 
and SMN2. Loss of SMN1 coupled with the predominant skipping of SMN2 exon 7 causes 
spinal muscular atrophy (SMA), a neurodegenerative disease. SMA patient cells devoid 
of SMN1 provide a powerful system to examine splicing pattern of various SMN2 exons. 
Until now, similar system to examine splicing of SMN1 exons was unavailable. We have 
recently screened several patient cell lines derived from various diseases, including SMA, 
Alzheimer’s disease, Parkinson’s disease and Batten disease. Here we report a Batten 
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disease cell line that lacks functional SMN2, as an ideal system to examine pre-mRNA 
splicing of SMN1. We employ a multiple-exon-skipping detection assay (MESDA) to 
capture simultaneously skipping of multiple exons. Our results show surprising diversity 
of splice isoforms and reveal novel splicing events that include skipping of exon 4 and 
co-skipping of three adjacent exons of SMN. Contrary to the general belief, MESDA 
captured oxidative-stress induced skipping of SMN1 exon 5 in several cell types, 
including non-neuronal cells. We further demonstrate that the predominant SMN2 exon 7 
skipping induced by oxidative stress is modulated by a combinatorial control that 
includes promoter sequence, endogenous context, and the weak splice sites. We also 
show that an 8-mer antisense oligonucleotide blocking a recently described GC-rich 
sequence prevents SMN2 exon 7 skipping under the conditions of oxidative stress. Our 
findings bring new insight into splicing regulation of an essential housekeeping gene 
linked to neurodegeneration and infant mortality. 
 
 
Introduction 
Alternative pre-mRNA splicing increases the coding potential of eukaryotic 
genome by producing multiple proteins from a single gene [1]. As per current estimate, 
more than 95% of human genes with two or more exons are alternatively spliced [2]. 
Splicing is catalyzed by spliceosome, a macromolecular machine, which is assembled de 
novo for the removal of each intron [3,4]. Splicing is also coupled with transcription as 
several splicing factors are recruited to spliceosome and/or pre-mRNA sequence through 
RNA polymerase [5]. Regulation of alternative splicing rests on non-spliceosomal factors 
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that bind to pre-mRNA sequences called exonic or intronic splicing enhancers (ESEs or 
ISEs) and silencers (ESSs or ISSs) [6–8]. Enhancer and silencer motifs promote or 
suppress splice-site (ss) selection, respectively. Due to the difference in arrangement of 
cis-elements within exonic and flanking intronic sequences, regulation of alternative 
splicing of each exon is unique [9,10]. Mutations within regulatory sequences and/or 
aberrant expression of splicing factors due to genotoxic and/or oxidative stress (OS) 
result in defective splicing [11–17]. However, there are very limited studies capturing 
OS-triggered aberrant splicing of multiple exons in a single transcript of an essential 
human gene. Also it is not known if deleterious effect of OS on splicing of a specific 
exon could be prevented by strengthening of a ss.  
Humans have two near identical copies of Survival Motor Neuron gene: SMN1 
and SMN2 [18]. Hereafter, SMN (in italics) refers to a gene or a transcript, whereas SMN 
(in normal case capital letters) refers to a protein. Both SMN genes code for identical 
proteins; however, SMN2 predominantly generates a short transcript due to skipping of 
exon 7, producing a truncated protein (SMNΔ7) that is highly unstable [19–21]. 
Therefore, SMN1 serves as the primary gene for production of full-length SMN, a 
multifunctional protein containing nucleic acid binding, Tudor, Sm binding, Calpain 
cleavage, ZPR1 binding and Gemin2 binding domains (Figure 1) [22–28]. Interaction of 
SMN with Gemin2 is essential for the formation of a large heteromeric complex (SMN 
complex) that participates in snRNP biogenesis, an important housekeeping function 
[29,30]. SMN is also implicated in transcription, DNA recombination, signal 
transduction, stress granule formation, vesicular transport and motor neuron trafficking 
[31–37]. The inability of SMN2 to compensate for the loss of SMN1 results in spinal 
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muscular atrophy (SMA), a leading genetic cause of infant mortality [38]. The exact 
function of SMN2 remains unknown, although, several lines of evidence support its role 
in cellular metabolism. For instance, a SMA mouse model expressing very high levels of 
SMNΔ7 showed prolonged lifespan [39]. Further, deletion of SMN2 has been associated 
with higher incidence of amyotrophic lateral sclerosis (ALS) and lower motor neuron 
disease [40,41]. In addition, SMN2 serves as a spare gene with a potential to be corrected 
in SMA. Indeed, recent reports of correction of SMN2 exon 7 splicing in animal models 
have shown promise for SMA therapy [42–47]. Most lead compounds to show 
therapeutic potential in animal models have been initially found to correct SMN2 exon 7 
splicing in cultured SMA patient cells. In particular, publically available GM03813 cell 
line that lacks SMN1 has emerged as a cell-based model system for the preliminary 
screening of potential SMA drugs [48–54]. GM03813 cell line has also been useful in 
validating regulatory cis-elements and transacting factors that modulate SMN2 exon 7 
splicing [48,51–55]. On the other hand, there is no systematic study on SMN1 splicing 
regulation in a publically available SMN2-lacking cell line.  
Both SMN1 and SMN2 have similar gene organization i.e. nine exons and eight 
introns (Figure 2A). A critical cytosine (C) to thymidine (T) mutation at the 6th position 
(C6U transition in transcript) of exon 7 and an adenosine (A) to guanosine (G) transition 
at the 100th position (A100G) of intron 7 cause SMN2 exon 7 skipping [19,56]. Both, 
C6U and A100G mutations create binding sites for an inhibitory protein hnRNP A1 that 
weakens the 3ʹ′ ss of SMN2 exon 7 [56]. An additional G to A mutation at the 236th 
position (G236A) of non-coding exon 8 creates a SMN2- specific signature motif 
(CTNAG) that could be cleaved by DdeI restriction endonuclease (Figure 2A). Therefore, 
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DdeI digestion has been useful in distinguishing SMN2 transcripts from SMN1 transcripts 
[19]. Based on studies in SMA patient cells as well as in mouse models carrying SMN2, 
skipping of SMN2 exons 3, 5 and 7 have been confirmed [18,48,53,57]. There is also 
evidence to suggest very small but detectable skipping of SMN1 exon 5 and exon 7 in 
certain cell types [18,19,58]. However, it is not known if splicing of two or more exons of 
SMN is co-regulated. Also, there is no report of skipping of SMN1 exon 3. In general, 
there is a lack of a reliable assay to capture the relative abundance of the major splice 
variants of SMN1 and SMN2.  
Paraquat (PQ), an herbicide and oxidative stress (OS)-causing agent, has been 
linked to the increased risks of neurological disorders, including Parkinson’s disease [59]. 
Incidentally, PQ treatment of neuronal cells have been shown to cause enhanced skipping 
of exons 5 and 7 of SMN2but not SMN1 [60]. Although not independently validated, 
these findings put SMA patients into the category of high-risk candidates who are likely 
to be affected the most under the conditions of OS. In addition, OS-induced enhanced 
skipping of SMN2 exon 7 raises the fundamental question whether any of the strategies 
aimed at the correction of SMN2 exon 7 splicing in SMA will retain its efficacy under the 
conditions of OS. Given a high degree of sequence conservation between SMN1 and 
SMN2, it is likely that some of the yet uncharacterized splicing events in OS are common 
to both, SMN1 and SMN2. A definitive answer to this question awaits further 
experimentation in specific cell types that express either SMN1 or SMN2.  
Here we report a systematic analysis of splice isoforms generated by SMN1 and 
SMN2 under normal and OS conditions. Our study also addresses an important question 
of neuronal versus non-neuronal regulation of alternative splicing of various SMN exons. 
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One of the defining aspects of this study is the application of a multiple-exon-skipping 
detection assay (MESDA) that captures the relative abundance of all major splice variants 
of SMN. We also take advantage of a unique cell type (GM20384) that we 
serendipitously discovered to lack SMN2 transcripts probably due to a partial or complete 
deletion of SMN2 alleles. Our findings reveal novel splice variants, including those 
generated by an unexpected skipping of exon 4 and/or several adjacent exons of SMN. 
We show that OS affects alternative splicing of several exons of SMN1 and SMN2 in 
both, neuronal and non-neuronal cells. Our results suggest an OS-induced collaborative 
skipping of SMN2 exons 5 and 7. Further, we demonstrate that skipping of SMN2 exon 7 
under OS is dependent upon several factors including promoter sequence, endogenous 
context and the strength of ss. We also demonstrate that an antisense oligonucleotide 
(ASO)-based strategy to correct SMN2 exon 7 splicing retains its efficacy under the 
conditions of OS. 
 
 
Results 
Identification of a cell line that lacks SMN2 
To explore the possibility that different pathological conditions can affect splicing of 
SMN exon 7, we screened a number of publically available patient cell lines, including 
batten disease (BD), Parkinson’s disease and Alzheimer’s disease cell lines (Table 1, 
Figure 2B). As a control, we also used undifferentiated neuronal SH-SY5Y cells (lane 1, 
Figure 2B). SMN1/ SMN2 transcripts were analyzed by a sensitive radioactive RT-PCR 
using forward and reverse primers annealing to exon 6 and exon 8, respectively. 
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Importantly, PCR products contained the SMN2-specific DdeI restriction site within exon 
8 (Figure 2A). Therefore, after DdeI digestion of PCR products, samples from cells 
containing both, SMN1 and SMN2, produced four bands (Figure 2B). The slowest 
migrating band (top band) in a polyacrylamide gel represented the exon 7 included 
transcripts from SMN1, whereas, three fast migrating bands originated from SMN2. 
Despite similar amount of starting material (RNA) used for RTPCR, we observed 
varied intensity of expected four bands in different cell types. This could be due to a 
combination of factors, including but not limited to variations in SMN1/SMN2 copy 
numbers, transcription rate and splicing regulation. In order to compare side-by-side the 
relative proportions of SMN1 versus SMN2 transcripts in various cell types, loading of 
PCR products in polyacrylamide gel was adjusted (Figure 2B). Our assay reliably 
detected the presence and/or absence of major transcripts specific to SMN1 and/or SMN2. 
For instance, the SMN1-associated top band was absent in GM03813, a well-studied 
SMA type I patient fibroblast cell line (Figure 2B, lane 14). Except GM03813, all other 
cell lines in our screening showed the presence of SMN1. Noticeably, GM20384, a BD 
patient lymphocyte cell line, lacked all bands corresponding to SMN2, suggesting a 
complete or partial deletion of both SMN2 alleles (Figure 2B, lane 3). None of the other 
five BD patient lymphocytes showed the loss of SMN2 transcripts. To further ascertain 
that all exon 7-included products in GM20384 originated from SMN1, we sequenced ten 
clones derived from the top band (full-length transcript). All clones lacked SMN2 
associated signature mutations in exons 7 and 8, confirming the absence of the intact 
SMN2 gene. Of note, donor of GM20384 had a mutation in CLN3 gene that is generally 
associated with BD (Table 1) [61]. However, irrespective of the presence or absence of 
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SMN2, CLN3 mutations did not produce any change in splicing pattern of SMN1 in any of 
the BD patient cell lines we tested (Figure 2B). In addition, splicing pattern of SMN1 in 
GM20384 cells was similar to those in non-BD cell types. We believe that GM20384 
cells provide a valuable tool to understand SMN1-specific splicing regulation. 
 
A unique assay captures relative expression of major splice isoforms of SMN1 and 
SMN2 
To determine the relative abundance of major splice variants of SMN1/ SMN2 in a one-
step reaction, we developed a PCR-based assay that we named ‘‘MESDA’’. The 5ʹ′ and 3ʹ′ 
primers used in MESDA annealed to SMN exons 2b and 8, respectively. Our rationale to 
use 5ʹ′ primer in exon 2b was based on the fact that this exon is constitutively spliced. 
Also, use of 5ʹ′ primer in exon 2b versus constitutively spliced exon 1 or exon 2a resulted 
in shorter PCR products that can be better resolved on a polyacrylamide gel. To maintain 
the sensitivity and an accurate estimate of the relative molecular abundance of amplified 
products of different sizes, we performed a limited-cycle radioactive PCR in which only 
one of the primers was 5ʹ′-radiolabeled. Considering that the 5ʹ′ and 3ʹ′ primers employed 
in MESDA annealed to exons 2B and 8 of SMN, respectively, we were able to capture 
multiple splice variants, including the transcripts generated by simultaneous skipping of 
three exons of SMN. MESDA also identified novel splice variants due to an entirely 
unexpected splice site pairings. Cloning and sequencing confirmed identity of splice 
variants generated by MESDA. GenBank accession numbers of novel splice isoforms of 
SMN reported here are given in Table 2.  
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We employed MESDA to first profile major splice variants of SMN1 and SMN2 
in GM20384 and GM03813 cells, respectively. SMN1 in GM20384 cells produced one 
predominant band corresponding to the full-length transcript (Figure 3B, lane 2). In 
addition, SMN1 showed very small but detectable skipping of exon 5 and exon 3. These 
results reveal for the first time the possibility of alternative splicing of SMN1 exon 3 that 
codes for a critical Tudor domain. Previous studies have shown that Tudor domain plays 
an important role in nucleocytoplasmic trafficking of SMN [25]. GM03813 cells showed 
two prominent bands corresponding to the full-length and exon 7-skipped transcripts of 
SMN2. Similar to SMN1 splice variants in GM20384 cells, we also detected skipping of 
SMN2 exon 5 and exon 3 in GM03813 cells. However, unlike SMN1, SMN2 showed co-
skipping of exons 5 and 7 as well as exons 3 and 7 (Figure 3B, lanes 1 and 2). We also 
observed much weaker bands representing Δ3,5 and Δ3,5,7 transcripts in GM03813 and 
GM20384 cells. As controls, we used GM20383 lymphocytes and undifferentiated 
neuronal SH-SY5Y cells. Since these cells contain both, SMN1 and SMN2, they produced 
a mixture of transcripts representing all SMN splice isoforms. Interestingly, the results of 
MESDA revealed almost identical splicing pattern of SMN in SH-SY5Y and GM20383 
cells, suggesting similarity in splicing of SMN between neuronal and non-neuronal cells. 
However, compared to other cell types examined, we observed higher expression of 
major SMN splice variants in SH-SY5Y cells. Using cloning and sequencing, we next 
characterized the relative abundance of SMN1 and SMN2 transcripts for specific splice 
variants in SH-SY5Y cells. Some splice variants were also sequenced in other cell lines. 
In general, we sequenced between 8 and 17 clones from major isoforms amplified by 
MESDA. DdeI digestion combined with sequence analysis confirmed that isoforms 
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lacking exon 7 came mostly from SMN2 (Figure 4C and Figure S1). Based on sequence 
analysis, transcripts containing exon 7 but lacking exon 5 or exon 3 were generated 
mostly from SMN1 (Figure S1). It remains to be seen if these results were affected by 
potentially different copy numbers of SMN1 and SMN2 genes in SH-SY5Y cells. Our 
detection of SMN transcript lacking exons 5 and 6 (Δ5,6) in GM20383 lymphocytes was 
a novel and an unexpected finding. This transcript is generated by an unusual pairing 
between the 5ʹ′ ss exon 4 and the 3ʹ′ ss exon 7. Considering that the 3ʹ′ ss SMN1 exon 7 is 
much stronger than the 3ʹ′ ss SMN2 exon 7, we expected a higher occurrence of 
SMN1Δ5,6 compared to SMN2Δ5,6. Indeed, sequence analysis revealed that an 
overwhelming majority of Δ5,6 transcripts generated were from SMN1 (Figure S1A). 
 
Effect of OS on splicing of SMN exons  
Having established that various exons of SMN1/SMN2 are alternatively spliced, we set 
out to distinguish between general versus neuronal cell-specific effect of OS on SMN pre-
mRNA splicing. To induce OS, neuronal and non-neuronal cells were treated with 1 mM 
PQ and transcripts were analyzed by MESDA 24 h post treatment. Of note, a previous 
study has shown that 1 mM of PQ is sufficient to produce a significant oxidative stress in 
neuronal SH-SY5Y cells [60]. We observed OS-induced increase in skipping of SMN2 
exon 7 in all cell types treated with PQ (Figure 4 and Figure S2). Based on results of 
DdeI digestion (Figure 4C), the strongest effect of OS on splicing of SMN2 exon 7 was 
observed in GM20383 lymphocytes followed by neuronal SHSY5Y cells. Substantial 
skipping of SMN2 exon 7 was also observed in GM03813 fibroblasts treated with PQ. 
Based on these findings, we conclude that response to PQ-induced OS on splicing of 
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SMN2 exon 7 is universal. In addition, DdeI digestion analysis underscores that OS-
induced skipping of exon 7 is associated mostly with SMN2 (Figure 4C). Supporting the 
reduced vulnerability of SMN1 exon 7 to skipping under OS, we detected very low levels 
of SMN1 exon 7-skipped products in PQ-treated SHSY5Y cells (Figure 4C, lane 8). 
 We observed an increase in PQ-induced skipping of SMN1 exon 5 in GM20384 
lymphocytes, suggesting that pre-mRNA splicing of human SMN1 is sensitive to OS 
(Figure 4B). To validate that the effect of OS on SMN1 exon 5 splicing is not specific to 
lymphocytes and/or related to BD-causing mutations in CLN3 gene, we isolated and 
cloned RT-PCR products lacking exon 5 from PQ-treated SH-SY5Y cells. Based on 
sequence analysis, conditions of OS led to an appreciable increase in SMN1Δ5 transcripts 
compared to SMN2Δ5 (Figure S1). These results confirm that skipping of exon 5 is one 
of the major SMN1-associated events in cells undergoing OS. Unlike SMN1, most SMN2 
transcripts that went through exon 5 skipping also lacked exon 7. Consistently, we 
observed an enhanced co-skipping of SMN2 exons 5 and 7 in PQ-treated GM03813 
fibroblasts, GM20383 lymphocytes and neuronal SH-SY5Y cells (Figure 4B). 
Interestingly, PQ-induced OS caused a noticeable reduction in intensity of several fast 
migrating exon 3-skipped splice variants (Δ3, Δ3,5 and Δ3,7) in SH-SY5Y cells. 
Consistent with these findings, results of quantitative real-time PCR (qPCR) using 
various junction primers supported a decrease in skipping of exon 3 in PQ treated SH-
SY5Y cells (Figure S3). However, due to a near background level of expression of Δ3 
transcripts, suppression of exon 3 skipping under OS was not accompanied by an 
appreciable increase in the exon 3-included transcripts. Conditions of OS produced three 
additional novel SMN1 splice variants that we captured in neuronal SH-SY5Y cells 
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(Figures 4A and 4B). The first such variant lacked SMN1 exons 4 and 7 (SMN1Δ4,7) and 
co-migrated with the SMNΔ3 transcript in a polyacrylamide gel (Figure 4B). Considering 
skipping of constitutive exon 4 has not been previously reported and skipping of SMN1 
exon 7 is an infrequent occurrence, presence of SMN1Δ4,7 was very surprising. The 
second novel variant lacked SMN1 exons 3 and 4 (SMN1Δ3,4) and co-migrated with 
Δ3,5,7 transcripts on a polyacrylamide gel (Figures 4A and 4B). The third novel SMN1 
splice variant that we captured lacked exons 5, 6 and 7 (SMN1Δ5,6,7). Occurrence of 
SMN1Δ5,6,7 reveals for the first time the feasibility of a rare phenomenon where three 
adjacent exons of SMN are skipped.  
All internal exons of SMN are divisible by three. Thus, skipping of one or more 
internal exons of SMN does not create a premature termination codon. Consequently, 
none of the alternatively spliced variants of SMN are natural substrates of nonsense-
mediated decay (NMD). To analyze the translated products of various alternatively 
spliced transcripts of SMN1 and SMN2, we performed western blot analysis of PQ-treated 
GM20384 and GM03813 cells that carry SMN1 and SMN2, respectively. In both cell 
types, we noticed a decrease in SMN levels at 24 h post PQ treatment (Figure 4D). 
However, we were unable to detect translated products corresponding to any of the short 
transcripts generated from either SMN1 or SMN2. This could be attributed to several 
factors, including low levels of exon-skipped transcripts, slow rate of translation under 
the conditions of OS and unstable nature of Δ7-translated products. Of note, skipping of 
SMN exon 7 is known to create a degradation signal [21]. 
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Translation efficiency of SMN transcripts lacking internal exons 
In order to determine whether proteins encoded by transcripts that lack one or more 
internal SMN exons could be produced, we employed an alternative approach. We 
induced SMN2 exon skipping in HeLa cells using two ASOs: E3/I3Jxn and E5/I5Jxn 
(Figure 5A). E3/I3Jxn and E5/I5Jxn blocked the 5ʹ′ ss of exon 3 and exon 5, causing 
massive skipping of exon 3 and exon 5, respectively (Figure 5B). Targeting ASOs did not 
discriminate between SMN1 and SMN2 transcripts that code for identical proteins. Also, 
ASOs were designed not to interfere with the translational machinery because they 
annealed to sequences that are removed during pre-mRNA splicing. Our approach 
provided high levels of SMN exon-skipped transcripts that served as the needed templates 
for protein synthesis. As a result, we were able to detect proteins generated from 
transcripts lacking either exon 3 or 5 (Figure 5C, lanes 2 and 3). SMNΔ5 appeared to be 
stable and migrated very close to the full-length SMN. On the other hand, SMNΔ3 seems 
to be less stable. Poor stability of SMNΔ3 could be attributed to its misfolding due to the 
loss of the Tudor-domain coded by exon 3. Our results validate that SMNΔ3 and SMNΔ5 
transcripts could be translated. Whether SMNΔ3 and SMNΔ5 proteins play any 
physiological role is a matter of future investigation. 
 
Effect of promoter on OS-induced skipping of SMN exon 7 
Promoter structure (sequence) has been shown to affect alternative splicing of specific 
exons in several genes including fibronectin (FN), calcitonin-gene-related product 
(CGRP) and CD44 [62,63,64]. SMN promoter has been localized in a 2 kb region 
upstream of the coding sequence that starts within exon 1 [65]. Using reporter assays, two 
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earlier studies support similarity of promoter activity between SMN1 and SMN2 [65,66]. 
Based on effect of small compounds that act as inhibitors of histone deacetylase 1, recent 
reports suggest the role of promoter sequences in splicing regulation of SMN exon 7 
[50,67]. However, there is no study to implicate a direct role of SMN promoter sequence 
on usage of exon 7. To address the promoter-specific splicing regulation of SMN2 exon 7 
under normal and OS conditions, we employed SMN minigenes with three different 
promoters: cytomegalovirus (CMV), thymidine kinase (TK) and wild type SMN1/SMN2 
promoters (Figure 6A). Several CMV promoter-containing minigenes encompassing 
SMN genomic sequences from exon 6 through exon 8 cloned in pCI vector (Promega) 
have been reported [19,68,69]. We took advantage of CMV promoter containing short 
minigenes that maintained an earlier reported deletion within intron 6 [68]. Due to 
decreased size, these minigenes provide desired benefit of high transfection efficiency 
without any apparent change in splicing pattern of SMN exon 7. To generate minigenes 
under the control of wild type SMN1 and SMN2 promoters, we replaced CMV promoter 
with ~3.5 kb genomic sequences harboring promoter region of SMN1 and SMN2, 
respectively. Wild type SMN1 and SMN2 promoters used in this study were the same as 
reported in an earlier study that confirmed similarity of transcriptional regulation between 
two SMN genes [66]. To generate TK promoter-containing minigenes, we subcloned 
SMN genomic sequences from pCI-based SMN minigenes into commercially available 
pTK-GLuc vector (New England Biolabs). Other than variations in promoter structures, 
vector-specific sequences downstream of promoters brought additional differences in the 
contexts of the three minigenes we used (Figure 6A and Figure S4). Therefore, the design 
of our minigene constructs allowed us to simultaneously examine the effect of promoters 
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as well as sequences upstream of the SMN splicing cassette. We employed neuronal SH-
SY5Y cells to examine the splicing pattern of SMN minigenes expressed under the 
control of different promoters. We simultaneously monitored the splicing pattern of exon 
7 derived from endogenous SMN1 and SMN2.  
Among three promoters used in this study, we observed substantially higher levels 
of SMN expression with CMV promoter. For the purposes of comparison of splice 
variants, we adjusted loading of PCR products for different promoter samples. All 
minigenes expressing SMN under the control of various promoters recapitulated the 
splicing pattern of endogenous gene, with predominant exon 7 skipping in SMN2, and 
predominant exon 7 inclusion in SMN1 (Figure 6B). However, unlike minigenes under 
the control of TK and CMV promoters, wild type promoter produced noticeably less exon 
7 skipping (Figure 6B, lane 4). These results provide the first direct evidence of the role 
of promoter structure in modulation of SMN exon 7 splicing. However, compared to a 
reported 10-fold decrease in usage of the extra domain I (EDI) exon of FN when 
expressed under control of a CMV promoter [64], impact of SMN promoter on percentage 
of exon 7 skipping could be considered as less prominent (Figure 6B, compare lanes 1 
and 2 with lanes 9 and 10). Effect of promoter structure on SMN exon 7 splicing was 
further supported by an appreciable change in the levels of exon 7 inclusion when CMV 
promoter was exchanged with TK promoter in SMN minigenes (Figure 6B, compare 
lanes 5 and 6 with lanes 9 and 10). Interestingly, SMN2 transcripts derived from 
endogenous gene showed ~13% less exon 7 skipping as compared to SMN2 minigene 
expressed under wild type promoter (compare Figure 6B with Figure 6C). This difference 
could be attributed to the context of the endogenous gene, which is subjected to 
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chromatin remodeling during transcription elongation. Considering rate of transcription 
elongation and transcriptional pausing affects the outcome of alternative splicing 
[5,70,71], a moderate difference in splicing of SMN2 exon 7 between full endogenous 
gene and minigene is expected.  
Treatment of SH-SY5Y cells with PQ caused noticeable increase in skipping of 
SMN exon 7 from all minigenes expressed under different promoters. However, 
distinctions between SMN1 and SMN2 exon 7 splicing under the conditions of OS were 
more pronounced in the context of endogenous promoter followed by the expression 
under wild type promoter. For instance, under the conditions of OS, levels of exon 7-
containing SMN2 transcripts decreased ~2-fold and more than 2.5-fold and in the context 
of wild type and endogenous promoters, respectively (Figure 6B, lanes 1 and 2; Figure 
6C). At the same time, levels of exon 7-containing SMN1 transcripts in these contexts 
decreased only marginally. SMN1 expressed under the control of TK promoter produced 
appreciable exon 7 skipping. Also, SMN1 expressed under the control of TK promoter 
caused the highest levels exon 7 skipping under the conditions of OS (Figure 6B, lanes 7 
and 8). Overall, our results support the role of promoter sequence in regulation of SMN 
exon 7 splicing under the conditions of OS. However, promoter sequences were not the 
sole regulatory elements to affect OS-induced SMN exon 7 splicing. Considering SMN1 
expressed under all promoters maintained the high levels (>60%) of exon 7-included 
transcripts even under the conditions of OS, cis-elements within SMN exon 7 and/or 
within flanking intronic sequences also contribute towards OS-induced exon 7 skipping 
(Figure 6B, lanes 4, 8 and 12). 
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A short ASO targeting an intronic GC-rich silencer fully prevents OS-induced 
skipping of SMN2 exon 7 
One of the fundamental questions in stress-related studies is to establish whether exon-
specific aberrant splicing under OS is preventable. Considering the well-characterized 
nature of various negative cis-elements, SMN2 exon 7 splicing offers an ideal system to 
test this hypothesis. We have earlier reported that a 15-nucleotide-long intronic splicing 
silencer N1 (ISS-N1) and an overlapping 8-nucleotide-long GC-rich sequence play 
critical role in SMN2 exon 7 skipping (Figure 7A) [48,53,72,73]. An 8-mer ASO (3UP8) 
targeting GC-rich sequence prevents SMN2 exon 7 skipping with high target specificity 
without any off-target effect on splicing of other SMN exons [53]. Therefore, we used 
3UP8 to examine whether it will alleviate the negative effect of PQ-induced OS on 
splicing of SMN2 exon 7. We first treated GM03813 cells with 50 nM of 3UP8 for 24 h 
and then induced OS by exposing the cells to 1 mM PQ. Cells were harvested 24 h post 
PQ treatment and transcripts were isolated for analysis by MESDA. As shown in Figure 
7B, 3UP8 was able to fully prevent SMN2 exon 7 skipping even under PQ-induced OS. 
As expected, the effect of 3UP8 was exon 7 specific since this ASO did not change the 
splicing pattern of other SMN2 exons. We also used a control ASO with a single 
mismatch mutation. The control ASO had no effect on splicing of SMN2 (Figure 7B). To 
validate that the effect of 3UP8 is not due to a general stimulation of splicing machinery, 
we examined the splicing pattern of Procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 
(PLOD2) exon 14 that we determined to be also affected by PQ-induced OS. 3UP8 had 
no stimulatory effect on splicing of PLOD2 exon 14 (Figure S5).  
 
 43 
Since OS affects SMN2 exon 7 splicing the most, leading to a decrease in the 
production of the full-length transcripts, we next examined whether treatment with PQ 
has an effect on levels of SMN protein in SMA patient cells. For this, we performed 
western blot analysis using lysates from cells treated similarly as described in Figure 7B. 
Consistent with the decrease in full-length transcript, OS produced a reduction in levels 
of SMN (Figure 7C). However, we did not detect SMNΔ7, a truncated protein likely to 
be produced by translation of SMN2 exon 7-skipped transcript, the most predominant 
splice variant generated under OS. This could be due to high instability of SMNΔ7 shown 
to contain a protein degradation signal [21]. Similar signal would affect stability of 
SMNΔ5,7 that could be generated by translation of the second most predominant 
transcript lacking exons 5 and 7. Gemin2 is a critical SMN-interacting partner 
responsible for the formation of SMN complex that participates in snRNP biogenesis 
[24–26]. PQ induced decrease in SMN levels was accompanied by a similar reduction in 
Gemin2, suggesting a potential adverse effect of PQ on snRNP biogenesis. Remarkably, 
ASO treatment that restored SMN2 exon 7 inclusion also produced increased levels of 
SMN and Gemin2 (Figure 7C). Considering several ASO-based strategies to correct 
SMN2 splicing in SMA have been proposed [42–47], our findings are significant as they 
suggest that these strategies will retain their efficacy even under OS conditions. 
 
 
Discussion 
Occurrence of aberrant splicing under the conditions of OS is an area of growing 
interest due to its correlation with major human diseases including cancer, cardiovascular 
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and neurodegenerative disorders. The fundamental issue of specificity with which OS 
affects splicing of certain exons of particular genes in specific tissues remains poorly 
understood. Here, we use human spinal muscular atrophy genes (SMN1 and SMN2) as a 
representative system to understand the impact of OS on alternative splicing of various 
exons of two nearly identical genes. The full-length transcripts from both genes code for 
SMN, an essential protein that plays a central role in gene regulation through snRNP 
biogenesis [24]. Skipping of any of the seven internal exons of SMN results in the loss of 
a fully functional protein that contains several overlapping domains with defined roles. 
Our study addresses an important question of prioritization of splicing events by which 
each copy of a duplicate gene responds differently to the conditions of OS.  
Publically available SMA patient fibroblast cell line (GM03813) that lacks SMN1 
has been widely used for drug screening as well as for understanding transcriptional and 
posttranscriptional regulation of SMN2. However, analogous cell line to examine SMN1-
specific transcriptional and posttranscriptional regulation has not been found. 
Consequently, a side-by-side comparison of the major splice variants of SMN1 and SMN2 
has not been reported. We serendipitously discovered a BD patient cell line (GM20384) 
that lacked major transcripts specific to SMN2. Such occurrence could be due to complete 
or partial deletion of SMN2 genes. The splicing pattern of SMN1 exon 7 in GM20384 
cells appeared to be identical to those observed in other cell types including BD, 
Parkinson’s disease, Alzheimer’s disease and neuronal SH-SY5Y cell lines, all of which 
carried SMN2. Here, we took advantage of GM20384 cell line as a model system to 
examine SMN1-specific splicing regulation.  
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In order to reliably capture the relative abundance of major transcripts of SMN, 
we resorted to develop MESDA. The defining feature of MESDA was the simultaneous 
evaluation of splicing of five internal exons (exons 3, 4, 5, 6 and 7), among which exons 
3, 5 and 7 are known to be alternatively spliced. On the expected lines, GM03813 cells 
produced two abundantly expressed splice variants corresponding to the full-length and 
SMN2 exon 7-skipped (SMN2Δ7) transcripts (Figure 3B, lane 1). In addition, GM03813 
cells generated SMN2Δ5,7 and SMN2Δ5 as the third and fourth most abundant 
transcripts, respectively. Low levels of SMN2Δ5 as compared to SMN2Δ5,7 was 
somewhat surprising as it suggested a cooperative mode of action in which spliced 
intermediates lacking SMN2 exon 7 served as a preferred substrate for exon 5 skipping. 
GM03813 cells produced very low levels of SMN2Δ3, SMN2Δ3,7, SMN2Δ3,5 and 
SMN2Δ3,5,7 transcripts, demonstrating the feasibility of all combinations of co-skipping 
events of three alternate exons of SMN2. Among low abundant novel isoforms, we 
identified Δ5,6 transcript in GM20383 lymphocytes (Figure 3B, lane 3). The infrequent 
occurrence of this splice variant could be ascribed to a rare paring of the 5ʹ′ ss of exon 4 
with the 3ʹ′ ss of exon 7, which itself is an alternatively spliced exon. Considering C6U 
mutation in SMN2 creates a weak 3ʹ′ ss of exon 7, we observed substantially less 
SMN2Δ5,6 transcripts compared to SMN1Δ5,6 transcripts in GM20383 lymphocytes.  
Beyond a handful studies reported more than a decade ago on exon 7- and exon 5-
skipped transcripts [18,19,58], our understanding of transcript diversity generated by 
endogenous SMN1 remains very limited. Therefore, several of our findings reported here 
on SMN1 splicing constitute a significant advancement towards a better understanding of 
an overall posttranscriptional regulation of SMN1, which serves as the primary source for 
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maintaining healthy SMN levels in general population. Our results established that the 
skipping of SMN1 exons 3 and 5 is a general phenomenon that occurs in neuronal and 
non-neuronal cells alike. Based on the conserved nature of a sequence spanning from 
exon 2a through exon 6 of SMN genes, one could speculate that the mechanism of 
splicing of exons 3 and 5 is the same for SMN1 and SMN2. However, lack of SMN1Δ5,7 
transcripts owing to the absence of SMN1 exon 7 skipping was not accompanied by a 
proportionate gain in SMN1Δ5 transcripts, suggesting that inclusion of SMN1 exon 7 has 
a favorable effect on inclusion of exon 5. This could be due to the supporting role of a 
new sequence and/or structural context created by the inclusion of exon 7. Interestingly, 
we observed about 13-fold more SMN1 exon 3 skipping as compared to SMN2 exon 3 
skipping in neuronal SHSY5Y cells. Also, as compared to SMN2Δ3 transcripts, less 
proportion of SMN1Δ3 transcripts underwent through co-skipping with exon 5 (Figure 
S1). These results suggest an inverse correlation between skipping events of exon 3 and 
exon 5 of SMN1. Our subsequent finding that PQ-induced enhanced skipping of SMN1 
exon 5 suppresses generation of Δ3 transcripts supports such mechanism (Figure 4B). It 
remains to be seen if such correlation is due to the predominant inclusion of exon 7 in 
SMN1.  
Effect of PQ-induced OS on splicing in different cell types (GM03813, 
GM20384, GM20383 and SH-SY5Y) revealed remarkable similarities as well as 
differences between two SMN genes. Supporting an earlier report [60], PQ-induced OS 
produced a significant skipping of SMN2 exon 7, whereas SMN1 exon 7 splicing 
remained mostly unaffected (Figure 4C). However, the sensitivity of our assay combined 
with the cell types used demonstrated that high susceptibility of SMN2 exon 7 to skipping 
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under the conditions of OS is more general than previously thought. Consistently, all 
SMN2-containing cells in our study showed substantial SMN2 exon 7 skipping under 
conditions of OS. We show that OS-induced skipping of SMN2 exon 5 happens primarily 
(if not exclusively) as co-skipping of SMN2 exons 5 and 7 (Figure 4B, lane 2). By 
contrast, skipping of SMN1 exons 5 under conditions of OS takes place almost always 
without skipping of SMN1 exon 7 (Figure 4B, lane 4). Our results also demonstrate that 
OS-induced skipping of SMN exon 5 occurs in both, neuronal and non-neuronal cells. 
Exon 5 of SMN codes for a recently described proline-rich calpain cleavage domain [27]. 
Owing to the low levels of SMN1Δ5 transcripts, we could not detect SMNΔ5 protein 
under the conditions of OS (Figure 4D). However, our finding that SMNΔ5 is stably 
translated is significant (Figure 5C). Future studies will address if the calpain cleavage 
domain lacking protein (SMNΔ5) generated by SMN1Δ5 has any physiological 
significance.  
Skipping of any of the internal exons of SMN maintains the reading frame. 
Therefore, NMD pathway that degrades mRNAs carrying a premature termination codon 
is not applicable for the reduced levels of any of the short SMN transcripts. We detected 
three novel SMN1 isoforms (SMN1Δ4,7; SMN1Δ3,4 and SMN1Δ5,6,7) generated under 
the conditions of OS. It is not known if low abundance of these splice variants are in part 
due to their poor stability caused by a non-NMD mechanism. Presence of SMN1Δ4,7 
underscores the occurrence of a rare splicing event of exon 4 skipping in which the 5ʹ′ ss 
of exon 3 and the 3ʹ′ ss of exon 5 are required to pair. Considering exons 3 and 5 are also 
alternatively spliced, skipping of exon 4 represents a unique event that guarantees 
promotion of inclusion of both, exons 3 and 5. Therefore, our finding of SMN1Δ4,7 
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reveals the first mutually exclusive event with a significance to the prevention of 
skipping of two alternatively spliced exons of SMN1. Also, generation of SMN1Δ4,7 
comes at the expense of competing events that lead to production of two novel isoforms: 
SMN1Δ3,4 and SMN1Δ5,6,7. Presence of SMN1Δ5,6,7 underscores a unique splicing 
event requiring a rare long-distance pairing between the 5ʹ′ ss of exon 4 and the 3ʹ′ ss of 
exon 8. Another significant observation of our study was the stimulatory effect of OS on 
splicing of exon 3 (Figures S2 and S3). It remains to be seen if decrease in exon 3 
skipping under the conditions of OS contributes at least in part towards generation of 
some of the novel splice variants describe above.  
Increasing evidence support transcription-coupled splicing regulation. Effect of 
transcription on alternative splicing could be exerted through transcription initiation at 
specific promoters as well as through transcriptional pausing [5]. Well-known factors that 
affect alternative splicing in a promoter-specific manner include steroid hormone nuclear 
receptor coactivators, human papilloma virus (HPV) transcriptional activator E2 and 
peroxisome proliferator-activated receptor coactivator-1a (PGC-1a) [64]. Our finding that 
large wild type promoter sequence in our reporter system suppresses skipping of SMN 
exon 7 provided the first direct evidence of the role of promoter in regulation of SMN 
exon 7 splicing. Effect of promoter sequence on regulation of SMN exon 7 splicing was 
also observed under the conditions of OS. In particular, OS-induced differential splicing 
regulation between SMN1 and SMN2 was much more apparent in the context of the wild 
type promoter as compared to CMV and TK promoters. Decreased ATP level in OS is 
likely to slow down or even pause transcription elongation with a significant consequence 
to ss selection and exon usage [70,71]. Generation of a long endogenous transcript 
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requires an extensive transcription elongation step. Therefore, it is likely that the effect of 
OS is exerted mostly at the level of transcription elongation. Our finding that endogenous 
SMN2 produced the highest degree of exon 7 skipping under the conditions of OS also 
supports the role of transcription elongation in OS-induced splicing regulation of SMN2 
exon 7. Recently, transcriptional elongation regulator 1 (TCERG1) has been found to 
regulate alternative splicing of the short isoform of B-cell lymphoma-extra (BCL-xs) 
[74]. It remains to be seen if analogous mechanism accounts for the regulation of SMN2 
exon 7 splicing under the conditions of OS. However, our results do not preclude the role 
of additional factors that act through transcription initiation albeit variably at different 
promoters expressing SMN minigene under the conditions of OS.  
Translation of specific transcripts is selectively affected under the conditions of 
stress [75]. Our finding that ASO-mediated prevention of SMN2 exon 7 skipping under 
the conditions of OS is able to restore the levels of SMN and Gemin2 suggests that OS 
does not affect selective repression of SMN translation. Given the prominent role of SMN 
in cellular metabolism, it is imperative that cells maintain a minimum SMN level even 
under the conditions of OS. Selective kipping of exon 7 from one gene (SMN2) but not 
from the other (SMN1) supports this argument. Although Δ7 and Δ5,7 were the most 
abundant SMN2 transcripts generated under OS, we could not detect their corresponding 
translated products. This could be due to a protein degradation signal coded by the exon 
7-skipped transcripts [21]. Our ASO based approach ruled out an analogous degradation 
mechanisms for the translated product generated from Δ3 and Δ5 splice variants. Cells 
prioritize mRNA translation and storage under stress-associated conditions [75]. Hence, it 
is possible that shorter splice variants of SMN served as decoy molecules to capture 
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microRNAs (miRNAs) and relieve full-length transcripts of miRNA repression. This 
mechanism will allow a better synthesis of SMN even from the low levels of full-length 
transcripts. A recent report provides a strong proof of principle for such mechanism in an 
analogous system [76]. miRNA-associated translational repression is generally associated 
with the 3ʹ′ untranslated regions (UTRs) [77]. However, it (repression) could also occur 
through targets within isoform-specific coding sequences [77,78]. Given the fact that PQ 
treatment generates an altered 3ʹ′ UTRs due to overwhelming skipping of the last coding 
exon (exon 7) and also produces additional splice variants, there is a plausible possibility 
of miRNA-associated control of SMN levels in stress-associated conditions. Now that we 
have confirmed the vulnerability of various SMN exons to skipping under the conditions 
of OS, future experiments would address the mechanism of OS-induced aberrant splicing 
regulation of SMN and the physiological role of various SMN transcripts generated under 
stress-associated conditions.  
In summary, our findings uncover the surprising diversity of SMN transcripts 
expressed under normal and OS conditions. We validate our findings employing several 
complementary approaches including MESDA and a unique cell type devoid of major 
SMN2 transcripts. Our findings underscore an added vulnerability of SMA patients to the 
conditions of OS and demonstrate the efficacy of an ASO-based strategy in splicing 
correction under OS. Our results provide the first direct evidence of role of SMN 
promoter sequence in regulation of SMN exon 7 splicing under normal and OS 
conditions. In addition to a better understanding of SMA pathogenesis, our findings bring 
new perspective to splicing regulation of a model housekeeping gene associated with one 
of the leading genetic causes of infant mortality. 
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Materials and Methods 
Plasmid constructs 
Minigene splicing cassettes pSMN1ΔI6 and pSMN2ΔI6 have been described previously 
[68]. Designs of newly constructed minigenes and primer sequences for cloning are given 
in supporting data (Table S1, Figure S4). Briefly, pTK-SMN1ΔI6 and pTK-SMN2ΔI6 
constructs, in which SMN minigene sequences were placed under the control of Herpes 
Simplex Virus (HSV) thymidine kinase (TK) promoter, were generated as follows. SMN1 
and SMN2 sequences were amplified by polymerase chain reaction (PCR) using 
pSMN1ΔI6 and pSMN2ΔI6 as templates, respectively. The amplification was performed 
with Phusion DNA Polymerase (New England Biolabs) and a pair of primers, P42 and 
P43. PCR products were then digested with HindIII and BamHI and inserted into pTK-
GLuc vector (New England Biolabs) treated with the same restriction enzymes. To 
generate splicing cassettes pWTP-SMN1 and pWTP-SMN2 in which SMN1 and SMN2 
minigene sequences were placed under the control of human SMN1 and SMN2 promoters, 
respectively, we started with PCR amplification of the SMN1 and SMN2 promoter 
sequences (~3.5 kb) using T1 and C1 clones, respectively [66]. The promoter sequences 
were amplified using Phusion DNA Polymerase and primers 5ʹ′SMN-pro-BglII and 
3ʹ′SMN-pro-XhoI. The amplified SMN1 and SMN2 promoter sequences were 
subsequently digested with BglII and XhoI and ligated into pSMN1ΔI6 and pSMN2ΔI6 
minigenes subjected to partial digestion with the same restriction enzymes. Partial 
digestion was used since pSMN1ΔI6 and pSMN2ΔI6 minigenes contain two BglII 
restriction site. For partial digestion several µg of pSMN1ΔI6/pSMN2ΔI6 were treated 
with XhoI (6.4 U) at 37 °C overnight; next morning BglII (4 U) was added to the reaction 
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mixture and digestion continued for another 15 min followed by phenol:chloroform 
extraction and ethanol precipitation. The precipitated products were separated on a 1% 
agarose gel, the band of interest corresponding to 4.2 kb was excised from the gel and the 
DNA product was recovered from the gel using QIAquick Gel Extraction Kit (Qiagen) as 
per manufacturer’s instructions. The recovered DNA corresponded to either BglII- and 
XhoI-digested pSMN1ΔI6 or pSMN2ΔI6, which, as mentioned above, were used in 
ligation reaction with SMN1 and SMN2 promoters and Quick Ligation Kit (New England 
Biolabs). The identity of novel minigene clones was verified by sequencing. All primers 
were obtained from Integrated DNA Technologies (Table S1). All restriction enzymes 
used were from New England Biolabs. 
 
Cell culture and ASOs 
All tissue culture media and supplies were purchased from Life Technologies. Human 
neuroblastoma SH-SY5Y cells were cultured in 1:1 mixture of Minimum Essential 
Medium (MEM, catalog # 11095) and F12 medium supplemented with 10% fetal bovine 
serum (FBS). Primary patient fibroblasts, immortalized B-lymphocytes as well as cells 
from healthy individuals were obtained from Coriell Cell Repositories (CCR). 
Description of cells from CCR used in this study is given in Table 1. These cells were 
grown according to the provided instructions. In brief, all primary fibroblasts were grown 
in minimal essential medium (MEM, catalog # 10370) supplemented with 2 mM 
GlutaMAX-I and 15% FBS. Only in case of primary fibroblasts from Alzheimer patient 
(Repository number AG04159), the amount of FBS in growth medium was 10%. B-
lymphocytes were grown in RPMI1640 (catalog # 11875) medium supplemented with 
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15% FBS. The following ASOs used in this study: 3UP8, 5ʹ′-
mG*mC*mU*mG*mG*mC*mA*mG-3ʹ′; 3UP8/64A (CONT), 5ʹ′-
mG*mC*mU*mG*mU*mC*mA*mG-3ʹ′; E3/I3Jxn, 5ʹ′ 
mU*mA*mU*mC*mC*mU*mU*mA*mC*mC*mU*mC*mU*mU*mG*mA*mG*mC*
mA*mU-3ʹ′; E5/I5Jxn, 5ʹ′-
U*mU*mU*mA*mC*mU*mU*mA*mC*mU*mG*mG*mU*mG*mG*mU*mC*mC*m
A*mG-3ʹ′. All ASOs were obtained from Dharmacon Inc. They incorporated 2ʹ′-O-methyl 
modification (indicated by ‘‘m’’) and phosphorothioate backbone (indicated by *) as 
described earlier [48]. 
 
PQ treatment 
PQ (Paraquat, methyl viologen dichloride hydrate, catalog #856177) was obtained from 
Sigma. PQ treatment of pre-plated adherent cells was done as follows. Sixteen to 
eighteen hours before the treatment GM03813 cells were plated at a density of ~1.1x105 
cells per well of 6-well plates or ~6.2x105 per 100 mm tissue culture dish. For SH-SY5Y, 
~1.9x106 and 0.5x106 SHSY5Y cells were seeded in 100 mm dishes. In case of SH-
SY5Y, cells plated at a higher density were subjected to PQ treatment, while cells seeded 
at a lower density served as an untreated control. Lower cell density insured that 
untreated control SH-SY5Y cells do not become confluent at the end of PQ treatment. PQ 
was added with fresh growth medium at a final concentration of 1 mM; fresh medium 
without PQ was also added to control untreated cells. 200 mM stock solution of PQ in 
phosphate buffered saline (PBS) was prepared immediately before usage. In case of B-
lymphocytes that grow in suspension as aggregates, right before PQ addition cell clumps 
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were disaggregated by pipetting and cells were seeded at a density of ~1.4x105 cells per 
ml in a desired volume. PQ was added to a final concentration of 1 mM. In case of 
untreated control lymphocytes, PQ was omitted from growth medium. Unless noted 
otherwise, PQ treatment continued for 24 h, after which cells were collected for whole 
cell lysates/total RNA preparation. 
PQ treatment combined with transfection of minigenes was done as follows. SH-
SY5Y cells were plated at a density of ~2.8x105 cells per one well of a 6-well plate. Next 
day the cells were transfected with 1 µg of different minigenes using Lipofectamine 2000 
(Life Technologies) following the manufacturer’s recommendations. Six hours after 
transfection cells were washed once and conditioned medium harvested from growing 
SH-SY5Y cells was added to the wells. Twelve hours post transfection, cells in each well 
were trypsinized and collected in a total volume of 4 ml; 2.5 ml of this cell suspension 
were transferred to a new well of 6-well plate and freshly prepared PQ was immediately 
added to a final concentration of 1 mM (PQ treated cell), while 1.5 ml of this suspension 
were plated in another well of 6-well plate and used as an untreated control. Following 21 
hours of PQ treatment, cells were collected for total RNA preparation.  
PQ treatment combined with transfection of ASOs was done as follows. 
GM03813 primary fibroblasts were plated at a density of ~8x105 cells per 100 mm tissue 
culture dish. Total number of six dishes was seeded. Twenty-four hours later cells were 
transfected with 50 nM of a given ASO (two plates were transfected with each ASO) 
using Lipofectamine 2000 following the manufacturer’s recommendations. Following 
another 24 hours the medium was changed, and freshly prepared PQ was added to one of 
each pair of transfected plates; the other plate served as a PQ untreated control. PQ 
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treatment continued for 24 hours, after what cell were washed several times with ice-cold 
PBS and collected by scrapping. For total RNA preparation ~1/4 of cells from each dish 
was used, while 3/4 were used for making cell lysates. 
 
ASO transfections 
Delivery of ASOs into HeLa cells was done by reverse transfection using Lipofectamine 
2000. Complexes of Lipofectamine 2000 and ASOs were prepared following the 
manufacturer’s recommendations. The complexes were allowed to form for 20 minutes at 
room temperature, after what each complex (1 ml, in Opti-MEM I Reduced Serum 
Medium) was mixed with 4 ml of HeLa cell suspension in a 60 mm dish. Total number of 
HeLa cells used for transfection varied from ~2.0x106 to ~2.5x106 cells. The final ASO 
concentration was 100 nM. Next day culture medium was changed for the fresh one. 
About 38 hour post transfection the cells were washed several times with ice-cold PBS 
and collected by scraping. About 4/5th of cells were used for making cell lysates, while 
1/5th of cells were used for preparing total RNA. 
 
RT-PCR 
For reverse transcription and PCR (RT-PCR), total RNA was isolated using Trizol 
reagent (Life Technologies) following the manufacturer’s recommendations. To generate 
cDNA, reverse transcription was carried out using a SuperScript III reaction kit (Life 
Technologies). For cDNA synthesis random primers (Promega), an oligo(dT)12–18 primer 
(Life Technologies) or gene-specific primer 3ʹ′E8-Dde were employed. Generally, 0.5 to 
1 µg of total RNA was used per 5 µl of Reverse transcriptase (RTase) reaction. Minigene-
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specific spliced products were amplified using Taq DNA polymerase and the following 
primer combinations: P1 and P2 for SMNΔI6 minigenes [68], P43 and P45 for pTK 
vector-based minigenes, and P31 and 3ʹ′Jun E8/bb for minigenes with SMN promoters. 
For PCR amplification of endogenous SMN the following pairs of primers were used: 
either N-24 and P26 or P25 and P31 for exon 7 splicing [55]; 5ʹ′hSMN-E2b and P2–2 for 
MESDA. Of note, there were no differences in endogenous SMN splicing pattern whether 
cDNA produced with oligo(dT)12–18 or with a gene specific primer was used for MESDA. 
PCR reactions were performed either in the presence of a trace amount of [a-32P] dATP 
(3,000 Ci/mmole; Perkin-Elmer Life Sciences) or with the 5ʹ′-end-P32-labeled primer, 
5ʹ′hSMN-E2b. End-labeling of 5ʹ′hSMN-E2b was done using c-ATP (3,000 Ci/mmole, 
Perkin-Elmer Life Sciences) and T4 Polynucleotide Kinase (New England Biolabs). To 
distinguish splice isoforms originated from SMN2, PCR products amplified with N-24 
and P26 or P25 and P31 were subjected to overnight DdeI digestion, followed by 
phenol:chloroform extraction and ethanol precipitation [55]. In all cases PCR products 
were resolved on a 6% native polyacrylamide gel. Analysis and quantifications of splice 
products were performed using a FPL-5000 Image Reader and Multi Gauge software 
(Fuji Photo Film Inc). Results were confirmed by at least three independent experiments. 
All primer sequences used in RTPCR are given in supporting data (Table S1). 
 
Western blot analysis  
Whole-cell extracts from HeLa, GM20384 and GM03813 were prepared using ice-cold 
RIPA buffer (Boston BioProducts) supplemented with either Complete EDTA-free 
protease inhibitor cocktail (Roche Applied Science) or Halt Protease Inhibitor Single-Use 
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cocktail (Thermo Scientific). Protein concentrations were determined using BCA protein 
assay kit (Thermo Scientific). Protein samples were resolved on an SDS-polyacrylamide 
gel (11 or 12%) and transferred on polyvinylidene fluoride membrane (Bio Trace PVDF, 
Pall Life Sciences). The following primary and secondary antibodies were used: mouse 
monoclonal anti-SMN (BD Transduction Laboratories), mouse monoclonal anti-Gemin2 
(Sigma-Aldrich), rabbit polyclonal anti-actin (Sigma-Aldrich), horseradish-peroxidase-
conjugated secondary antibodies against mouse (Jackson Immuno Research) and rabbit 
(GE Healthcare). After probing for SMN, membranes were stripped (15 min at room 
temperature) using Restore Western Blot Stripping Buffer (Thermo Scientific) and re-
probed for β-actin. Immunoreactive proteins were visualized with SuperSignal West Dura 
Extended Duration Substrate or SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific). The membranes were scanned using UVP BioSpectrum AC Imaging 
System (UVP). Results were confirmed by at least three independent experiments. 
 
Statistical analysis  
All calculations were performed in Excel (Microsoft Office 2011 edition). Data were 
expressed as mean ± standard error of the mean (SEM). Statistical analyses were 
performed using the unpaired Student’s t-test. Unless otherwise mentioned P values were 
two-tailed and the level of statistical significance was set at P <0.05. 
 
Identification of SMN splice isoforms 
Endogenous SMN spliced products were amplified using Taq DNA polymerase and either 
primers 5ʹ′hSMN-E2b and P2-2 or 5ʹ′hSMN-E2b and 3ʹ′E8-Dde. cDNA produced with 
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oligo(dT)12-18 primer was used as a template. PCR amplification was performed for 30 to 
35 cycles. PCR products were resolved on a 6% native polyacrylamide gel and visualized 
by ethidium bromide staining. Bands corresponding to different splice isoforms were 
excised from a gel, and the “crush and soak” method48 followed by ethanol precipitation 
was used to recover PCR products. The recovered products were subsequently cloned in a 
pGEM-T easy vector following the manufacturer’s recommendations (Promega). 
Recombinant clones were identified by white/blue colony screening on indicator plates. 
Eight or more clones were randomly selected for each splice variant. Clones were 
purified using QIAprep Spin Miniprep Kit (Qiagen) and sequenced. SMN1 and SMN2 
splice isoforms were distinguished based on the absence and presence of DdeI restriction 
site in exon 8, respectively, and/or by the nucleotide identity at position +6 in exon 7. 
 
Quantitative real-time PCR (qPCR)  
Total RNA from PQ treated and untreated SH-SY5Y cells was isolated using Trizol 
reagent (Life Technologies) following the manufacturer’s recommendations. To generate 
cDNA, reverse transcription was carried out using a SuperScript III reaction kit (Life 
Technologies) with oligo(dT)12-18 (Life Technologies) as a primer. 1 µg of total RNA was 
used per 10 µl of Reverse transcriptase (RT) reaction. All qPCR reactions were 
performed in triplicates on a Stratagene MxPro 3005P qPCR System. In amplification 
step 3 µl of 1:20 diluted RT reaction were used as a template in 20 µl of qPCR reaction. 
Reaction also contained 300 nM of each primer and 1X FastStart Universal SYBR Green 
Master (ROX) mix (Roche Applied Science). For negative control, nuclease-free water 
was used instead of cDNA. The primer sets for each assay were designed to anneal to 
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specific exon and exon-exon junctions to distinguish different splice isoforms and avoid 
amplification of genomic DNA.  The amplicon sizes were between 85 and 172 bp. The 
following primers were used for amplification of SMN splice isoforms: primers 5ʹ′E1 and 
3ʹ′E1+2a for all SMN isoforms (total SMN); primers 5ʹ′E6 and 6ʹ′E6+7 for exon 7 included 
transcripts (7+); primers 5ʹ′E6 and 6ʹ′E6+8 for exon 7 skipped transcripts (Δ7); primers 
5ʹ′E5+6 and 3ʹ′E6 for exon 5 included transcripts (5+); primers 5ʹ′E4+6 and 3ʹ′E6 for exon 
5 skipped transcripts (Δ5); primers 5ʹ′E3+4 and 3ʹ′E4 for exon 3 included transcripts (3+); 
primers 5ʹ′E2b+4 and 3ʹ′E4 for exon 3 skipped transcripts (Δ3). For normalization, we first 
used Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) transcripts that we 
amplified using primers 5'GAPDH and 3'GAPDH (reference gene). Subsequently all 
splice variants (from PQ treated and untreated samples) were normalized by total SMN 
from untreated cells. All primer sequences used in qPCR are given in Supplemental Table 
S1.  
 
Statistical analysis  
Relative quantities with standard deviations were calculated by using delta-delta CT 
method by Excel (Microsoft Office 2011 edition). Data were expressed as ± standard 
deviation. Statistical analyses were performed using the unpaired Student’s t-test. Unless 
otherwise mentioned, P values were two-tailed and the level of statistical significance 
was set at P <0.05.  
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Figure Legends 
Figure 1. Diagrammatic representation of SMN mRNA and SMN protein. Number of 
amino acids encoded by each exon is indicated. Exons as well as domains they encode 
are shown as boxes. Domain functions are indicated. 
 
Figure 2. Splicing of endogenous SMN exon 7. A, Diagrammatic representation of 
exon/intron organization of SMN1 and SMN2 genes. Exonic sequences are shown as 
colored boxes and intronic sequences are shown as lines/broken lines. Sizes of exons and 
introns are given. Size of the 3ʹ′ UTR is based on the prevalently reported SMN1 
transcript (NCBI accession number NM_000344). B, Splicing patterns of endogenous 
SMN1 and SMN2 exon 7 in different cell lines. Name of cell lines used are given on the 
top of the gel. Spliced products were analyzed by RT-PCR. We used 1 µg of total RNA 
per 5 µl of reverse transcription reaction and generated cDNA employing random 
primers. SMN transcripts were amplified using primers P25 and P31. To distinguish 
transcripts originated from SMN2, PCR products were digested with DdeI [55]. SMN1 
and SMN2 transcripts are indicted on the right of the gel. Exon 7-included (+) and exon 
7-skipped (-) products are indicated on the left of the gel. Based on RT-PCR results, the 
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presence and absence of SMN1/SMN2 gene is marked by (+) and (-) respectively. The 
percentage of SMN2 exon 7 skipping was calculated based on the total value of SMN2 
exon 7-included and exon 7-skipped products [55]. The last 81 nucleotides of exon 1 are 
translated. Several mutations that distinguish SMN1 and SMN2, including DdeI restriction 
site, as well as location of primers used for amplification of endogenous SMN transcripts 
are indicated. 
 
Figure 3. Detection of multiple exon skipping events in endogenous SMN. A, 
Diagrammatic representation of the SMN gene. Exonic and intronic sequences are 
depicted as in (Figure 2A). Dotted lines indicate skipping of previously reported exons 
and/or novel splice variants. Annealing positions of primers used for MESDA are shown. 
B, Multiple splice isoforms of endogenous SMN pre-mRNA in different cell lines. Name 
of cell lines used are given on the top of the gel. Splice products were analyzed by RT-
PCR. We used 1.4 µg of total RNA per 10 µl of reverse transcription reaction and 
generated cDNA employing oligo(dT)12-18 primer. SMN transcripts were amplified using 
primers 5ʹ′hSMN-E2b (anneals within Exon 2b) and P2–2 (anneals within Exon 8). 
Diagrammatic representation of splice variants is given on the left of the gel; their sizes 
are indicated on the right of the gel with names of skipped exons given in brackets. For 
intra-lane comparison of bands, pictograms (shown on right) were generated for each 
lane by MultiGauge software version 3.0 (FUJIFILM). The identity of splice variants was 
established by sequencing. Novel splice variant is marked by a star. Note that 567-
nucleotide-long Δ5,6 variant moves slower than 573-nucleotide-long Δ3 variant. FL, full-
length; NS, non-specific. The number of SMN1 and SMN2 transcripts for each of splice 
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variants, except for the full-length and Δ7, was determined by sequencing of at least 8 
randomly selected clones per variant (Figure S1). 
 
Figure 4. Effect of PQ treatment on splicing of SMN. A, Diagrammatic representation of 
the SMN gene. Exonic and intronic sequences are depicted as in (Figure 2A). Dotted lines 
indicate exon skipping that generated novel splice variants. Annealing positions of 
primers used for MESDA are shown. B, Detection of multiple exon skipping events in 
endogenous SMN in the presence (+) and absence (-) of PQ. Names of cell lines used are 
given on the top of the gel. Total RNA was prepared from cells treated with 1 mM of PQ 
for 24 hours. Splice products were analyzed by RT-PCR as described in Figure 3B. 
Diagrammatic representation of splice variants is given on the left of the gel; their sizes 
are indicated on the right of the gel with names of skipped exons given in brackets. The 
identity of splice variants was confirmed by sequencing. Note that 513-nucleotide-long 
Δ5,6,7 variant moves slower than 519-nucleotide-long Δ3,7 variant. Novel splice variants 
are marked by stars. FL, full-length; NS, non-specific. For intra-lane comparison of 
bands, pictograms were generated for each lane (Figure S2). C, Splicing patterns of 
endogenous SMN exon 7 in the presence (+) or absence (-) of PQ. Names of cell lines 
used are given on the top of the gel. Total RNA was prepared from cells treated with 1 
mM of PQ for 24 hours. Spliced products were analyzed by RT-PCR as described in 
panel B except primers P25 and P31 were used for PCR amplification step. To 
distinguish transcripts originated from SMN2, PCR products were digested with DdeI 
[55]. SMN1 and SMN2 transcripts are indicted on the right of the gel. Exon 7-included (+) 
and exon 7-skipped (-) products are indicated on the left of the gel. The percentage of 
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SMN2 exon 7 skipping was calculated as in Figure 2B. D, Western blot showing 
translated products generated from SMN in GM20384 and GM03813 cells treated with 
PQ for 24 h. We loaded 50 and 80 µg of protein from GM20384 and GM03813 cell 
lysates, respectively. Primary antibodies used for probing are indicated on the left of the 
gel. Although the predicted molecular mass of SMN is 32 kDa, it migrates as 40 kDa 
band due to posttranslational modifications. 
 
Figure 5. Translational efficiency of transcripts generated by ASO-induced skipping of 
SMN exons in HeLa cells. A, Diagrammatic representation of SMN pre-mRNA showing 
annealing positions of ASOs. Exonic and intronic sequences are depicted as in (Figure 
2A). B, Splicing pattern of endogenous SMN in HeLa cells treated with various ASOs. 
Names of ASO used are given on the top of the gel. HeLa cells were transfected with 100 
nM of an individual ASO. Cells were collected for total RNA preparation ,38 hours post 
transfection. Spliced products were analyzed by RT-PCR as described in Figure 3B. All 
spliced products represent mixture of transcripts generated from both, SMN1 and SMN2. 
C, Western blot showing SMN protein isoforms generated from transcripts in panel B. 
Cells were collected for whole-cell lysate preparation ,38 hours post transfection. In order 
to capture the low abundance of SMNΔ3 isoform, we loaded 50 µg of protein from 
sample treated with E3/I3 Jxn ASO. Protein loading was confirmed by re-probing the blot 
with anti-b-actin antibodies. Primary antibodies used for probing are indicated on the left 
of the gel; whereas, SMN isoforms are shown on the right of the gel. SMN is present in 
all lanes. SMNΔ3 is detectable in lane 2, whereas SMNΔ5 is detectable in lane 3. 
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Figure 6. Effect of PQ on splicing of different SMN minigenes. A, Diagrammatic 
representation of promoter and exon/intron organization in different minigenes as 
compared to endogenous SMN. Promoters and exons are shown as boxes, introns are 
indicated as lines. Alternatively spliced exons 3, 5 and 7 are shown as colored boxes. 
Dotted lines indicate deleted sequences. Wild type refers to the minigenes under the 
control of human SMN1/2 promoters; TK, minigenes under the control of thymidine 
kinase promoter; CMV, minigenes under the control of CMV promoter. In CMV and TK 
minigenes, solid bar before exon 6 refers to a vector-specific sequences (Figure S4). 
Locations of primer pairs for the amplification of spliced products have been marked by 
arrows. B, In vivo splicing pattern of different SMN1 and SMN2 minigenes. Data were 
generated using total RNA from SH-SY5Y cells transfected with 1 µg of an indicated 
minigene and treated with PQ for 21 h. Minigene splice products were analyzed by RT-
PCR. We used 0.5 µg of total RNA for 5 µl of reverse transcription reaction and 
generated cDNA employing oligo(dT)12–18 primer. Loading was adjusted so that the 
intensity of bands between samples was comparable. Exon 7-included and skipped 
products are indicated on the left of the gel. Due to the change in location of the primer 
annealing sites, SMN spliced products generated from different vectors have variable 
lengths. The results were analyzed as previously described [55]. Abbreviations are same 
as described in panel A. C, Effect of PQ on splicing of endogenous SMN exon 7. Splice 
products were analyzed by RT-PCR as described in panel B, except we used N-24 and 
P26 primers for PCR to specifically amplify endogenous SMN. Of note, P26 anneals to 
exon 8 region, which is absent in minigenes [55]. To distinguish spliced variants 
originated from SMN2, PCR products were digested with DdeI [55]. The percentage of 
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SMN2 exon 7 skipping was calculated as described in Figure 2B. Labeling was the same 
as described in panel A and Figure 2B. 
 
Figure 7. Treatment of SMA patient fibroblasts with 3UP8 ASO abrogates the negative 
effect of PQ. A, Diagrammatic representation of the ASO target area in SMN intron 7. 
Negative regulators of exon 7 splicing, GC-rich sequence, ISS-N1 and hnRNPA1 binding 
sites are highlighted with boxes. Annealing positions and sequences of ASOs (3UP8 and 
CONT) are given in 3ʹ′ to 5ʹ′ direction. 3UP8 and CONT (3UP8/64A) ASOs are the same 
as reported [53]. Numbering of nucleotides starts from the first position of intron 7. B, 
Splicing pattern of endogenous SMN2 in SMA patient fibroblasts transfected with 
different ASOs in the presence (+) or absence (-) of PQ. GM03813 fibroblasts grown in 
100 mm dishes were transfected with 50 nM of an ASO. About 24 hours after 
transfection, PQ was added to cells with a fresh growth medium at a final concentration 
of 1 mM. Cells were collected for total RNA/protein preparation 24 h post treatment. 
Spliced products were analyzed by RT-PCR. We used 1.2 µg of total RNA per 10 µl of 
reverse transcription reaction and generated cDNA employing 3ʹ′E8-Dde primer. Splice 
isoforms are indicated on the left of the gel as shown in panel (i). Mock refers to 
untransfected cells. Relative abundance of SMN spliced isoforms was calculated in each 
sample and is shown as a bar diagram given in panel (ii). Error bars based on standard 
error of the mean have been described in panel (iii). *, P < 0.05; **, P < 0.01; NS, not 
statistically significant. C, Western blot showing the levels of SMN and its interacting 
partner, Gemine2, in SMA patient fibroblasts transfected with 3UP8 or control (CONT) 
ASO in the presence (+) and absence (2) of PQ. We used 20 µg of total protein for each 
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sample. Equal protein loading was confirmed by re-probing the blot with anti-b-actin 
antibodies. Primary antibodies used for probing are indicated on the left of the gel. 
 
 
Supplementary Figure Legends 
Figure S1. Distribution of splice forms revealed by cloning and sequencing. A, Relative 
abundance of SMN splice isoforms. All splice variants except Δ5,6 were cloned from 
SH-SY5Y cells. Splice variant Δ5,6 was cloned from GM20383 cells. B, Evaluation of 
SMN splice isoforms generated under OS caused by PQ treatment of SH-SY5Y cells. 
Cells were treated with 1 mM PQ for 24 hours and analyzed by RT-PCR, cloning and 
sequencing. 
 
Figure S2. Pictogram showing relative abundance of transcripts generated in various cell 
types undergoing through OS. Peak values are derived from the band intensities in 
lanes shown in Figure 4B. Pictograms were generated by MultiGauge software version 
3.0 (FUJIFILM). Abbreviation: FL, Full-length transcript. 
 
Figure S3. Comparison of different splice variants in PQ treated and untreated SH-SY5Y 
cells as determined by qPCR. A, Relative expression of splice isoforms from control 
untreated and 1 mM PQ treated cells. qPCR was performed as described in Materials and 
Methods S1. Total SMN from untreated SH-SY5Y was used for normalization. The 
values are mean ± SD. Abbreviations for transcripts: Total, total SMN; 7+, exon 7-
included; Δ7, exon 7 skipped; 5+, exon 5-included; Δ5, exon 5 skipped; 3+, exon 3-
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included; Δ3, exon 3 skipped. *, P < 0.05; **, P < 0.01. B, Log2 transformed fold 
changes in SMN splice isoform levels between control untreated and 1 mM PQ treated 
calculated based on the results shown in Panel (A). The values are mean ± SD. 
Abbreviations for transcripts: Total, total SMN; 7+, exon 7-included; Δ7, exon 7 skipped; 
5+, exon 5-included; Δ5, exon 5 skipped; 3+, exon 3-included; Δ3, exon 3skipped. *, P < 
0.05; **, P < 0.01. 
 
Figure S4. Diagrammatic representation of minigenes placed under the control of 
different promoters. A, SMN1 and SMN2 minigenes (pSMN1ΔI6 and pSMN2ΔI6) under 
the control of CMV promoter. Cloning strategy is described earlier [61]. B, SMN1 and 
SMN2 minigenes (pTK-SMN1ΔI6 and pTKSMN2ΔI6) under the control of TK promoter 
were generated by subcloning into pTK-GLuc vector (New England Biolabs). Cloning 
strategy is described in Materials and methods. C, SMN1 and SMN2 minigenes (pWTP-
SMN1ΔI6 and pWTP-SMN2ΔI6) under the control of wild type SMN promoters were 
generated by replacing CMV promoter with human SMN1 and SMN2 promoters, 
respectively. Cloning strategy is described in Materials and Methods. 
 
Figure S5. Results showing specificity of 8-mer ASO targeting GC-rich sequence. A, 
Diagrammatic representation of the ASO target area as described in Figure 7A. B, 
Splicing pattern of endogenous PLOD2 in SMA patient fibroblasts transfected with 
different ASOs in the presence (+) or absence (-) of PQ. Transfection, PQ treatment and 
RNA isolation procedures were the same as described in Figure 7. PLOD2 spliced 
products were analyzed by RT-PCR. RNA was converted to cDNA using an oligo(dT)12–
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18 primer. PLOD2 transcripts were amplified using E13-PLOD2 and E15-PLOD2 primers 
that anneal to exons 13 and 15, respectively. Primer sequences are given in Table S1. 
 
 
Table 1. Cell lines used in this study. 
No. Cell types Source Disease Description Cell type 
1 SH-SY5Y 
(CRL-
2266) 
ATCC 
  
NB Unique marker on 
Chromosome 1 
Neuroblastoma 
2 GM20383 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
3 GM20384 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
4 GM20381 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
5 GM20382 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
6 GM08820 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
7 GM08794 CCR 
 
BD/CL Juvenile CL, CLN3 
mutations 
B-lymphocyte 
8 ND00013 CCR 
 
PD Late onset DNA panel B-lymphocyte 
9 ND00002 CCR 
 
PD Young onset DNA panel B-lymphocyte 
10 ND00092 CCR 
 
Ctrl PD Convenience control B-lymphocyte 
11 AG04159 CCR 
 
AD Familial, type 3 Fibroblast 
12 GM03814 CCR 
 
SMA Carr Mother (SMN1+/-) Fibroblast 
13 GM03815 CCR 
 
SMA Carr Father (SMN1+/-) Fibroblast 
14 GM03813 CCR 
 
SMA  Child (SMN1-/-), SMA 
Type I 
Fibroblast 
Abbreviations, ATCC, American type cell collection; CCR, Coriell cell repositories; 
NB, Neuroblastoma; BD, Batten disease; CL, Ceroid lipofuscinosis; PD, Parkinson’s 
disease; Ctrl, Control; AD, Alzheimer’s disease; SMA, Spinal muscular atrophy; Carr, 
Carrier. 
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Table 2. Description and GenBank accession numbers of spliced variants reported in this 
study. 
Exon Gene Cell line Treatment* GenBank accession number 
Δ5 SMN1 GM20384 PQ-treated JQ657798 
Δ 3 SMN1 GM20384 PQ-treated JQ657800 
Δ 5,7 SMN1 GM20384 PQ-treated JQ657799 
Δ 5,6,7 SMN1 GM20384 PQ-treated JQ657801 
Δ 5,6 SMN1 GM20383 Untreated JQ732166 
Δ 5,6 SMN2 GM20383 Untreated JQ732167 
Δ 5 SMN1 SH-SY5Y PQ-treated JQ657802 
Δ 3 SMN2 SH-SY5Y PQ-treated JQ690861 
Δ 3,4 SMN1 SH-SY5Y PQ-treated JQ745297 
Δ 4,7 SMN2 SH-SY5Y PQ-treated JQ690864 
Δ 3,7 SMN2 SH-SY5Y PQ-treated JQ690862 
Δ 3,5 SMN1 SH-SY5Y PQ-treated JQ657803 
Δ 3,5,7 SMN2 SH-SY5Y PQ-treated JQ690863 
Δ 5,7 SMN2 SH-SY5Y Untreated JQ690865 
Δ 3,7 SMN1 SH-SY5Y Untreated JQ690867 
Δ 3,5 SMN2 SH-SY5Y Untreated JQ690866 
Δ 3,5,7 SMN1 SH-SY5Y Untreated JQ690868 
*Represents whether splice isoforms were detected in untreated and/or *cells. PQ-treated 
refers to treatment of cells with 1 mM PQ for 24 h. 
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Table S1. List of primers used in this study. 
No
. 
Name Type Sequence (5' to 3') Annealing 
site 
Primers for PCR 
1 P2 Reverse GCATGCAAGCTTCCTTTTTTCTTTCCCAA
CAC 
E8 
2 P1 Forward CGACTCACTATAGGCTAGCC pCI-bb 
3 P2-2 Reverse CTTCCTTTTTTCTTTCCCAACAC E8, 
MESDA 
4 P25 Reverse CTCGAAGCGGCCGCAGCTCATAAAATTA
CCA 
E8 
5 P26 Reverse GTACAATGAACAGCCATGTC E8 
6 P31 Forward CATGAGTGGCTATCATACTG E6 
7 P42 Forward GCTAGCAAGCTTATAATTCCCCCACCAC
CTCCC 
E6 
8 P43 Reverse GGCTGGATCCTGTCATTTAGTGCTGCTC
TATG 
E8 
9 P45 Forward ACGCGTGTGGCCTCGAACACC pTK-bb 
10 N-24 Forward CCAGATTCTCTTGATGATGCTGATGCTT
TGGG 
E6 
11 5ʹ′SMN-
pro-
BglII 
Forward CTGGAGATCTGGTACCACAAGCCCATAC
CAC 
SMN 
promoter 
12 3ʹ′SMN-
pro-
XhoI 
Reverse GAATCTCGAGATCCCGGGCCCGCGGGTG
CG 
SMN 
promoter 
13 3ʹ′E8-
Dde 
Reverse CTACAACACCCTTCTCACAGCTC E8, 
MESDA 
14 3ʹ′Jun 
E8/bb 
Reverse TATCATGTCTGCTCGAAGCGG pCI bb 
15 5'hSMN
-E2b 
Forward GAATACTGCAGCTTCCTTACAACAG E2b, 
MESDA 
16 E13-
PLOD2 
Forward CCGATCAGAGATGAATGAAAGGAAC E13 
17 E15-
PLOD2 
Reverse TGCCAGAGGTCATTGTTATAATGGG E15 
Primers for qPCR 
18 5ʹ′E6 Forward CCTCCCATATGTCCAGATTCTCTTGA E6 
19 3ʹ′E6+7 Reverse TCTTTTTGATTTTGTCTGAAACCCATA Jxn E6/E7 
20 3ʹ′E6+8 Reverse TGCTCTATGCCAGCATTTCCATAT Jxn E6/E8 
21 5ʹ′E5+6 Forward TTCCTTCTGGACCACCAATAA Jxn E5/E6 
22 5ʹ′E4+6 Forward AGACTGGGACCAGGAAAGATAA Jxn E4/E6 
23 3ʹ′E6 Reverse ATAGCCAGTATGATAGCCACTCAT E6 
24 5ʹ′E3+4 Forward AGAACAAAATGCTCAAGAGAATGA Jxn E3/E4 
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Table S1 continued 
25 5ʹ′E2b+4 Forward TGCAGCTTCCTTACAACAGAATGA Jxn 
E2b/E4 
26 3ʹ′E4  Reverse CTTTCCTGGTCCCAGTCTTG E4 
27 5ʹ′E1 Forward CGCGGGTTTGCTATGGCGAT E1 
28 3ʹ′E1+2a Reverse CAGAATCATCGCTCTGGCCTGT Jxn 
E1/E2a 
29 5ʹ′GAPD
H 
Forward AACAGCGACACCCACTCCTC  
30 3ʹ′GAPD
H 
Reverse CATACCAGGAAATGAGCTTGACAA  
Abbreviations, MESDA, multi-exon-skipping detection assay; E, Exon; Jxn, Junction; 
bb, backbone. Extra sequences for cloning are shown in Italic; junction sites are in bold. 
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Figure 1. Diagrammatic representation of SMN mRNA and SMN protein. 
 
 
 
Figure 2. Splicing of endogenous SMN exon 7. 
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Figure 3. Detection of multiple-exon skipping events in endogenous SMN. 
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Figure 4. Effect of PQ treatment on splicing of SMN.  
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Figure 5. Translational efficiency of transcripts generated by ASO-induced skipping of 
SMN exons in HeLa cells. 
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Figure 6. Effect of PQ on splicing of different SMN minigenes. 
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Figure 7. Treatment of SMA patient fibroblasts with 3UP8 ASO abrogates the negative 
effect of PQ.  
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Figure S1. Distribution of splice forms revealed by cloning and sequencing. 
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Figure S2. Pictogram showing relative abundance of transcripts generated in various cell 
types undergoing through OS. 
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Figure S3. Comparison of different splice variants in PQ treated and untreated SH-SY5Y 
cells as determined by qPCR. 
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Figure S4. Diagrammatic representation of minigenes placed under the control of 
different promoters. 
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Figure S5. Results showing specificity of 8-mer ASO targeting GC-rich sequence. 
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Abstract 
Survival Motor Neuron 2 (SMN2) is a human-specific gene evolved as a 
consequence of SMN1 gene duplication followed by gene conversion. SMN2 is known to 
rescue embryonic lethality due to loss of SMN1, but still cause spinal muscular atrophy 
(SMA), the most frequent genetic cause of infant mortality. The inability of SMN2 to 
fully compensate for the loss of SMN1 in SMA is due to SMN2 exon 7 skipping that 
reduces the levels of full-length SMN, a multifunctional protein expressed in all cell 
types. Recent cell-based studies have shown vulnerability of various SMN2 exons to 
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skipping under conditions of oxidative stress (OS), which is a common factor behind 
several neurodegenerative diseases. However, in vivo study to validate the OS-associated 
aberrant splicing of SMN2 has not been performed. Here we employ healthy transgenic 
(TG) and mild SMA mouse (allele C) models to examine OS-induced aberrant splicing of 
various SMN2 exons. Our results reveal unique tissue-specific signature of SMN2 splice 
isoforms generated under OS. We observed profound differences between male and 
female reproductive organs with respect to the SMN2 splice isoforms produced by OS. 
Employing a super minigene harboring SMN2 promoter, all internal exons and flanking 
intronic sequences, we demonstrate transcription-coupled splicing regulation of various 
SMN2 exons under normal and OS conditions. Our results of proteome analysis of mouse 
brain revealed OS-induced downregulation of hnRNP H, a multifunctional proteins, 
involved in pre-mRNA splicing and 3ʹ′-end processing. We confirm hnRNP H as a 
positive regulator of SMN levels and likely serves as a disease-modifying factor for 
SMA. Considering OS reduces the levels of SMN with a consequence to the severity of 
SMA and several other neurodegenerative diseases, our findings are instructive for 
adopting strategies and evaluating efficacy of potential drugs based on SMN2, which 
remains the most promising target for SMA therapy.  
 
 
Introduction 
Alternative pre-mRNA splicing is an essential mechanism to increase the 
diversity of transcripts generated from a single gene (Xing and Lee, 2007). All human 
genes with two or more exons are alternatively spliced in one or more tissues at one or 
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more stages of development or distress (Nilsen and Graveley, 2010). Alternative splicing 
confers immense variability to the functional RNA motifs (sequence and structural) with 
implications to RNA-protein interactions that regulate and facilitate multitude of 
functions including RNA stability, RNA trafficking, mRNA translation, protein trapping 
and chromatin remodeling. Splicing is catalyzed by spliceosome, a complex and dynamic 
machinery, comprised of hundreds of proteins that are differently assembled at different 
introns (Matlin and Moore, 2007; Wahl et al., 2009). To add further complexity to the 
process, splicing is coupled with transcription, 5´ RNA capping and polyadenylation 
(Muñoz et al., 2010). A combinatorial control of cis-regulatory elements and transacting 
factors regulate alternative splicing (Wang and Burge, 2008; Xiong et al., 2015). 
Mutations within regulatory sequences cause defective splicing resulting into genetic 
diseases (Cooper et al., 2009; Tazi et al., 2009). Conditions of oxidative stress (OS) and 
genotoxic stress can also trigger aberrant splicing (Akaike et al., 2014; Disher and 
Skandalis, 2007; Dutertre et al., 2010). Mechanism of aberrant splicing under conditions 
of OS, however, remains poorly understood.  
Humans have two nearly identical Survival Motor Neuron (SMN) genes; SMN1 
and SMN2 (Lefebvre et al., 1995). SMN1 predominantly produces full-length (FL) 
transcript and FL protein SMN, whereas, SMN2 predominantly produces truncated 
transcript and truncated protein SMNΔ7 due to skipping of exon 7 (Lorson et al., 1999). 
Unlike SMN, SMNΔ7 is highly unstable and quickly degraded (Cho and Dreyfuss, 2010; 
Vitte et al., 2007). SMN has been implicated in a variety of functions including 
transcription, snRNP biogenesis, DNA recombination, stress granule formation, vesicular 
transport, signal transduction, and motor neuron trafficking (refs. in Howell et al., 2014). 
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Deletions or mutations of SMN1 coupled with the inability of SMN2 to compensate for 
the loss of SMN1 leads to spinal muscular atrophy (SMA), a leading genetic disease of 
children and infants (Nurputra et al., 2013). Mouse contains a single copy of Smn gene, 
which is equivalent to SMN1. Supporting the indispensable nature of SMN, deletion of 
Smn in mouse leads to early embryonic lethality (Schrank et al., 1997). However, 
introduction of SMN2 into mouse carrying deleted Smn recapitulates SMA phenotype 
(Monani et al., 2000). While role of SMN2 remains elusive, it serves as a promising target 
for SMA therapy by compounds that elevate the levels of SMN by enhancing SMN2 
transcription and/or by correcting SMN2 exon 7 splicing (Howell et al., 2014). Recent 
reports expand the role SMN as a disease-modifying factor in other neurodegenerative 
diseases including Parkinson’s disease and amyotrophic lateral sclerosis (Acsadi et al., 
2011; Tsuiji et al., 2013; Turner et al., 2014). Since SMN2 contributes towards the overall 
cellular pool of SMN, it is likely to impact the severity of other diseases in addition to 
SMA.  
OS is the driving cause behind several chronic diseases including cancer, 
cardiovascular diseases and neurodegenerative diseases. Paraquat (PQ, 1,1ʹ′-dimethyl-
4,4ʹ′-bipyridinium) is an environmental toxin and OS stimulant that is widely implicated 
in reactive oxygen species formation and mitochondrial dysfunctions (Cicchetti et al., 
2009; Fei et al., 2008; Smith et al., 2012). PQ is commonly used in cell and animal-based 
models to understand the pathogenesis of PD, as well as, to uncover the mechanism by 
which OS impacts various pathways in the cells and tissues (Kamel, 2013; Le et al., 
2014; Ryan et al., 2013). An early study has shown enhanced skipping of SMN2 exons 5 
and 7 in neuronal cells treated with PQ (Maracchioni et al., 2007). We have recently 
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developed a multi-exon-skipping detection assay (MESDA) that captures the relative 
abundance of transcripts in a single reaction (Singh et al., 2012). Employing MESDA, we 
have shown that splicing of multiple exons of SMN1 and SMN2 are affected by PQ-
induced OS in both neuronal and non-neuronal cells (Singh et al., 2012). However, there 
is no in vivo study on how OS affects splicing of various exons of SMN2 in a tissue-
specific manner.  
Here we investigate body-wide impact of PQ-induced OS on splicing of various 
exons of SMN2 in a transgenic mouse model harboring SMN2. Our results reveal unique 
patterns of SMN2 splice isoforms expressed in different tissues in normal and OS 
conditions. We show drastic differences in splicing regulation of SMN2 exons between 
male and female reproductive organs subjected under OS. We validate our findings 
employing a mild SMA mouse model generated on a different background harboring 
SMN2 and a hybrid Smn gene. To demonstrate the transcription-coupled splicing 
regulation of various SMN2 exons under normal and OS conditions, we employ a super 
minigene harboring wild type (WT) SMN2 promoter, all SMN2 internal exons and their 
flanking intronic sequences. We demonstrate that splicing of various SMN2 exons under 
normal and OS conditions is governed by a combinatorial control in which WT promoter 
plays an essential role. Our results of proteome analysis of mouse brain revealed OS-
induced downregulation of several proteins including hnRNP H, a glycine-rich RNA-
binding protein associated with pre-mRNA splicing and 3ʹ′-end processing. We confirm 
hnRNP H as a positive regulator of SMN levels and likely a disease-modifying factor for 
SMA.  
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Results 
Time and dose-dependent signature of OS-induced splice isoforms of SMN2 
To analyze the impact of OS on pre-mRNA splicing of SMN2 in vivo, we used previously 
generated transgenic (TG) mouse model (FBV strain) harboring SMN2 on the 
background of Smn (Monani et al., 2000). Since Smn is equivalent to human SMN1, TG 
model is ideally suited to test the impact of OS on SMN2 splicing in the presence of the 
normal levels of SMN. To induce OS in vivo and reliably capture majority of splicing 
events at the early time points, we treated TG mice with 70 mg/kg body weight (bw) of 
PQ through intraperitoneal (IP) injection. We selected this high dose of PQ based on 
previous studies (Migliaccio et al., 1999). All animal experiments were carried out with a 
single treatment of PQ. Except for the time course experiments, samples were collected at 
24 h post PQ treatment. Each treatment group comprised of four animals (two males and 
two females). Since we did not observe gender-specific differences on splicing of SMN2, 
males and females were analyzed together. Barring few exceptions, most mice survived 
beyond 24 h of treatment with a high dose of PQ (Figure S1). Confirming the induction 
of OS, we recorded increased levels of 4-hydroxynonenal (4-HNE) and phosphorylated 
AKT (pAKT) in brain samples of PQ-treated animals (Figure S1).  
To capture the earliest effect of OS on splicing of SMN2, we performed MESDA 
in liver samples harvested at different time points post PQ treatment. To reduce the 
background, we used SMN2-specific primer to generate cDNA. Since liver would have 
the fastest uptake of a compound delivered through IP route, we expected to capture early 
splicing events triggered by PQ in liver. Indeed, evidence of OS-induced aberrant 
splicing of SMN2 appeared as early as 8 h post PQ treatment (Figure 1B, see lanes 5-8). 
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For instance, we observed >50% decrease in the levels of the FL transcripts accompanied 
by ~2-fold increase in co-skipping of exons 5 and 7 (Figures 1C and 1D, see Δ5,7 
variant). Simultaneously, we observed ~15% increase in skipping of exon 7 (Figure 1C, 
see Δ7 variant). At 12 h post PQ treatment, the relative abundance of splice isoforms 
remained similar to that of 8 h post PQ treatment (Figures 1C and 1D). However, at 24 h 
post PQ treatment, there was a near total loss of the FL transcripts accompanied by a 
substantial increase in co-skipping of SMN2 exons 5 and 7. Interestingly, there was no 
appreciable change in the levels of Δ5 and Δ7 isoforms between 12 h and 24 h post PQ 
treatment time points (Figures 1C and 1D). At 36 h post PQ treatment, we observed a 
noticeable decrease in the levels of Δ5,7 transcripts accompanied by an increase in the 
levels of the FL transcripts. However, recovery of the FL transcripts was not complete 
even after 48 h post PQ treatment (Figures 1C and 1D). These results underscore that the 
occurrence of co-skipping of SMN2 exons 5 and 7 in response to OS is a signature event 
that climaxes during the first 24 h of the PQ treatment. We detected several faint bands 
corresponding to skipping of multiple SMN2 exons in liver samples collected at various 
time points post PQ treatment. Most of these bands represented splice isoforms lacking 
SMN2 exon 3 and/or 5 (Figure 1B, see variants Δ3,7, Δ3,5,7, Δ3,5-7 and Δ3-5,7 and Δ3-
7). Our results also revealed novel isoforms generated during conditions of OS. These 
variants are Δ5-7,Δ3,5-7, Δ3-5,7 and Δ3-7 (Figure 1B).  
Results of time course experiment described above revealed the best time to 
capture all aberrantly spliced variants of SMN2 is ~24 h post PQ treatment. Therefore, we 
used this time point to assess the impact of lower PQ doses on splicing of various SMN2 
exons. Effect of OS was minimal, marginal and substantial at low (10 mg/kg bw), 
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medium (25 mg/kg bw) and high (50 mg/kg bw) doses of PQ, respectively (Figures 1E-
G). Interestingly, two out of 20 animals showed noticeably higher levels of Δ3-5,7 and 
Δ3-7 transcripts after 8 and 12 h of treatment (70 mg/kg bw), respectively (Figure 1B, 
lanes 7 and 9). Another PQ-treated (50 mg/kg bw) animal showed increased levels of 
Δ5,7,  Δ3,7 and Δ3,5,7 variants (Figure 1E, lane 15). These findings underscore 
individual susceptibility to OS on splicing of various SMN2 exons. Overall, our results 
establish co-skipping of SMN2 exons 5 and 7 as the hallmark of aberrant splicing under 
severe conditions of OS. However, under milder OS conditions created by low PQ 
concentrations, we observed SMN2 exon 7 skipping as the noticeable event (Figure 1F).  
 
Differential effect of OS on splicing of various exons of SMN2  
We next employed MESDA to determine the tissue-specific splicing of SMN2 exons. For 
this, we analyzed tissues collected at 24 h post PQ treatment (70 mg/kg bw; IP injection) 
of TG mice. As expected, Δ7 was the major transcript followed by FL in most untreated 
tissues including brain, heart, kidney, liver, lung, muscle and spinal cord (Figure 2A). 
Relative proportion of Δ5,7 variant was a distant third in all untreated samples. As shown 
in figure 2A, PQ-induced OS led to a near total disappearance of FL transcripts 
accompanied by an increase in the levels of Δ5,7 transcripts in the above-mentioned 
tissues. Regarding tissue-specific differences on OS-induced splicing of various SMN2 
exons, we observed a relatively high proportion of Δ5,7 transcripts in brain and spinal 
cord and a low proportion of Δ5,7 transcripts in heart and muscle. Levels of Δ5 splice 
variant remained very low during OS in all tissues examined. With respect to the short 
splice variants, we observed elevated levels of Δ3,7 and Δ3,5,7 transcripts in various 
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tissues subjected to OS. However, these transcripts represented a small fraction of the 
overall transcripts generated under conditions of OS. Regarding novel splicing events, 
conditions of OS led to a small but noticeable increase in co-skipping of exons 5, 6 and 7 
in all tissues (Figure 2A, see Δ5-7 variant). However, levels of other novel splice variants 
such as Δ3-7, Δ3,5-7 and Δ3-5,7 appeared to be not affected by conditions of OS. Unlike 
human SMN2, we observed no noticeable effect of OS on splicing of any of the mouse 
Smn exons in any of the tissues tested (Figure S2). 
To independently validate the results of MESDA, we analyzed transcripts by PCR 
employing primers annealing to flanking exonic sequences of a skipping exon. Here 
again, we used SMN2-specific primers to generate cDNA. We first examined splicing 
pattern of SMN2 exon 7 that has the highest propensity of skipping under normal and OS 
conditions (Figure 2B, lanes 1-14). Confirming the results of MESDA, we observed 
overwhelming skipping of SMN2 exon 7 in tissues harvested from the PQ-treated 
animals. We next determined the splicing pattern of SMN2 exon 5 by PCR using forward 
and reverse primers annealing to exons 4 and 6, respectively. Consistent with the results 
of MESDA, PQ-induced OS caused small but noticeable skipping of SMN2 exon 5 in all 
tissues examined (Figure 2B, lanes 15-28). Finally, we examined splicing of SMN2 exons 
2a, 2b and 3 by PCR employing forward and reverse primers annealing to exons 1 and 4, 
respectively. PQ-induced OS produced small but noticeable skipping of SMN2 exon 3 in 
all tissues examined (Figure 2B, lanes 29-42). Once again, these findings were consistent 
with results of MESDA. Parallel experiments on Smn did not produce any noticeable 
effect of OS on splicing of exons 3, 5 and 7 in any tissue examined (Figure S2). 
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We next employed quantitative real-time PCRs (qPCRs) as a complementary 
assay to determine the cumulative frequency of skipping of a specific SMN2 exon. For 
qPCR, we prepared cDNA using oligo(dT) as primer. Using a non-TG mouse, we 
confirmed that our primer combinations do not amplify Smn transcripts. We performed 
these experiment in tissues harvested at 24 h post PQ treatment (70 mg/kg bw). To 
determine the levels of total SMN2 transcripts, we used forward and reverse primers 
annealing to exon 1 and exon 1/exon 2a junction, respectively. We chose this primer 
combination based on the fact that neither exon 1 nor exon 2 is alternatively spliced 
(Figure 2C). Also, we used different sets of exon-exon junction primers to evaluate one 
or two exon skipping events at a time (Figure 2C). Final values were normalized against a 
non-fluctuating control in the same tissue. Results were expressed in terms of relative 
abundance of transcripts in normal and OS conditions (Figure 2C). Since, oligo(dT) was 
used to prepare cDNA, all transcripts analyzed in this study were polyadenylated. Our 
results revealed that PQ-induced OS does not alter the overall levels of SMN2 transcripts, 
except a little increase in heart (Figure 2C). Considering data is normalized against 
internal controls, results should be interpreted with caution. For instance, a general 
decline in rate of transcription due to energy deficit created by OS will not be reflected.  
Consistent with the results of MESDA (Figure 2A), we observed substantial 
enrichment of Δ5,7 splice variant in all tissues harvested from PQ-treated animals (Figure 
2C). Further supporting the results of MESDA, levels of Δ5 and Δ7 transcripts were not 
significantly affected under conditions of OS. These results suggest that the transcription 
coupled splicing machinery has an inbuilt mechanism to maintain a steady level of Δ5 
and Δ7 transcripts. Such outcome is entirely feasible if an increased skipping of SMN2 
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exon 5 creates a favorable context for the skipping of SMN2 exon 7. Alternatively, it is 
also likely that skipping of SMN2 exon 5 preferentially happens in those transcripts that 
have already undergone through skipping of SMN2 exon 7. Although not quite obvious 
from MESDA profile (Figure. 2A), results of qPCR revealed a substantial OS-induced 
increase in skipping of SMN2 exon 3 (Figure 2C). This is due to the fact that the design 
of the qPCR experiment to amplify Δ3 transcripts included several splice variants 
including Δ3,7, Δ3,5,7 and Δ3-7. However, owing to technical limitations, we were 
unable to validate the levels of specific transcripts (such as Δ3,7 and Δ3,5,7) by qPCR. 
We used brain samples to quantify intron-retention products by qPCR. Our results 
revealed no significant difference in intron-retention products between normal and PQ-
treated samples (Figure S3). Thus, enhanced skipping of specific exons or exon 
combinations appears to be the major consequence of OS on SMN2 splicing. We also 
evaluated the effect of PQ-induced OS on splicing of SMN2 exons in reproductive organs 
(Figure S4). The splicing pattern in uterus/ovary was almost identical to those observed 
in spinal cord. Consistent with an earlier report (Chen et al., 2008), we observed FL 
transcript as the major splice isoform in testis of untreated animals. PQ-induced OS did 
not produce an appreciable change in the splicing of any of the SMN2 exons (Figure S4).  
 
Effect of OS on splicing on SMN2 exons in a mild mouse model of SMA 
To assess the effect of OS on splicing of SMN2 in a mouse model with a different genetic 
background, we employed allele C model of SMA. Allele C model produces a mild 
phenotype in the form of the tail and ear necrosis (Osborne et al., 2012). There are 
several differences between TG and allele C mice that were generated by insertion of 
 99 
35.5 Kb and 42 kb fragments of human genome harboring SMN2, respectively (Osborne 
et al., 2012). The most important among those are the locus of gene insertion, size of 
promoter and levels of endogenous SMN. Generated on a C57BL/6J strain, allele C 
model harbors a full SMN2 gene along with a hybrid Smn gene at the same locus (Figure 
3A). Due to a larger insert, the size of SMN2 promoter in allele C mice is higher than in 
TG mice. The expression of SMN in allele C mice is about half to that of WT mice of 
identical strain (Osborne et al., 2012). Similar to TG mice, SMN2 gene of allele C mice 
generated Δ7 variant as the most abundant transcript followed FL transcript in all 
untreated tissues except in testis (Figure 3B). Further displaying the similarity with TG 
mice, untreated testis of allele C mice showed substantially higher levels of FL transcripts 
followed by Δ5 and Δ7 transcripts. We observed a noticeable expression of a large 
transcript (see 883-nt band in Figure. 3B) in all tissues of allele C mice. We cloned and 
sequenced this transcript that was found to contain a new 109-nt long exon that appeared 
to have originated by exonization of an Alu-like sequence within intron 6. (Figure 3A). 
For the ease of explanation, we call this new exon as 6B. Consequently, we term FL 
transcript containing exon 6B as SMN6B. Although less abundant, we could validate the 
expression of SMN6B in all tissues of TG mice by PCR using forward and reverse 
primers annealing to exons 6 and 6B, respectively. We also validated the expression of 
SMN6B by cloning and sequencing of a very faint band obtained by MESDA performed 
on human postmortem tissues. The relative abundance of SMN2 splice isoforms in 
different human tissues matched with those in allele C as well as in TG mice (Figure S5).  
Following the same approach that we used for TG mice (Figure 2), we determined 
the effect of OS on splicing of various SMN2 exons in different tissues of allele C mice. 
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Briefly, 6 to 8 week old mice were treated with PQ (70 mg/kg bw) through an IP 
injection. Animals were sacrificed at 24 h post PQ treatment and tissues were harvested 
for analysis by MESDA. As shown in Figure 3B, PQ-induced OS caused a noticeable 
decrease in FL transcripts accompanied by an increase in Δ5,7 transcripts in all tissues. 
Generation of Δ3,5,7 transcripts significantly enhanced in response to OS in brain, spinal 
cord and heart. We observed a small but noticeable increase in several splice variants 
including Δ5-7, Δ3,7 and Δ3,5-7 in all tissues of PQ-treated mice. However, levels of 
SMN6B and several other transcripts were not significantly affected in any of the tissues 
examined.  
The hybrid Smn gene of allele C mice contains a portion of SMN2 gene including 
the last 115 nucleotides of intron 6, entire exon 7, entire intron 7 and entire exon 8 
(Figure 3A). Remaining sequences including promoter come from Smn gene. Hence, 
hybrid Smn provided an opportunity to check the effect of upstream sequences including 
Smn promoter on splicing of SMN2 exon 7. In addition, employment of MESDA allowed 
us to examine the impact of SMN2 exon 7 skipping on upstream Smn exons. Interestingly, 
the hybrid context caused almost total skipping of SMN2 exon 7 in all tissues except 
testis that showed very small but detectable levels of FL transcripts. These results suggest 
that the hybrid Smn provides a negative context for SMN2 exon 7 splicing. Similar to 
SMN6B transcript generated by full SMN2 gene of allele C mice (Figure 3B), we 
observed a large transcript (see 825-nt band in Figure 3C) generated by hybrid Smn in all 
tissues of allele C mice. Upon sequencing, this transcript was found to contain a 108-nt 
long new exon that we term 6Bx. Due to absence of Alu-like sequences in mice, we 
observed no similarity between exon 6B and 6Bx. Results of sequencing of 825-nt band 
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also revealed direct joining of 6Bx with SMN2 exon 8, suggesting skipping of exon 7. 
Therefore, we designated 825-nt band as 6BxΔ7 (Figure 3C). While 6BxΔ7 is the unique 
product of hybrid Smn, we confirmed the occurrence of 6Bx-included FL transcripts 
generated from the endogenous Smn of a non-transgenic mice (not shown). Since 
skipping of SMN2 exon 7 had already peaked in most of the untreated tissues, it was not 
possible to see any appreciable effect of OS on levels of FL transcripts. Confirming that 
predominant skipping of exon 7 has no effect on splicing of upstream Smn exon 5, we 
were unable to detect Δ5,7 splice isoform under both normal and OS conditions. 
Similarly, most of the short splice variants of characteristics of SMN2 were absent in 
hybrid Smn. However, we observed a very small increase in levels of Δ6,7 transcripts in 
PQ-treated samples. Appearance of Δ6,7 transcript would result into the loss of the 5ʹ′ ss 
used for the generation of exon 6Bx. Consistently, we observed very small but noticeable 
decrease in levels of 6BxΔ7 most tissues examined. 
 
Effect of promoter on splicing of various SMN2 exons under normal and OS 
conditions 
To assess the impact of promoter sequence on splicing of SMN2 exons under normal and 
OS conditions, we generated a super minigene, SMN2WT3.3, harboring all SMN2 exons 
and ~3.3 kb SMN2 promoter sequence (WT3.3) (Figures 4A and S11). Our rationale to 
use WT3.3 was based on the fact that a previous study showed 3.2 kb SMN promoter as 
the appropriate size to achieve an efficient transcription in primary cultures of mouse 
spinal cord (Boda et al., 2004). SMN2WT3.3 retained ~150 bp of WT intronic sequences 
upstream and downstream of exons. Since SMN2 intron 7 contains several regulatory 
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elements critical for exon 7 splicing (Singh and Singh, 2011), we retained the entire 
intron 7. In addition, SMN2WT3.3 harbored exon 6B by retaining ~1 kb of intron 6 (Figure 
3). A 3X-FLAG tag was inserted in front of exon 1 to distinguish between endogenous 
and exogenous SMN2 transcripts. To capture the splicing of all internal exons in a single 
reaction, we modified MESDA protocol by shifting the annealing position of the forward 
primer to the 3X-FLAG sequence (Figure 4A). The reverse primer annealed to the 
beginning of SMN2 exon 8. A separate MESDA protocol was developed to capture 
endogenous SMN2 transcripts. These assays allowed selective amplification of transcripts 
generated from either minigene or endogenous gene (Figure 4A). Identities of transcripts 
were confirmed by sequencing. Unless otherwise mentioned, we performed our 
experiments in neuronal SH-SY5Y cells that are widely utilized as model for examining 
the effects stress-associated conditions. OS was introduced by treatment of SH-SY5Y 
cells with 1 mM PQ (Singh et al., 2012).  
Consistent with the splicing of endogenous SMN2 in neuronal tissues (Figure 2A), 
we recorded Δ7 transcript as the major transcript generated by SMN2WT3.3 in SH-SY5Y 
cells (Figure 4B, lane 1). As expected, proportion of FL transcript was higher in MESDA 
of endogenous transcripts as these transcripts represented both SMN1 and SMN2 (Figure 
4B, lane 9). Recapitulating the effect of OS in brain and spinal cord, PQ-induced OS led 
to an increase in co-skipping of exons 5 and 7 from SMN2WT3.3. Replacement of 3.3 kb 
SMN2 promoter with ~1.0 kb Smn promoter retained the splicing pattern of SMN2 under 
normal and OS conditions. This is likely due to shared transcription regulatory elements 
between SMN and Smn promoters (Figures 4A and S6). Among experimentally validated 
active elements common to both SMN and Smn are CRE-II, SP1, Ets, IL-6 and Elk-1 that 
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are localized within the 300 bp upstream of translation start site (Branchu et al., 2013; 
Majumder et al., 2004; Rouget et al., 2005). Interestingly, replacement of SMN2 promoter 
with a strong commercially available CMV promoter (~0.7 kb) produced an entirely 
different splicing pattern. For instance, CMV promoter caused enhanced co-skipping of 
exons 3 and 7, in addition to producing low levels of FL transcripts (Figure 4B, lanes 5). 
Conditions of OS further reduced the levels of FL transcripts and enhanced the levels of 
co-skipping of exons 3 and 7 (Figure 4B, lane 6). Surprisingly, conditions of OS caused a 
noticeable decrease in the levels of Δ5,7 transcripts in SMN2 with CMV promoter (Figure 
4B, lane 6). These differences could be attributed to an entirely different promoter 
structure of CMV promoter. As such, CMV promoter produced >20-fold more transcripts 
compared to SMN2 and Smn promoters (Figure S7). The compelling hypothesis emerging 
from our results (of in vivo and cell-based experiments) supports a role of promoter 
strength and splicing of various SMN2 exons. While exon 7 was vulnerable to skipping 
under normal and OS conditions in all promoter contexts examined, exon 3 was more 
vulnerable to skipping in the context of a strong promoter. Co-skipping of exons 5 and 7 
were favored in the context of the weak promoters.  
 
Suboptimal splice sites contribute towards OS-induced aberrant splicing of exons  
To assess the potential nature of cis-regulatory elements including the weak splice sites 
responsible for aberrant splicing under conditions of OS, we compared fourteen OS-
sensitive exons and their flanking intronic sequences. Except SMN2, other genes were 
randomly chosen. Other than Sbp2, we employed brain tissues to validate the expected 
OS-induced changes in the splicing pattern of these exons by RT-PCR employing primers 
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annealing to flanking exons (Figure 5). For Sbp2, we used multiple tissues to interrogate 
OS-induced changes in splicing of exon 3 and exon 3a, both of which share the same 5ʹ′ 
splice site (ss) but have a different 3ʹ′ ss. Underscoring the weak 3ʹ′ ss and/or 5ʹ′ ss as the 
possible cause of exon skipping under conditions of OS, seven of the nine skipping exons 
lacked the preferred R (purines) and/or G residues at the first and the last positions of 
exons, respectively. Exceptions to this rule were exon 6 of Tcerg1 and exon 18 of 
Smarcc2. Splice sites of these exons appeared to be suboptimal due to other reasons. For 
instance, the presence of a C residue at the 5th position of Tcerg1 intron 6 creates a 
mismatch base pairing with U1 snRNA, thus, hampering an efficient recruitment of the 
U1 snRNP at the 5ʹ′ ss of Tcerg1 exon 6 (Figure 5A). The 5ʹ′ ss of Smarcc2 exon 18 is 
likely to be weakened by a predicted strong stem-loop structure that effectively 
sequesters the 5ʹ′ ss.  
Sbp2 provided a good example of alternative 3ʹ′ ss usage in a tissue-specific 
manner under normal and OS conditions. Sbp2 exon 3 is comprised of exon 3a and exon 
3b (Figure S8). OS-induced enhanced skipping of exon 3a was pronounced in brain, 
heart, muscle and spinal cord (Figure 5A, lanes 12, 14, 22, 24). We observed 
predominant OS-induced skipping of exon 3 in lung (Figure 5A, lane 20). Kidney 
emerged as a unique tissue to have enhanced OS-induced skipping of both, exons 3 and 
3a (Figure 5A, lane 16). Interestingly, OS did not affect either of these exons in liver 
(Figure 5A, lane 18). Skipping of exon 3a in brain and several other tissues is possible 
only when the 3ʹ′ ss of exon 3b is strengthened with respect to the 3ʹ′ ss of exon 3. While 
intronic and exonic sequences at the 3ʹ′ ss of exon 3 are represented by U and A-rich 
motifs, respectively, intronic and exonic sequences at the 3ʹ′ ss of exon 3b are represented 
 105 
by C-rich motifs, respectively (Figure S8). Interestingly, there are additional differences 
at the 3ʹ′ ss of exon 3b between mouse and human genes. Hence, we did not observe a 
PQ-induced skipping of SBP2 exon 3a in neuronal SH-SY5Y cells (not shown). We 
analyzed five exons that are included in response to OS. All of these candidates had a 
favorable purine residue at the first position of exon. Four of these candidates also had a 
favorable G residue at the last position of exon. Under normal conditions, three of the 
five exons underwent predominant skipping (Plod2 exon 14, Uspl1 exon 2 and Atxn2 
exon 10). All three exons appear to have suboptimal 5ʹ′ ss due to poor base pairing 
between U1 snRNA and the 5ʹ′ ss. Analysis of exons and flanking intronic sequences 
showed a variety of enrich motifs (Figure S9). Nature of these motifs suggests role of 
multiple factors in splicing regulation under normal and OS conditions.  
 
Effect of OS on SMN and regulatory factors in TG brain 
To interrogate the role of factors that affect splicing and post-splicing events of SMN2 
under conditions of OS in vivo, we examined levels of several proteins in TG brain 
within the first 24 h of PQ treatment. We began with the determination of SMN levels, 
since an OS-induced decline in SMN levels will have a direct impact on snRNP assembly 
and genome-wide perturbations on splicing. Both Smn and SMN2 contribute towards 
overall SMN pool in TG mice. Hence, we used two different antibodies to distinguish 
total SMN from human SMN (hSMN). Consistent with the overwhelming skipping of 
SMN2 exons 5 and 7, we expected a drastic decline in the levels of hSMN in TG brain 
with OS. However, we observed a significant but disproportionately small reduction in 
hSMN in TG brain subjected to OS. Moreover, we did not detect hSMN isoforms 
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corresponding to SMN2∆7 and SMN2∆5,7 transcripts that are major splice isoforms 
generated under OS. Based on an earlier study (Cho and Dreyfuss, 2010), skipping of 
SMN2 exon 7 is likely to add a protein degradation signal at the C-terminus of hSMN∆7 
and hSMN∆5,7. Hence, we attribute the absence of hSMN∆7 and hSMN∆5,7 proteins to 
their rapid degradation. The fact that hSMN only partially contributes towards the overall 
pool of SMN in TG brain, a small decline in hSMN did not result into a significant 
change in the overall levels of SMN in TG brain subjected to OS.  
Gemin2 tightly interacts with SMN and contributes towards most (if not all) 
SMN-associated functions. We did not observe a significant change in Gemin2, 
suggesting that SMN-Gemin2 complex is not a limiting factor during the first 24 h of PQ-
induced OS. Eukaryotic initiation factor eIF4A2 is involved in microRNA-mediated 
translational repression (Meijer et al., 2013). Considering that the levels of eIF4A2 
remained unchanged suggests that the general microRNA-mediated translation 
suppression is not triggered during the initial stages of OS. Consistent with the 
insignificant change in the levels of serine/arginine (SR)-phosphorylating protein SRPK 
in TG brain subjected to OS, we did not observe a general change in the phosphorylation 
status of splicing factors. Nonetheless, these results should be treated with caution 
because enhanced phosphorylation of one protein could be masked by dephosphorylation 
of another protein of similar size. SF2/ASF, an SR protein, has been previously 
implicated in strengthening of the 3ʹ′ ss of SMN exon 7 (Cartegni and Krainer, 2002). The 
strength of a 3ʹ′ ss could be also altered by hnRNP K, a critical splicing factor with 
important role in neuronal differentiation (Cao et al., 2012). However, we recorded 
insignificant OS-induced changes in levels of SF2/ASF and hnRNP K in TG brain.   
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Splicing factors hnRNP A1 and hnRNP A2 are negative regulators of SMN2 exon 
7 splicing. These two proteins interact with both exon 7 and intron 7 of SMN2. While 
levels of hnRNP A1 in TG brain subjected to OS remained unaffected, we observed a 
small but significant decrease in the levels of hnRNP A2. These results suggest that the 
rules of exon skipping under conditions of OS are governed by factors that are not 
necessarily negative regulators. Indeed, we observed a small but noticeable decrease in 
levels of TIA1, a glutamine-rich protein that serves as a key regulator of stress granule 
formation. We have previously reported TIA1 as a positive regulator of SMN2 exon 7 
splicing. Role of TIA1 on SMN2 exon 7 splicing has been independently confirmed by a 
genetic mutation that leads to Welander distal myopathy (WDM). Mechanism by which 
TIA1 promotes exon inclusion involves interaction with the accessible uridine-rich 
intronic sequences close to the 5ʹ′ ss of an exon. Similar to TIA1, PSF is a glutamine-rich 
protein that stimulates SMN2 exon 7 inclusion. Based on sequence homology, PSF is 
grouped along with p54nrb/NONO proteins (Yarosh et al., 2015). However, unlike TIA1, 
we did not find a significant change in the levels of PSF and p54nrb proteins in TG brain. 
Levels of SRp55, a splicing factor implicated in defining the 5ʹ′ ss of an exon, also 
remained unchanged in TG brain.  
 
Proteome analysis reveals role of hnRNP H in OS-induced downregulation of SMN 
To capture novel regulatory factors that likely affect levels of SMN under conditions of 
OS, we performed two-dimensional (2D) gel electrophoreses of TG brains harvested at 
24 h post PQ treatment. We performed two independent experiments to ensure the 
reproducibility of our findings. After comparing the results of 2D gel electrophoresis, we 
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investigated four protein spots that were significantly altered in brains subjected to OS 
(Figure 7). Two of these proteins were upregulated, whereas, two were downregulated in 
PQ-treated group. We analyzed these proteins by mass spectrometry using MALDI-TOF 
and LC/MS (Table S2). While Lactate dehydrogenase B (LDHB) and phosphoglycerate 
mutase 1 (PGAM1) were identified as upregulated proteins, Alpha-enolase 1 (ENO1) and 
hnRNP H were identified as downregulated proteins. For the sake of clarity hnRNP H1 
and hnRNP H refer to gene/transcript and protein, respectively. To determine that the 
altered expressions of above proteins are due to transcription, we performed qPCR. 
Consistent with the OS-induced downregulation of ENO1 and hnRNP H proteins, we 
observed a small but noticeable decrease in their transcripts (Figure S10). However, we 
did not capture a significant change in Ldhb and Pgam1 transcripts in PQ-treated brain, 
suggesting that posttranslational modification(s) cause differential expression of LDHB 
and PGAM1. Interestingly, western blot analysis did not capture the expected decrease in 
hnRNP H in PQ-treated brain samples (not shown). Hence, the changed in the levels of 
hnRNP H captured in our proteome analysis is likely due to the post-translational 
modification of hnRNP H. Considering ENO1, LDHB and PGAM1 are involved in 
glycolysis and/or gluconeogesis pathways, their alteration during OS was not surprising. 
In particular, downregulation of ENO1 in striatum of PQ-treated mice mimicking 
Parkinson’s disease has been previously reported (Patel et al., 2007). However, given a 
recent report in which partial depletion of hnRNP H1 transcripts produced no effect on 
SMN2 exon 7 splicing (Wee et al., 2014), our finding of downregulation hnRNP H in PQ-
treated brain and its likely correlation with SMN levels was somewhat unexpected. 
Nonetheless, our result was not entirely surprising as effect could be due to substantial 
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depletion of a specific posttranslationally modified form of hnRNP H. Since hnRNP H is 
implicated in 3ʹ′-end processing and maintaining stability of certain mRNAs (Decorsière 
et al., 2011; Millevoi et al., 2009), it is also like that the effect of hnRNP H on SMN 
levels is in part through mRNA stabilization.  
To evaluate the effect of hnRNP H on splicing of SMN2 exon 7, we co-transfected 
HeLa cells SMN2 minigene and a mammalian vector overexpressing hnRNP H1 tagged 
with 3XFLAG- at its N-terminus. At 24 h post transfections cells were collected for 
protein lysate preparation and total RNA purification. We observed increase in exon 7 
inclusion in SMN2 minigene in cells overexpressing 3XFLAG hnRNP H1 (Figure 7C, 
panel ii). The positive effect on the endogenous SMN2 exon 7 was much smaller (Figure 
7C, panel iii). This could be due to masking of hnRNP H1 overexpression effect by the 
background of untransfected cells. Taken together, our results indicate that hnRNP H1 is 
a positive regulator of exon 7 splicing.  
We performed a siRNA-mediated depletion study in HeLa cells to systematically 
examine the role of hnRNP H1 in downregulation of SMN. For this, we transfected HeLa 
cells twice with 100 nM of siRNA targeting hnRNP H transcripts. The interval between 
two transfections was 48 h. Samples for RNA and protein analyses were collected every 
24 h for 7 days. As shown in Figure 7D, maximum decrease in the level of hnRNP H1 
protein was achieved 72 hours after the first transfection (by more than 10 times).  
Unexpectedly, at early time points (24, 48, 72 and 96 h) we observed small but 
reproducible increase in inclusion of SMN2 exon 7 (Figure 7E). In addition, splicing of 
exon 3 and co-skipping of exons 5 and 7 was affected by hnRNP H1 depletion as well 
(Figure 7E). Therefore, hnRNP H1 knockdown appears to effect splicing of several SMN 
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exons. Importantly, knockdown of this protein resulted in decrease of SMN transcript 
levels as indicated by the results of radioactive RT-PCR as well as real time RT-PCR 
(Figure 7E). The decrease in the level of total SMN transcripts was accompanied by the 
decrease in the level of SMN protein; here again maximum decline in SMN transcript and 
protein levels was observed 72 hours after the first transfection (Figure 7D). Similar 
result was obtained for SH-SY5Y cells transfected with siRNA against hnRNP H1 
(Figure 7G). 
To further investigate why hnRNP H1 depletion causes an unexpected increase in 
inclusion of exon 7, we tested whether knocking down of hnRNP H1 will alter the levels 
of factors that are known to regulate SMN2 exon 7 splicing (Figure 7F). We examined 
both positive (TIA1, and TIA1-related protein, TIAR) and negative (hnRNPA1, A2 and 
hnRNP U) regulatory factors. For this evaluation, we chose a single time point at 24h 
post second siRNA transfection (against hnRNP H1) when we observed the maximum 
depletion of hnRNP H1 and downregulation of SMN (Figure 7D). As shown in Figure 
7F, hnRNP H depletion was accompanied by the significant decrease in the levels of 
hnRNP A1 and hnRNP U. The effect on TIA1, TIAR and hnRNP A2 was much less 
significant if any. Since both hnRNP A1 and U are known to promote skipping of SMN 
exon 7 (Hua et al., 2008; Kashima and Manley, 2003; Kashima et al., 2007; Wee et al., 
2014; Xiao et al., 2012), their decrease may, at least in part, account for the improvement 
in exon 7 inclusion. Based on a previous report that HuR plays a role in SMN transcript 
stability (Farooq et al., 2009), we determined levels of HuR in hnRNP H1-depleted cells 
and observed no change in its levels at 24 h post second siRNA transfection (against 
hnRNP H1) when SMN was substantially downregulated (Figure 7D). Therefore, we 
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conclude that the observed reduction in SMN at least at the tested time point is not HuR-
mediated. 
 
 
Discussion 
Here we report a comprehensive analysis of OS-induced aberrant splicing of 
multiple exons of SMN2, a universally expressed human gene associated with SMA, the 
most frequent genetic cause of infant mortality. We employed healthy transgenic (TG) 
and mild SMA (allele C) mouse models to assess the tissue-specific effect of PQ-induced 
OS on splicing of various SMN2 exons. Based on the classical use of PQ across animal 
kingdom to unravel the molecular mechanisms of OS (Cho et al., 2010; Lenzken et al., 
2011; Yang and Hekimi, 2010), we chose PQ to induce OS in our study. Supporting the 
similarity of mechanisms of splicing in various SMN2 exons between human and mouse, 
splicing of SMN2 in various tissues of untreated TG and allele C mice matched with 
those in human tissues (Figures 2, 3 and S5). Hence, mouse models chosen for this study 
is likely mimic the early consequences of OS on splicing of various SMN2 exons in 
human tissues. In a most revealing manner, our results of MESDA, RT-PCR and qPCR 
demonstrated body wide susceptibility of SMN2 exon 7 to OS conditions in both TG and 
allele C mice (Figures 2 and 3). Barring testis, all tissues exposed to PQ showed near 
total skipping of exon 7. Our results support that factors responsible for OS induced 
skipping of exon 7 are almost universally present. In contrast to exon 7, we found tissue 
specific effect of OS on splicing of SMN2 exon 5, which showed maximum skipping in 
brain, spinal chord and uterus/ovary followed by kidney, lung and liver. Interestingly, 
 112 
expression of ∆7 and ∆5,7 transcripts in liver of TG mice peaked at 8 h and 24 h post PQ 
treatment, respectively (Figure 1B). Based on the timing of accumulation of different 
spliced transcripts, it is likely that early skipping of SMN2 exon 7 in OS is brought about 
by sudden change in the posttranslational modifications and/or nuclear import/export of 
splicing factors, whereas delayed skipping of exon 5 is effected by subsequent changes 
such as slow rate of transcription elongation. Generally, a faster rate of transcription 
elongation favors exon skipping due to lack of time for the recruitment of factors that 
define splice sites (Luco et al., 2011). However, opposite could also be true as a recent 
report supports recruitment of an inhibitory factor during slow transcription elongation 
leading to the skipping of exon 9 of CFTR (Dujardin et al., 2014). Effect of OS on SMN2 
exon 3 splicing appeared mild and was tissue specific. Most SMN2 exon 3 skipping 
occurred in lung followed by uterus/ovary, kidney and heart. Also, skipping of SMN2 
exon 3 occurred in combination with the skipping of other exon(s). Considering the 
distinct mode of regulation of transcription and splicing in testis, we observed no 
appreciable effect of PQ on splicing of any of SMN2 exons in testis.  
Allele C mice maintains about ~50% less SMN compared to normal mice 
(Osborne et al., 2012). Yet allele C and TG mice showed no appreciable difference in 
splicing pattern of various SMN2 exons in most tissues under both normal and OS 
conditions. Although expression of SMN6B, a novel splice isoform, appeared high in 
allele C mice, its levels were not affected by OS in any of the tissues examined. The 
relatively high abundance of SMN6B in allele C mice could be attributed to the locus of 
SMN2 insertion and/or size of promoter. Hybrid Smn gene provided a negative context 
for splicing of SMN2 exon 7. A negative context could be generated by several factors 
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including gain of a silencer, loss of an enhancer and perturbations in the co-
transcriptional splicing regulation. Absence of exon 5 skipping in hybrid gene ruled out 
any synergistic effect between Smn exons 5 and SMN2 exon 7. However, presence of 
Δ6,7 transcript in hybrid gene would suggest that overwhelming skipping of SMN2 exon 
7 negatively impacts splicing of upstream Smn exon 6, particularly under OS. Instead of 
detecting co-skipping of SMN2 exons 6 and 7 under OS, we observed bands 
corresponding to co-skipping of SMN2 exons 5-7. These results confirm that rules of 
splicing of upstream Smn exons are distinct from SMN2 exons.  
We employed a super minigene to examine the mechanism of transcription-
coupled splicing regulation of SMN2 exons. SMN2WT3.3 was able to generate FL 
transcript by splicing out all eight SMN2 introns. Due to variations of transfection 
efficiency, a true comparison of promoter strength between chromatin-associated 
endogenous SMN2 and chromatin-free SMN2WT3.3 is not possible. However, SMN2WT3.3 
offered an opportunity to compare the relative strength of promoter sequences on splicing 
of all SMN2 exons. We compared WT3.3 SMN2 promoter with Smn and CMV promoters. 
Given the nature of the common regulatory elements between SMN2 and Smn promoters, 
rate of transcription and splicing pattern of SMN2 exons were very similar. Consistent 
with a previous report (Echaniz-Laguna et al., 1999; Monani et al., 1999), truncation of 
SMN2 promoter from ~3.3 kb to ~0.6 kb, truncating GATA-2, AP1, N-Oct-3, HNF-3, 
SP1, ATF CRE and YY1 (Figure S12), increased the rate of transcription (Figure S7). 
However, rate of transcription from CMV promoter was >20 fold higher. Consequently, 
we observed a drastically different splicing pattern of SMN2 exons from CMV promoter. 
Supporting a point of view that faster elongation of transcription favors exon skipping 
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(Luco et al., 2011), we observed higher rate of skipping of exon 3, which is the closest 
exon from transcription start site to undergo skipping. Interestingly, skipping of skipping 
of exon 3 suppressed skipping of exon 5, particularly under conditions of OS. Replacing 
0.1 kb upstream of CMV (containing NF-kB, SP1, CREP/ATF and TATAA) with the 
sequence 0.1 kb upstream of SMN2WT3.3 TSS (harboring HNF-3, IRF-E/ISRE, Ets, 
TATAA, HINF, Pitla and N-Oct-3) increased inclusion of exon 3 (Figure S12). Since 
splicing of exons 3 and 5 was dependent upon promoter sequence, we hypothesize 
“recruitment coupling” as a plausible mechanism of transcription-coupled splicing 
regulation of these exons. According to this mechanism, promoter sequences help recruit 
splicing factors to pre-mRNA via C-terminal domain of RNA polymerase II (RNAP II) 
(Acuña and Kornblihtt, 2014). Transcription-coupled splicing regulation could also be 
realized through “kinetic coupling”, in which rate of transcription elongation is affected 
by chromatin structure (Acuña and Kornblihtt, 2014; Luco et al., 2011). However, since 
transiently transfected minigenes do not have chromatin structure, kinetic coupling could 
not be faithfully captured by our approach described here. Clues of kinetic coupling could 
be drawn from an in vivo study in which treatment of SMA mice with Trichostatin A, a 
HDAC inhibitor resulted into increased levels of FL SMN2 transcripts and SMN protein 
in different tissues (Avila et al., 2007). HDAC inhibitors are known to activate SMN2 
promoter and modify histone acetylation at the SMN2 gene (Evans et al., 2011; Hauke et 
al., 2009; Kernochan et al., 2005). However, it remains to be determined if promotion of 
SMN2 exon 7 inclusion by an HDAC inhibitor is due to kinetic and/or recruitment 
coupling. 
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Despite similarity between SMN and Smn promoters, Smn exons do not undergo 
skipping under normal and OS conditions. These results support eminent role of cis-
elements within transcribed pre-mRNA as the driving force of splicing regulation. These 
results are also consistent with the recruitment coupling model because factors recruited 
at the promoter need to be delivered at specific cis-elements located within pre-mRNA. A 
number of negative cis-elements that weaken the 3ʹ′ and 5ʹ′ ss of SMN2 exon 7 have been 
implicated in skipping SMN2 exon 7 (Singh and Singh, 2011). It has been also shown that 
the sequestration of a negative cis-element by an ASO prevents skipping of SMN2 exon 7 
under normal and OS conditions (Singh et al., 2012). Hence, a correlation could be 
expected between suboptimal splice site and susceptibility to aberrant splicing under 
conditions of OS. The first and the last positions of an exon directly participate in 
catalytic reaction (of splicing) at the 3ʹ′ and 5ʹ′ ss of an exon. Transcriptome-wide analyses 
show prevalence of R (purines) and G residues at the first and the last positions of human 
exons, respectively (Burge et al., 1999). Employing in vivo selections we have previously 
shown the positive impact of G residues at the first and the last positions of SMN exon 7 
(Singh et al., 2004a, b).  In particular, an A to G substitution (A54G) at the last position 
of SMN2 exon 7 was found to fully restore of SMN2 exon 7 inclusion even in the absence 
of several positive regulatory elements (Singh et al., 2004b). Mechanism by which A54G 
confers very strong stimulatory effect on SMN2 exon 7 involves destabilization of a stem-
loop structure (TSL2) that sequesters the 5ʹ′ ss of an exon 7 (Singh et al., 2007). 
Disruption of TSL2 by A54G facilitates recruitment of U1 snRNP through a strong base 
pairing between U1 snRNA and the 5ʹ′ ss of an exon 7. ISTL1, another RNA structure 
formed by a long-distance interaction within intron 7, affects SMN2 exon 7 splicing also 
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by sequestration of the 5ʹ′ ss of exon 7. An ASO that promoted SMN2 exon 7 inclusion 
under conditions of OS is predicted to disrupt ISTL1 (Singh et al., 2015). Hence, 
structural elements capable of affecting the accessibility of splice sites appear to serve as 
the primer for OS-induced aberrant splicing.  
A survey of fourteen OS-sensitive exons and their flanking intronic sequences did 
not reveal a common character of regulatory cis-elements. However, most skipping exons 
lacked the favorable residues at the first and the last positions of exon. Most of these 
exons also had predicted stem-loop structures that are likely to sequester the 5ʹ′ ss. In 
several cases the RNA:RNA duplex formed between U1 RNA and the 5ʹ′ ss appeared to 
be weak due to less than six continuous  base pairs. Exons that were susceptible to 
inclusion appeared to have favorable residues at the terminal exonic positions. Yet, the 5ʹ′ 
ss of most of these exons had poor base pairing with U1 RNA. We observed various 
enriched motifs within OS-sensitive exons and flanking intronic sequences. As with 
SMN2, it is likely that promoter sequences are critical for skipping of some of these 
exons.  
OS caused small but noticeable decrease in hSMN levels derived from SMN2. 
Consistently we observed decline in Gemin2, an SMN interacting protein responsible for 
most SMN functions. Skipping of SMN2 exon 7 creates an extension of reading frame 
that codes for a degron signal (Cho and Dreyfuss, 2010). Therefore, we were unable to 
detect proteins synthesized by aberrantly spliced SMN2 transcripts, majority of which 
lacked exon 7. It is likely that OS induced skipping of SMN2 exon 7 in most tissues 
serves as a regulatory step to limit the synthesis of SMN through a duplicate gene. 
However, significance of OS induced skipping of SMN1 exon 5 is somewhat intriguing as 
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it may synthesize a short protein with altered function. Currently, none of the 
alternatively spliced variants of human SMN have been assigned any specific function. 
Future studies will address if stable proteins coded by short SMN transcripts including 
SMN1∆5 retain some of the original functions or gain additional roles. 
OS did not affect levels of most splicing factors examines. However, we observed 
significant decrease in levels of TIA1 and hnRNP A2. These proteins have opposite 
effect on exon 7 splicing. While TIA1 promote inclusion of exon 7, and hnRNP A2 
promotes skipping of exon 7. Our proteome analysis revealed role of hnRNP H a 
potential regulator of SMN2 exon 7 splicing. We performed overexpression and depletion 
experiments to uncover a potential role of hnRNP H on SMN splicing and SMN mRNA 
stability. Our results indicate that hnRNP H is involved in multiple aspects of SMN 
transcript metabolism. Its effect on SMN exon 7 splicing appears to be complex. Both 
overexpression and depletion promoted exon 7 inclusion. A recent report suggests cross 
regulation among different hnRNP (Huelga et al., 2012). Indeed, depletion of hnRNP H 
caused decrease in levels hnRNP U and hnRNPA1 in HeLa cells. Since both of these 
proteins are negative regulators, a net positive effect could be expected on SMN2 exon 7 
splicing.  
A transcriptome-wide analysis of hnRNP H binding sites employing CLIP-seq 
revealed direct interacts with SMN exon 8 (from position 112 to 135 and from position 
227 to 256) (Katz et al., 2010). The latter region is located 291 nucleotides upstream of 
the classical hexamer, AAUAAA, which is required for cleavage and polyadenylation of 
the majority of eukaryotic pre-mRNAs. Involvement of hnRNP H in regulation of 
cleavage and polyadenylation has been previously shown for human beta-globin and p53 
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protein (Decorsière et al., 2011; Millevoi et al., 2009). In addition, CLIP-seq data 
implicated hnRNP H in regulation of alternative cleavage and polyadenylation as well, 
where this protein appear to bind upstream of the core polyadenylation site (PAS) and 
promote its usage (Katz et al., 2010). Our results of hnRNP H knockdown combined with 
the CLIP-seq data indicate that this protein may play a role in the processing of the 3ʹ′-end 
of SMN mRNA, with implications to its transcript stability. Very little is known about the 
3ʹ′-end processing (i.e. 3ʹ′-end cleavage and polyadenylation) of SMN transcript. While 
CA dinucleotide is the most optimal 3ʹ′-end cleavage site (Laishram, 2014), the SMN pre-
mRNA is cleaved at the 3ʹ′ of the less optimal UA dinucleotide. Recently, it has been 
shown that U1A protein directly binds to SMN pre-mRNA and inhibits its 3ʹ′ cleavage and 
polyadenylation (Workman et al., 2014). In addition, the authors identify a number of 
other proteins that interact with SMN 3ʹ′UTR using RNA pull down followed by mass 
spectrometry (Workman et al., 2014). However, since RNA molecule used for pull down 
experiments did not incorporate hnRNP H binding site identified by CLIP-seq, hnRNP H 
and possibly other proteins involved in the 3ʹ′-end processing could not be identified. 
Thus far, hnRNP H has been implicated in 3ʹ′-end processing of three mRNAs (Huelga et 
al., 2012; Katz et al., 2010; Millevoi et al., 2009) and translation of one mRNA (Song et 
al., 2012). Hence, our finding that hnRNP H affects SMN transcript and protein is an 
important addition to this group of proteins. 
Our study fulfills an important objective of validating various previous findings of 
cell-based experiments and uncovering several novel aspects of splicing regulation of a 
critical gene associated with a major genetic disease of infants and children. Although 
purpose of this study was to understand tissue-specific splicing regulation of various 
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SMN2 exons under OS, findings expanded the scope of this study connecting splicing to 
transcription, 3ʹ′-end processing and translations. While all these processes are connected 
in vivo, lack of appropriate tools hinders our ability to uncover mechanisms of 
coordination among these processes. Our claims are based on various complementary 
approaches including employment of two animal models, several amplification protocols, 
proteome analysis, cell-based assays and bioinformatics. We conclude by highlighting 
that SMN2 is an OS sensitive gene and aberrations in splicing of various SMN2 exons are 
early consequence of OS in all tissues except testis. We show that changing promoter 
sequence could alter the effect of OS on splicing of various SMN2 exons. Our results 
reveal potential causes of OS-induced aberrant splicing of different exons located on 
different genes. We demonstrate that OS downregulates hnRNP H. We also demonstrates 
that hnRNP is a modulator of splicing of various SMN2 exons and a regulator of stability 
of SMN mRNA.  
 
 
Materials and Methods 
Animals  
All experiments with mice and experimental guidelines were approved and monitored by 
the Institutional Animal Care and Use Committee at Iowa State University (Ames, IA, 
USA). For all animal experiment, male and female mice were housed in standard 
conditions: constant temperature (22 ± 1 °C), humidity (relative, 30%) and a 12 h 
light/dark cycle, where they were monitored daily for health. All mice had free access to 
food and water. Three mouse models were utilized in this study. Transgenic (TG) mice 
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with FVB/N background, which have two copies of SMN2 and one copy of Smn (Smn+/-
;SMN2+/+ ), were generated from breeding pairs obtained from Jackson Laboratory (JAX 
Strain 005024) (Monani et al., 2000). The FVB/NJ mice (Smn+/+) were purchased from 
Jackson Laboratory. The mice were adapted to their surroundings for at least 1 week 
prior to the experiment. Allele C mice with C57BL/6J background (SmnC/C, C is defined 
by a chimeric gene plus SMN2), were generated from breeding pairs obtained from 
Jackson Laboratory (Osborne et al., 2012). Ear punch or tail was taken from each mouse 
and used for genotyping (Jackson Laboratory).  
 
Experimental design 
Each group from phosphate buffered saline (PBS) and paraquat (PQ, methyl viologen 
dichloride hydrate, Sigma) treatment had four 6-8 week old carrier SMA mice with 1:1 
ratio of male weighing ~23 g and female weighing ~17 g. PQ stock solution in PBS was 
prepared immediately before usage (200 mM). Body weight (bw) was measured prior to 
and after PQ administration. Every individual mouse under PQ treatment group received 
a singly injection (0.25 ml) of various concentration of PQ from 10 to 70 mg/kg bw by 
intraperitoneal (IP) route, which has been used a similar dose range in adult male Swiss 
albino mice (Mitra et al., 2011). Each control group mice was given an IP injection of 
PBS (0.25 ml) at the same time. Once the mice are injected, they will be monitored twice 
daily until they are sacrificed. After different time points, mice were anaesthetized using 
isoflurane and then sacrificed by means of cervical dislocation. The tissues including 
brain, heart, kidney, liver, lung, muscle, spinal cord, testis, and uterus/ovary, were 
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dissected out carefully, flash-frozen immediately in liquid nitrogen or dry ice and stored 
at -80°C for further analysis.   
 
Transfection of cells and treatment 
All tissue culture media and supplies were purchased from Invitrogen. Human 
neuroblastoma SH-SY5Y cells were cultured in 1:1 mixture of Minimum Essential 
Medium (MEM) and F12 medium supplemented with 10% fetal bovine serum (FBS). 
SH-SY5Y cells were plated at a density of ~1.2x106 cells per one well of a 6-well plate. 
Next day, 1 µg of each plasmid were transfected using X-tremeGENE HP DNA 
transfection Reagent (Life Science) following the manufacturer’s recommendations. 
Twenty hours post transfection, freshly prepared PQ was immediately added to a final 
concentration of 1 mM. Following 21 hours of PQ treatment, cells were collected for total 
RNA preparation.  
hnRNP H protein was knocked down using siRNAs (ON-TARGETplus SMART 
pool; Dharmacon Inc.). An ON-TARGETplus non-targeting pool served as a control 
siRNA. For the knockdown, HeLa cells were reverse transfected with the siRNA pool 
twice with an interval of ∼48 h. For each transfection, a siRNA-Lipofectamine-2000 
complex was prepared following the manufacturer’s suggestions. The complex was then 
combined with HeLa cell suspension containing ∼1x106 cells in a total volume of 2 ml, 
and the cells were plated in one well of a 6-well plate. The final concentration for 
siRNAs was 100 nM. ~6 h post-transfection the growth medium was changed. The next 
day, the transfected cells were collected by trypsinization and equally split into two wells 
of a 6-well plate. ∼48 h after the first transfection the cells from one of these wells were 
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used for the second reverse transfection performed essentially as described above. For 
hnRNP H knockdown time-course experiments, the number of HeLa cells used for 
reverse transfection was up scaled, and 60 mm dishes were used instead of 6-well plates. 
Cells were collected every 24 hours for 7 days. To do so, cells were washed with ice-cold 
PBS three times and collected by scraping, 1/6 of the cells was used for total RNA 
purification, while the rest were used for making protein lysates. 
To co-transfect SMN2 minigene and 3XFLAG-hnRNP H1 mammalian expression 
vector, we also used Lipofectamine-2000. The amount of the minigene and 3XFLAG-
hnRNP H1 vector was 0.1 and 2 mg, respectively. Plasmid-Lipofectamine-2000 
complexes was prepared following the manufacturer’s recommendations and combined 
with HeLa cell suspension (~0.9x106 cells) in a total volume of 2 ml. The mixture was 
then plated in a well of 6-well plate. ~ 6 hours later the medium was changed. ~24 hours 
post transfection, HeLa cells were washed with ice-cold PBS three times and collected by 
scraping for total RNA purification and whole-cell lysate preparation.  
 
RT-PCR 
Total RNA was isolated from cells and mouse tissues using Trizol reagent (Life 
Technologies) following the manufacturer’s recommendations. RNA was subjected to 
DNase digestion using RQ1 RNase-free DNase (Promega). DNase-treated RNA was then 
further purified using a Qiagen RNeasy Mini RNA purification kit or phenol:chloroform 
extraction and ethanol precipitation. RNA concentration and quality was monitored using 
a NanoDrop spectrophotometer (Thermo Scientific). To generate cDNA, reverse 
transcription (RT) was carried out using a SuperScript III reaction kit (Life Technologies) 
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following the manufacturer’s recommendations. For cDNA synthesis gene-specific 
primer 3ʹ′E8-Dde were employed for SMN2 and hybrid Smn. To perform MESDA for 
mouse Smn, same total RNA were used and cDNA synthesis were employed by gene-
specific primer 3ʹ′mSmn-E8. To test simultaneously the transcripts of SMN2 and Smn 
using RT-PCR, same total RNA were used and cDNA synthesis was employed by 
oligo(dT)12-18 primer (Life Technologies). Generally, 1.6 µg of total RNA was used per 
10 µl reverse transcriptase reaction in mouse tissues. One microliter of cDNA was used 
in a 25 µl reaction. MESDA was performed as previously described (Seo et al., 2014; 
Singh et al., 2012). In all cases PCR products were resolved on a 5.3% native 
polyacrylamide gel. Analysis and quantifications of splice products were performed using 
a FPL-5000 Image Reader and Multi Gauge software (Fuji Photo Film Inc). All primer 
sequences used in RT-PCR are given in Table S3. 
 
Real-time quantitative PCR (qPCR) 
All reactions were performed in 96-well plates using the Stratagene Mx3005P PCR 
machine (Agilent technologies). Each reaction was diluted 1:20, and 1.5 µl of the cDNA 
was used in the final volume of 20 µl and contained 15 ng of total RNA with 300 nM 
concentration of each primer was mixed with the Master mix from Brilliant II SYBR 
master Mix with Rox (Agilent Technologies) or FastStart Universal SYBR Green Master 
(ROX) (Roche) manufactured by Roche. For negative control, cDNA was synthesized in 
absence of RTase during PCR amplification or nuclease-free water was used instead of 
cDNA samples. The amplicon sizes were < 200 bp. Genes showing threshold cycle 
values greater than 38 were considered as undetectable and less expressed. The primer 
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sets for each assay were designed to anneal to specific exon and exon-exon junctions to 
distinguish different spliced isoforms and avoid amplification of genomic DNA. 
Abundance of each isoform was calculated relative to the average of 3 PBS-treated 
samples using the ΔΔCt method. Values were normalized by dividing by the geometric 
mean of the abundance of three genes: β-actin (ACTB), Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), and Hydroxymethylbilane synthase (HMBS). All samples 
were used three biological replications and amplified in technical duplicates. Primers for 
amplification of normalizer genes are described (Singh et al., 2012; Stephens et al., 
2011).  
 
Western blot analysis 
The frozen samples were carefully thawed on ice and rinsed with ice-cold 1X PBS 
solution. Tissues were then homogenized in 100 µl/10 mg tissues in the presence of ice-
cold RIPA buffer (Boston BioProducts) containing mixture of protease inhibitors or 
protease & phosphatase inhibitor cocktail (Thermo Scientific). This was followed by 
sonication (10 sec) for six times at an interval of 1 min. Finally the lysate was kept on ice 
for 30 min and cleared by centrifugation at 12,000 rpm for 30 min at 4 °C. The harvested 
supernatant was collected then employed for protein measurements using Bradford 
protein assay (Bio-Rad).Protein samples were resolved on an 11% SDS-polyacrylamide 
gel electrophoresis. The separated proteins were transferred on polyvinylidene fluoride 
membrane (Bio Trace PVDF, Pall Life Sciences) using Transfer-Blot fast (Bio-Rad) for 
10 min at 1.3 A. The membrane was blocked with 5% nonfat dried milk in 0.05% Tween-
20 in Tris-buffered saline (TBST) with shaking at a room temperature for 1 h and then 
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probed with mouse anti-SMN-KH antibody (1:500, Millipore) in the above blocking 
solution with agitation at 4 °C overnight. Membranes were rinsed in TBST for four times 
for 10 min with shaking at room temperature. The membrane was incubated with 
horseradish-peroxidase-conjugated anti-mouse antibody (1:4,000, Jackson Immuno 
Research) in the blocking solution with shaking for 1h at room temperature. After 
washing, the membranes was treated with SuperSignal West Dura Extended Duration 
Substrate or SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Scientific) at room temperature for 5 min. Bound antibody complexes were developed 
using the ECL kit system and exposed to UVP. The membranes were scanned using a 
UVP BioSpectrum AC Imaging System. Densitometry measurements were done using 
Multi Guage software. The results reported as means ± SEM. After imaging, membranes 
were stripped using western blot Stripping Buffer (Thermo Scientific) after 
immunoblotting by incubation in stripping buffer for 15 min at room temperature with 
agitation. The membrane was washed four times with 1X TBST for 5 min each. The 
membrane was re-probed with mouse monoclonal anti-SMN antibody (1:2,000, BD 
Transduction Laboratories) followed by secondary anti-mouse antibody same as 
described above. Next, the membrane was re-proved with rabbit polyclonal anti-β-Actin 
(1:2,000, Sigma-Aldrich) followed by secondary anti-rabbit (1:2,000, GE Healthcare). 
Similarly, goat polyclonal TIA-1 (1:250, Santa Cruz Biotechnology) and TIAR 
(1:200, Santa Cruz Biotechnology) were used followed by secondary anti-goat (1:2,000, 
Santa Cruz Biotechnology). Mouse monoclonal GAPDH (1:500) was used followed by 
secondary anti-mouse. Polyclonal rabbit anti-AKT (1:1,000, Cell Signaling) and anti-
Ser473 phosphor-AKT (1:1,000, Cell Signaling) were used followed by secondary anti-
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rabbit. For 4-HNE, the membranes were incubated with anti-4-HNE (R&D Systems) 
followed by Alexa Fluor 680 goat anti-mouse (Invitrogen). Western blot images were 
captured with a LI-COR Odyssey machine (LI-COR). 
 
Construct plasmids  
To make transfectable size of a super minigene, SMN2WT3.3, harboring all SMN2 exons 
and 3.3 kb SMN2 promoter sequence (WT3.3), we used a plasmid harboring Homo 
Sapiens chromosome 5 clone CTC-566F17, complete sequence [GeneBank: 
AC022119.4] (Spectragenetics) and pWTP-SMN2 (Singh et al., 2012). We performed the 
overlapping extension PCR strategy with multiple-steps PCR by using Phusion High-
Fidelity DNA polymerase (New England BioLabs) and primers (Table S4). The 
generated PCR fragments were subcloned into pGEM-T-easy vector (Promega) following 
the manufacturer’s recommendations (Figure S11). To evaluate protein levels and 
distinguish between endogenous and exogenous SMN2, three copies of the FLAG tag 
(3XFLAG) sequences were inserted to the 5ʹ′ end of translation start site of SMN2.  
To generate splicing cassette SMN2CMV and SMN2Smn, harboring 
Cytomegalovirus (CMV) promoter (~0.6 kb) and mouse Smn promoter (~1.2 kb), 
respectively, we replaced human SMN2 promoter of WT3.3 with CMV promoter and 
mouse Smn promoter. For these, we started with PCR amplification of CMV and mouse 
Smn promoter sequences using pCI mammalian expression vector (Promega) and mouse 
genomic DNA from allele C as templates, respectively. The promoter sequences were 
amplified using primers 5ʹ′CMV-pro-BglII and 3ʹ′CMV-pro-XhoI and primers 5ʹ′Smn-pro-
BglII and 3ʹ′Smn-pro-XhoI. The amplified CMV or Smn promoter sequences was 
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subsequently digested with BglII and XhoI and ligated into pSMN2ΔI6 minigene 
subjected to partial digestion with the same restriction enzyme (Singh et al., 2012). The 
SMN2ΔI6 sequences under control of the CMV or Smn promoter was replaced with  
reduced SMN2 by using XhoI and NotI restriction enzyme. Different sizes of human 
SMN2 promoter (~0.6 kb and ~1.2 kb) were generated by the strategy described above 
using WT3.3 as a template. The identity of novel minigene clone was verified by 
sequencing.  
Human 3XFLAG-hnRNP H1 mammalian expression vector was generated as 
follows. hnRNP H1 sequence was amplified by PCR using cDNA prepared from HeLa 
cells as a template. PCR was performed with Taq DNA polymerase (New England 
BioLabs, Ipswich, MA) and a pair of primers: 5′hnRNP H and 3′hnRNP H. The amplified 
sequence was then cloned in the MluI-SalI restriction sites of the 3XFLAG-hTIA1 
mammalian expression vector (Singh et al., 2011). 3XFLAG-hnRNP H1 mammalian 
expression vector was sequenced before being used. All primers were obtained from 
Integrated DNA Technologies or DNA facility in Iowa State University (Tables S3 and 
S4). All restriction enzymes and Quick Ligation Kit were from New England Biolabs. 
 
Sample preparation for IEF 
TG brain tissues were homogenized in ReadyPrep Protein Extraction Kit (Bio-Rad) 
containing protease inhibitors by sonication. Insoluble material was discarded via 
centrifugation at 16,000 x g for 30 min. Extracted proteins were cleaned up by acetone 
precipitation methods (TECH TIP#49, Thermo Scientific) and the concentration of 
proteins was measured via Bradford protein assay (Bio-Rad). 
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Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
Isoelectric focusing (pH3-10, 18 cm strip) using 500 µg samples was conducted at 20 °C 
at GE electrophoresis unit in accordance with the manufacturer’s instructions (GE). Prior 
to running the second dimension, the strips were incubated for 10 min with equilibration 
buffer (), first with 1% DTT. Equilibrated strips were inserted onto SDS-PAGE gels 
(20x24 cm, 15%) and 2D gels were run. When the runs were completed, the 2D gels were 
subjected to coomassie blue staining. Digitalized images were quantitatively analyzed 
using Progenesis SameSpots in accordance with the manufacturer’s instructions. Each 
spot was normalized by total valid spot intensity and the spots that a fold change greater 
than 2, an anova (p) less than 0.05 and a power greater than 0.8 were selected. Selected 
protein spots were enzymatically digested. Trypsin fragments were analyzed using 
MALDI-TOF. Sequence tag searches were conducted using the MASCOT program. 
 
Statistical analysis 
For Kaplan-Meier survival curves, log-rank tests used. For qPCR, relative quantities with 
standard error were calculated by using ΔΔCT method Excel (Microsoft Office 2011 
edition). For Western blot, the statistical analysis was done using two-tailed test followed 
by Prism 6 software to compare the control and PQ treated group. Data were expressed as 
± standard error of the mean (SEM). Statistical analyses were performed using the 
Student’s t-test. Unless otherwise mentioned, P values were two-tailed and the level of 
statistical significance was set at P < 0.05. 
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Figure Legends 
Figure 1. Time and dose dependent effects of PQ treatment on splicing of SMN2 in 
mouse TG model. (A) Diagrammatic representation of the SMN genes. Exonic sequences 
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are shown as colored boxes or circles, whereas intronic sequences are shown as 
lines/broken lines. Circles and dotted lines on the top indicate skipping of previously 
reported exons and/or dotted lines on the bottom indicate a novel splice variant. 
Annealing positions of primers used for MESDA are shown. Sizes of exons and introns 
are not to the scale. (B) Detection of multiple exon skipping events in SMN2 at different 
time points. Livers from 70 mg/kg bw PQ through IP injection were harvested at different 
time intervals post treatment for analysis of transcripts. Time used is given on the top of 
the gel. At different time intervals, first two lanes are male and the rest lanes are female. 
Splice products were analyzed by performing MESDA with radioactive PCR. 
Diagrammatic representation of splice variants is given on the left of the gel; their sizes 
are indicated on the right of the gel with names of skipped exons given in brackets. The 
identity of splice variants was established by sequencing. A pound sign marks novel 
splice variants, submitted to GenBank (Table S1). (C) Bar diagram showing the relative 
abundance of transcripts of FL, Δ7, Δ5, and Δ5,7 as percent of total from (B). (D) Bar 
diagram showing the fold change of mRNA levels of FL, Δ7, Δ5, and Δ5,7 from (B). 
Level of mRNA from 0 hour group was normalized to values of 1. Error bars represent 
standard error. Stars above PQ-treated bars indicate a statistical significance (*, P < 0.05; 
**, P < 0.01). (E) Detection of multiple exon skipping events in SMN2 in the various PQ 
concentration. Livers from a series of PQ concentration through IP injection were 
harvested at 24 h for analysis of transcripts. PQ concentrations are given on the top of the 
gel. At different dose concentrations, first two lanes are male and the rest lanes are 
female. Diagrammatic representation of splice variants is described in Figure 1B. (F) Bar 
diagram showing the relative abundance of transcripts of FL, Δ7, Δ5, and Δ5,7 as percent 
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of total with a dose dependent from (E). (G) Bar diagram showing the fold change of 
mRNA levels of FL, Δ7, Δ5, and Δ5,7 with a dose dependent from (E). Level of mRNA 
from PBS group was normalized to a value of 1. Descriptions of abbreviations are given 
in Supplementary Table S5. 
 
Figure 2. Effect of PQ treatment on splicing of human SMN2 in various tissues. (A) 
Detection of multiple exon skipping events in SMN2 from various tissues in presence of 
PBS and PQ treatment. All tissues from 70 mg/kg bw PQ through IP injection were 
harvested at 24 h for analysis of transcripts. Name of tissues used are give on the top of 
the gel. Splice variants is given on the left of the gel with names. For intra-lane 
comparison of bands, bar diagrams were generated for each lane. Bar diagrams showing 
the relative abundance of transcripts of FL, Δ7, Δ5, and Δ5,7 as percent of total. (B) 
Detection of exon 7, 5 and 3 skipping events in human SMN2 in presence of the PBS and 
PQ. Splice products were analyzed by performing radioactive PCR (Singh et al., 2011). 
Diagrammatic representation of splice variants is same as described in Figure 2A. (C) 
Comparison of different splice variants of SMN2 in different tissues determined by 
qPCR. Circles indicate skipping of previously reported exons. Annealing positions and 
names of primers used for qPCR are shown. Products are indicated with names of 
skipped (Δ) or included (+) exon given. Tissue-specific expression of splice isoforms in 
presence of PBS or PQ treatment. Expression levels relative to PBS treated brain for each 
isoform was normalized to values of 1. Error bars represent standard error. Stars above 
PQ treated bars indicate statistical significance (*, P < 0.05; **, P < 0.01). Descriptions 
of abbreviations are given in Supplementary Table S5. 
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Figure 3. Effect of PQ on splicing of human SMN2 and hybrid Smn in various tissues in 
allele C. (A) Diagrammatic representation of allele C transgene; hybrid Smn followed by 
42 kb SMN2 genomic sequence. The promoter structure of SMN2 and Smn is shown with 
transcription start site (TSS) at the + position and (putative) upstream binding sites for 
different transcription factors. Exons are shown as colored boxes or circles, whereas 
introns are shown as lines/broken lines. Sizes of exons and introns are given and are not 
to the scale. Transcription factor binding elements were identified from published papers 
(Branchu et al., 2013; Echaniz-Laguna et al., 1999; Germain-Desprez et al., 2001; 
Majumder et al., 2004; Martín et al., 2002; Monani et al., 1999; Rouget et al., 2005). (B) 
Detection of multiple exon skipping events in SMN2 from various tissues in presence of 
PBS and PQ treatment. Analysis of splice products and descriptions of diagrammatic 
representation of splice variants were the same as described in Figure 2A. Note that we 
observed the slow migration band containing partial of intron 6 (SMN6B) than FL SMN2. 
Bar diagrams were generated for each lane. Bar diagrams showing the relative abundance 
of transcripts of SMN6B, FL, Δ7, Δ5 and Δ5,7 as percent of total. (C) Detection of 
multiple exon skipping events in hybrid Smn from various tissues in presence of PBS and 
PQ treatment. Analysis of splice products and descriptions of diagrammatic 
representation of splice variants were the same as described in Figure 2A. Note that we 
observed the slow migration band containing partial of intron 6 (Smn6BxΔ7) than FL 
hybrid Smn. Bar diagrams were generated for each lane. Bar diagrams showing the 
relative abundance of transcripts of hybrid Smn6BxΔ7, FL hybrid Smn, and hybrid SmnΔ7 
as percent of total. Descriptions of abbreviations are given in Supplementary Table S5. 
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Figure 4. Effect of PQ on splicing of different SMN2 minigenes. (A) Diagrammatic 
representation of promoter and exon/intron organization in different minigens as 
compared to endogenous SMN2. Promoters, 3XFLAG tag, and exons are shown as boxes 
or circles, whereas introns are indicated as lines/broken lines. Alternatively spliced exons 
3, 5, and 7 are shown as circles. Wild type (WT) refers to the mingene under the control 
of human SMN2 promoter; Smn, minigene under the control of mouse Smn promoter; 
CMV, minigene under the control of CMV promoter. Locations of primer pairs for the 
amplification of spliced products have been marked by arrows. The promoter structure 
and transcription factor binding elements are described in Figure 3A. (B) Detection of 
multiple exons in SMN2 from minigenes derived SMN2 transcripts under control of 
different promoters and their endogenous SMN1/SMN2 transcripts in SH-SY5Y cells 
under normal and OS conditions. Analysis of splice products were the same as described 
in Figure 2A. Bar diagrams showing the relative abundance of transcripts of FL, Δ7, Δ5, 
Δ5,7 and Δ3,7 as percent of total. 
 
Figure 5. Effect of U1snRNP base paring on OS-induced aberrant splicing of exons. (A) 
Nucleotides involved in base paring formed between the 5ʹ′ ss of exons and U1 snRNA 
are indicated by vertical bars. Wobble base pairing are indicated by filled circles. Exons 
are indicated by capital letters, while introns are indicated by small-case letters.  
(Putative) RNA structures are underlined. In vivo exons skipping events in presence of 
PBS (-) and PQ (+) treatment. Splice products were analyzed by performing a PCR. 
Detection of exons included events in the endogenous genes in presence of PBS and PQ 
treatment. Name of genes is given on the top of the gel; their sizes are indicated on the 
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right of the gel. (B) Detection of exons excluded events in the endogenous genes in 
presence of PBS and PQ treatment in vivo. Analysis of splice products were the same as 
described in above. 
 
Figure 6. Effect of PQ treatment on the levels of several proteins in the brain of TG 
mouse. (A) Representative western blots showing the expression levels of SMN 
interaction proteins and splicing regulators in presence of PBS and PQ treatment in TG 
mouse models. We used 30 µg of total protein for each sample. The same membrane was 
stripped and re-probed for evaluating all target proteins. Equal protein loading was 
confirmed by re-probing the blot with anti-β-actin and GAPDH antibodies. Primary 
antibodies used in the blot are indicated on the left of the gel. (B) Bar diagram showing 
average expression level of each target protein, normalized to β-actin. Error bars 
represent standard error. Stars above PQ-treated bars indicate statistical significance (*, 
P< 0.05; **, P< 0.01).  
 
Figure 7. Proteome analysis of control and PQ treated TG brains. (A) Location of target 
proteins is also mentioned in the gels by the arrows. (B) Target proteins that differentially 
expressed in TG mice brain after PQ treatment separated on a 2D-IEF-SDS-PAGE gel 
were identified by MALDI-TOF MS analysis. Target proteins are magnified. Bar 
diagram showing the relative expression of identified proteins in the absence and 
presence of PQ. Error bars represent standard error. Stars above PQ treated bars indicate 
statistical significance (*, P < 0.05). (C) Effect of hnRNP H1 on splicing of SMN exons 
in HeLa cells. Western blot showing levels of hnRNP H1 (i) and in vitro splicing pattern 
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of minigenes (ii), in vivo splicing pattern SMN exon 7 (iii) and all exons (iv) in the 
presence of the overexpressed human hnRNP H1. (D) Time dependent effect of depletion 
of hnRNP H1 in HeLa cells. Western blot showing the effect of the siRNAs on the level 
of corresponding proteins. (E) Time dependent effect of siRNA effect on splicing of 
endogenous SMN exon 7. Spliced products were analyzed by RT-PCR and qPCR. (F) 
Western blot showing the effect of the siRNA on the level of corresponding proteins in 
HeLa cells. (G) Western blot showing the effect of the siRNA on the level of 
corresponding proteins in SH-SY5Y cells. 
 
 
Supplementary Figure Legends 
Figure S1. PQ increased 4-HNE, OS marker. (A) Kaplan-Meier survival analysis of TG 
on time dependent effect of after PQ treatment. (B) (i) Western blot analysis 
demonstrating the expression levels of 4-HNE proteins in control or PQ-treated samples 
with different time point. We used 35 µg of total protein for each sample. (ii) Bar 
diagram showing the expression of 4-HNE proteins for (B (i)). (C) (i) Western blot 
analysis demonstrating the expression levels of pAKT and AKT proteins in control or 
PQ-treated samples. We used 50 µg of total protein for each sample. (ii) Bar diagram 
showing the expression of pAKT/AKT proteins for (C (i)). Antibodies are given on the 
left gel; their sizes are indicated on the right of the gel. The values were normalized 
against β-actin as an endogenous control. Error bars represent standard error. Stars above 
bars indicate a statistical significance  (*, P < 0.05). 
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Figure S2. Effect of PQ treatment on splicing of mouse Smn in various tissues. (A) 
Detection of multiple-exon skipping events in mouse Smn from various tissues in the 
presence of PBS and PQ treatment. Mouse Smn transcripts were amplified using primers 
annealing to exon 1 and exon 8. Name of tissues used are given on the top of the gel. 
Diagrammatic representation of splice variants is same as described in Figure 1. (B) 
Detection of exon 7, 5 and 3 skipping events in mouse Smn in presence of the PBS and 
PQ. Splice products were analyzed by performing radioactive PCR (Singh et al., 2011). 
Name of tissues used are give on the top of the gel. Diagrammatic representation of splice 
variants is given on the left of the gel; their sizes are indicated on the right of the gel. 
Descriptions of abbreviations are given in Supplementary Table S5. 
 
Figure S3. Expression of intron retention in presence of PBS or PQ treatment in brain 
samples. (A) Schematic of specific isoform-targeting primers. Circles indicate skipping 
of previously reported exons. Annealing positions and names of primers used for qPCR 
are shown. cDNA was generated using random primers. Each intron retention was 
amplified using primers 5ʹ′ primer (anneals within exon) and 3ʹ′ primer (anneals intron 
near by 5ʹ′ss). (B) Expression levels relative to PBS each intron was normalized to values 
of 1. Error bars represent standard error. Stars above PQ treated bars indicate statistical 
significance (*, P < 0.05).  
 
Figure S4. Effect of PQ treatment on splicing of human SMN2 and mouse Smn in sex 
organs. (A) Detection of multiple exon skipping events in SMN2 from sex organs in 
presence of PBS and PQ treatment. Analysis of splice products and descriptions of 
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diagrammatic representation of splice variants and bar diagram were described in Figure 
2. (B) Schematic of specific isoform-targeting primers. Circles indicate skipping of 
previously reported exons. Annealing positions and names of primers used for qPCR are 
shown. cDNA was generated using oligo(dT)12-18 primer. Expression of splice isoforms 
in sex organs in presence of PSB or PQ treatment was same as described in Figure 2. (C) 
Detection of multiple exon skipping events in mouse Smn from sex organs in presence of 
PBS and PQ treatment. Descriptions of abbreviations are given in Supplementary Table 
S5. 
 
Figure S5. The relative abundance of SMN2 splice isoforms in different human tissues. 
Top panel, Multiple splice isoforms of endogenous SMN pre-mRNA in different human 
tissues. Name of tissues used are given on the top of the gel. Splice products were 
analyzed by RT-PCR. Bottom panel, Splicing of endogenous SMN exon 7. Spliced 
products were analyzed by RT-PCR. Exon 7-included (+) and exon 7-skipped (-) 
products are indicated on the left of the gel. Based on RT-PCR results, the presence and 
absence of SMN1/SMN2 gene is marked by (+) and (-) respectively.  
 
Figure S6. Alignment of the proximal human (SMN2) and mouse (Smn) promoters. Stars 
annotate sequence identity. Hyphens designate the positions where gaps were introduced 
to maximize sequence identity. The arrow and red color corresponds to the +1 
transcription initiation site for each species. Translation start sites are highlighted with 
blue. Sequence alignment was done using MacVector software. Location numbers are 
relative to the TSS. Putative cis-elements are highlighted. 
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Figure S7. Expression of SMN transcripts derived from SMN2 minigenes in presence of 
PBS or PQ treatment in SH-SY5Y cells. (A) Schematic of specific isoform-targeting 
primers. Annealing positions and names of primers used for qPCR are shown. cDNA was 
generated using random primers. (B) Expression levels relative to WT0.6 was normalized 
to values of 1. Error bars represent standard error. Stars above PQ treated bars indicate 
statistical significance (*, P < 0.05, **, P < 0.01, ***, P < 0.001).  
 
Figure S8. Alignment of the proximal human (SBP2) and mouse (Sbp2) promoters. (A) 
Stars annotate sequence identity. Hyphens designate the positions where gaps were 
introduced to maximize sequence identity. The arrow and red color corresponds to the +1 
TSS for each species. Translation start sites are highlighted with blue. Sequence 
alignment was done using MacVector software. (B) Alignment of exon 3 and flanking 
intronic sequences. Capitalized nucleotides are exon 3. Lowercase is intron. Numbering 
of nucleotide starts -1, 1 and +1 from the beginning of intron 2, exon 3 and intron 3, 
respectively. Light green and light red annotates exon 2A and exon 3B, respectively. 
 
Figure S9. Effect of PQ treatment on alternative splicing of endogenous genes in TG 
brains. (A) Ten consensus sequences associated with exclusion exons identified by 
MEME are shown. The motifs in upstream and in downstream are shown in the left and 
right panels, respectively. Y-axes represent relative frequency. (B) Nine consensus 
sequences associated with inclusion exons identified by MEME are shown. The motifs in 
upstream and in downstream are shown in the upper and lower panels, respectively. Y-
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axes represent relative frequency. Entire exon and 100 nt flanking intronic sequences 
were analyzed. Output shows 4-6 width motif with more than 4 site counts. 
 
Figure S10. Validation of 2D-gel electrophoresis. Expression of mRNA by PQ treated 
brain tissues was measured by qPCR. Error bars represent standard error. Stars above PQ 
treated bars indicate statistical significance (*, P < 0.05).  
 
Figure S11. Design and construction of SMN2WT3.3. SMN2WT3.3 contained 3.3 kb SMN2 
promoter, 3XFLAG, all exons and 3ʹ′UTR. Each fragment is amplified and multiple-step 
PCRs were then performed.   
 
Figure S12. Transient transfection assays of SMN2WT3.3 and mutant CMVW0.1 constructs. 
(A) The human SMN2 promoter is shown with the TSS at the + position and (putative) 
upstream binding sites for different transcription factors. Promoter deletion positions are 
shown. Transcription factor binding elements were identified from published papers 
(Branchu et al., 2013; Echaniz-Laguna et al., 1999; Germain-Desprez et al., 2001; 
Majumder et al., 2004; Martín et al., 2002; Monani et al., 1999; Rouget et al., 2005). (B) 
The sequence 0.1 kb upstream of WT3.3 is highlighted in light blue. (C) Detection of 
multiple exons in SMN2 derived from minigene in SH-SY5Y cells. 
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Figure 1. Time and dose dependent effects of PQ treatment on splicing of SMN2 in 
mouse TG model. 
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Figure 2. Effect of PQ treatment on splicing of human SMN2 in various tissues. 
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Figure 3. Effect of PQ on splicing of human SMN2 and hybrid Smn in various tissues in 
allele C. 
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Figure 4. Effect of PQ on splicing of different SMN2 minigenes. 
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Figure 5. Effect of U1snRNP base paring on OS-induced aberrant splicing of exons. 
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Figure 6. Effect of PQ treatment on the levels of several proteins in the brain of TG 
mouse. 
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Figure 7. Proteome analysis of control and PQ treated TG brains. 
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Table S1. Description and GenBank accession numbers of splice variants reported in this 
study. 
Exon Gene Genotype of Strain GenBank accession number 
Δ3,7 SMN2 Smn+/-;SMN2+/+ KF217140 
Δ3,5,7 SMN2 Smn+/-;SMN2+/+ KF217141 
Δ5,6,7 SMN2 Smn+/-;SMN2+/+ KF217142 
Δ3,4,5,7 SMN2 Smn+/-;SMN2+/+ KF217143 
Δ3,5,6,7 SMN2 Smn+/-;SMN2+/+ KF217144 
Δ3,4,5,6,7 SMN2 Smn+/-;SMN2+/+ KF217145 
 
 
Table S2. A list of altered proteins from PQ treated TG brain.  
 
Mowse: Molecular Weight Search 
 
 
 
 
 
 
 
 
 
 
 
 
Protein ID Mowse 
score 
Mass pI Coverage 
(%) 
Change in 
PQ 
Heterogeneous nuclear 
ribonucleoprotein H1 
120 49454 5.89 8 Down 
Alpha-enolase 1 304 47453 6.37 23 Down 
Lactate dehydrogenase B 83 36834 5.7 7 Up 
Phosphoglyceratemutase 1 50 28928 6.67 4 Up 
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Table S3. List of primers used in this study for PCR. 
No
. 
Name Type Sequence (5ʹ′ to 3ʹ′) Annealing 
site 
1 5SMNE2B Forward GAATACTGCAGCTTCCTTACAA
CAG 
E2B 
2 P2-2 Reverse CTTCCTTTTTTCTTTCCCAACAC E8 
3 3E8-Dde Reverse CTACAACACCCTTCTCACAGCT
C 
E8 
4 5SmnE1 Forward TGGGCAGTGGCGGAGCGGGC E1 
5 3SmnE8 Reverse ACCCCATCTCCTGAGACAGAGC E8 
6 N-24 Forward CCAGATTCTCTTGATGATGCTG
ATGCTTTGGG 
E6 
7 5SmnE6 Forward GAGTGGCTACCACACTGGCTAC E6 
8 3SmnE8 Reverse CACGCTCTGCTGCTGACTTAGG E8 
9 5SMNE4 Forward GGCCAAGACTGGGACCAGG E4 
10 3SMNE6 Reverse CATATAATAGCCAGTATGATAG
CC 
E6 
11 5SmnE4 Forward CGCTCAGAAGTAAAGCACACAG
CAAG 
E4 
12 3SmnE6 Reverse GAGATTAGCATACTGCCCAGGG E6 
13 5SMNE1 Forward GAGCAGCGGCGGCAGTGGTG E1 
14 3SMNE4 Reverse TCACTTTCATCTGTTGAAACTTG
G 
E4 
15 5SmnE1 Forward GTGGCGGAGCGGGCTCCGAG E1 
16 3SmnE4 Reverse CTTGCTGTGTGCTTTACTTCTGA
GCG 
E4 
17 5FLAG Forward GATGACAAGACGCGTGCGAT  
18 5Ex1 Forward CGCGGGTTTGCTATGGCGAT E1 
19 3SMNE8 Reverse TAGTGCTGCTCTATGCCAGCATT
TC 
E8 
20 5Tiar Forward CTCTCCAGAGATGTGACAGAAG
TC 
E2 
21 3Tiar Reverse AATTTCTGGACTCAAATCCCC E5 
22 5Tmem55b Forward GCACCTCCAGGAAAGAAGTATG
TC 
E3 
23 3Tmem55b Reverse CATCGTGCCAAGGTTCGGTC E5 
24 5Tcerg1 Forward CACCCACAACACAAGACCAGAC
C 
E5 
25 3Tcerg1 Reverse CCACTCAGAAACTGCTGTTGCC
C 
E7 
26 5Smarcc2 Forward CCTGGAACAGTGGGGTCTTATT
AAC 
E17 
27 3Smarcc2 Reverse CAGAGTCTCCTGCTCCGTCCATT
C 
E20 
 
 154 
Table S3 continued 
28 5SMNE1 Forward CCAAATCTGCTCCATGGAACTC
TTTTC 
E4 
29 3SMNE4 Reverse GCATCAGCATCATCAAGAGAAT
CTGG 
E6 
30 5Apaf Forward GATGTGAGATCAGCAAACGAGA
GG 
E17 
31 3Apaf Reverse CTAAAGGTGGCCGACTGCAGAG E19 
32 5Tia1 Forward GCCCAAGACTCTATACGTCGG E1 
33 3Tia1 Reverse GGTGCAAACGCTGCTTTGATG E6 
33 5Plod2 Forward CCGATCTGAGATGAATGAAAGG
AAC 
E13 
34 3Plod2 Reverse TGCCAGAAGTCATTGTTAAGAT
GGG 
E15 
35 5Uspl1 Forward GGAGTTCGGGTCCACTG E1 
36 3Uspl1 Reverse CTTGCCTTTCGCTCTACAAG E3 
37 5Atxn2 Forward TCAAGAGCTGCTTCTCACA E9 
38 3Atxn2 Reverse AGGAGCAGCTGCTTCAC E11 
39 5Cftr Forward GTTCTTGGAGAAGGTGGAGTC E11 
40 3Cftr Reverse CAGAGGAATCGTCTACTGAGAA
CC 
E13 
41 
5ʹ′hnRNP H 
Forward ATATATACGCGTATGTTGGGCA
CGGAAGGTGGAG 
MluI 
42 
3′hnRNP H Reverse 
ATATAGTCGACCTATGCAATGT
TTGATTGAAAA TCACTGG 
SalI 
Note: Enzyme sites are in bold and underline. 
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Table S4. List of primers used in this study for SMN2i minigene. 
No. Name Type Sequence (5ʹ′ to 3ʹ′) Enzyme 
1 5FLAG Forward GCATCTCGAGATGGACTACAAAGAC
CATGACGGTGAT 
XhoI 
2 3Ex1 Reverse GAACAGCACGGAATCCTCCTGCT  
3 5Ex1 Forward ATGAGCAGCGGCGGCAGTGGTG  
4 3Int1 Reverse GAAACTTAACGGAGTGGGAAAAGAC
GTAGAAAAAC 
 
5 5Int1 Forward CACTCCGTTAAGTTTCCTGTGGCTTT
ATTTAGGATTT 
 
6 3Int2a Reverse GCACTATACGTACGGAGGATATCAC
CTGATTTAACTAACTC 
BsiWI 
7 5Int2a Forward TATCCTCCGTACGTATAGTGCAGGG
GGTGGTCAAAAGAG 
BsiWI 
8 3Int2b Reverse CTAAATATCCGGAGCATGTTCCTAA
ATAACAGAAAATTTAATAG 
BspEI 
9 5Int2b Forward GAACATGCTCCGGATATTTAGACCC
CAAGCCTTTCTCATTAC 
BspEI 
10 3Int4 Reverse CCAAATCGATATCTATTTTGCATCAT
TATCTTATTTCCTTTTC 
EcoRV 
11 5Int4 Forward CAAAATAGATATCGATTTGGTACAT
GAAATTTCACTTAATC 
EcoRV 
12 3Int5 Reverse AAGACGTTAATTAACAAACAAAACC
CAGAGGTTTAGTTCAAA 
PacI 
13 5Int5  Forward TTGTTTGTTAATTAACGTCTTTGTTT
AGGGGAAAAAAAAGAAAT 
PacI 
14 3Int6b Reverse TTAAGTTGCCTGCAGGTGACAGAGC
GAGACTCCGTCTCAAAAAA 
SbfI 
15 5Int6b  Forward CTCTGTCACCTGCAGGCAACTTAAT
TTCTGATCATATTTTGTTG 
SbfI 
16 5Ex8-st Forward GAAATGCTGGCATAGAGCAGCAC  
17 3Ex8-end Reverse GCATGCGGCCGCACAAAATGCTAT
GGTGGCATCCATATC 
NotI 
18 5CMVpr
om 
Forward GCATAGATCTTCAATATTGGCCATT
AGCCA 
Bglll 
19 3CMVpr
om 
Reverse GCATCTCGAGGATCTGACGGTTCAC
TAAACGAGC 
XhoI 
20 5SMNpr
om 
Forward CTGAAGATCTGGTACCACAAGCCCA
TACCAC 
Bglll 
21 3SMNpr
om 
Reverse GAATCTCGAGATCCCGGGCCCGCGG
GTGCG 
XhoI 
22 5SMNpr
0.7 
Forward GAATAGATCTGCTCGGGAGGTCGAG
GCTGC 
Bglll 
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Table S4 continued 
23 5SMNpr
1.3 
Forward GAATAGATCTCGTGGAGTTAAAAAT
ATATATATACTATG 
Bglll 
24 5Smn-pr Forward GAATAGATCTCTGCAGGCAAGCTCT
CCTCTTTTAG 
Bglll 
25 3Smnpro Reverse GAATCTCGAGGCCTGCTACCACGGA
CGCT 
XhoI 
26 3FLAG Reverse GATCTTTATAATCACCGTCATGGTC  
Note: Enzyme sites are in bold and underline. 
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Table S5. Abbreviations used in this study. 
Abbreviation Full Name 
2D Two-demensional 
BRN Brain 
BW Body weight 
E, Ex Exon 
ENO1 Alpha-enolase 1 
FL Full length 
FVB Friend Virus B-Type 
hnRNP Heterogeneous nuclear ribonucleoprotein  
HRT Heart 
IEF Isoelectric focusing 
In, Int Intron 
IP Intraperitoneal 
ISS-N1 Intronic splicing silencer N1 
KDN Kidney 
LDHB Lactate dehydrogenase B 
LNG Lung 
LVR Liver 
MESDA Multiple exon skipping detect assay 
MSL Muscle 
Mowse Molecular Weight Search 
NTG Non-transgenic 
OS Oxidative stress 
PBS Phosphate buffered saline 
PGAM1 Phosphoglyceratemutase 1 
Pr or Pro Promoter 
PQ Paraquat 
SDS Sodium dodecyl sulface 
SMA Spinal muscular atrophy 
SMN Survival motor neuron (protein) 
Smn Survival motor neuron (mouse gene) 
SMN1 Survival motor neuron 1 (human gene) 
SMN2 Survival motor neuron 2 (human gene) 
SPC Spinal cord 
SS Splice site 
TG Transgenic 
TSS Transcription start site 
TST Testis 
UTR Untranslated region 
UTS/OVR Uterus/ovary 
Δnumber Skipping of exon number 
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Figure S1. PQ increased 4-HNE, OS marker. 
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Figure S2. Effect of PQ treatment on splicing of mouse Smn in various tissues. 
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Figure S3. Expression of intron retention in presence of PBS or PQ treatment in brain 
samples. 
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Figure S4. Effect of PQ treatment on splicing of human SMN2 and mouse Smn in sex 
organs.  
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Figure S5. The relative abundance of SMN2 splice isoforms in different human tissues. 
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Figure S6. Alignment of the proximal human (SMN2) and mouse (Smn) promoters. 
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Figure S7. Expression of SMN transcripts derived from SMN2 minigenes in presence of 
PBS or PQ treatment in SH-SY5Y cells. 
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Figure S8. Alignment of the proximal human (SBP2) and mouse (Sbp2) promoters.  
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Figure S9. Effect of PQ treatment on alternative splicing of endogenous genes in TG 
brains. 
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Figure S10. Validation of 2D-gel electrophoresis. 
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Figure S11. Design and construction of SMN2WT3.3. 
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Figure S12. Transient transfection assays of SMN2WT3.3 and mutant CMVW0.1 constructs. 
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Abstract 
Spinal muscular atrophy (SMA), a leading genetic disease of children and infants, 
is caused by mutations or deletions of Survival Motor Neuron 1 (SMN1) gene. SMN2, a 
nearly identical copy of SMN1, fails to compensate for the loss of SMN1 due to 
overwhelming skipping of exon 7. Both SMN genes contain nine exons (exons 1, 2A, 2B, 
3, 4, 5, 6, 7 and 8) and theoretically code of an identical protein. The major proteins 
generated from SMN1 and SMN2 are SMN and SMNΔ7, respectively. Unlike SMN, 
SMNΔ7 is an unstable protein due to the loss of the sixteen C-terminal amino acids 
(coded by exon 7) accompanied by a gain of four amino acids (EMLA) coded by exon 8. 
We have recently developed a multiple-exon-skipping detection assay (MESDA) to 
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capture the relative abundance of various transcripts generated by SMN. Employing 
MESDA, we have identified a novel splice variant SMN6B that is generated by 
exonization of a portion of intron 6. We term this new exon as 6B that appears to be 
conserved within primates and is generated from the exonization of an Alu-like sequence. 
We analyzed various tissues from a mouse model of SMA to confirm the universal 
expression of SMN6B. Translation of SMN6B generates SMN6B protein in which the 
sixteen C-terminal amino acids coded by exon 7 are replaced by the sixteen C-terminal 
amino acids coded by exon 6B. Despite low abundance of SMN6B transcripts due to 
nonsense-mediated decay, we detect SMN6B protein using polyclonal antibodies. We 
demonstrate that SMN6B interacts with Gemin2, a critical protein associated with most 
functions linked to SMN. Our findings expand the diversity of SMN isoforms and reveal 
an important evolutionary event with significance to a novel function of SMN genes in 
humans.   
 
 
Introduction 
Humans have two nearly identical copies of survival motor neuron genes; SMN1, 
and SMN2 (Lefebvre et al., 1995). Both SMN genes contain 9 exons and code for an 
identical protein, SMN. SMN1 has a full-length transcript, producing full-length SMN 
protein, while SMN2 predominantly generates an exon 7-deleted (Δ7) transcript due to a 
C6U mutation in exon 7, producing mostly SMNΔ7 protein that is highly unstable (Cho 
and Dreyfuss, 2010; Lorson et al., 1999; Vitte et al., 2007). The loss of SMN1 results in 
spinal muscular atrophy (SMA), the second most common lethal autosomal disorder 
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(Pearn, 1978). Supporting the essential role of SMN in vertebrates, loss of Smn in mouse 
is embryonic lethal (Schrank et al., 1997). SMN contains multiple domains including 
nucleic acid binding-, Tudor, Sm binding-, Calpain cleavage, ZPR1 binding-, and 
Gemin2 binding-domains (Cauchi, 2010; Fuentes et al., 2010; Gangwani et al., 2001; 
Lorson and Androphy, 2000; Pellizzoni et al., 2002; Renvoisé et al., 2006; Todd et al., 
2010). Known functions of SMN include snRNP biogenesis , transcription, DNA 
recombination, stress granule formation, signal transduction, vesicular transport, and 
motor neuron trafficking (Battle et al., 2006; Bowerman et al., 2007; Fallini et al., 2011; 
Peter et al., 2011; Rossoll et al., 2002; Strasswimmer et al., 1999; Takaku et al., 2011; 
Winkler et al., 2005; Zou et al., 2011). Given the high degree of conservation of protein 
sequence of vertebrate SMN, it is believed that the SMN functions are conserved in 
vertebrates. Human SMN genes are unique with regards to the splicing regulation of 
various exons (Singh et al., 2012). Potential novel functions of SMN isoforms coded by 
alternative spliced transcripts in humans have not yet been explored.   
We have recently developed a multi-exon-skipping-detection assay (MESDA) to 
capture the relative abundance all possible SMN isoforms in a single reaction (Seo et al., 
2014; Singh et al., 2012). MESDA provides a powerful tool for the identification of yet 
unknown SMN splice variants harboring novel exons. One of the potential sources of 
novel exons are Alu like sequences that are abundantly represented in the human intronic 
sequences and account for ~10% of the human genome (Lander et al., 2001; Li et al., 
2001). Intronic Alu like sequences are known to be recruited in the coding region through 
exonization and ~5% of human alternative exons are derived from Alu-elements (Sorek 
et al., 2002). Because Alu elements are primates specific (Kapitonov and Jurka, 1996; 
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Schmid, 1996), they have played an important role in the evolution of primates. 
However, it remains to be seen if intronic Alu-like sequences of SMN carry any specific 
significance.  
More than 95% of human genes with two or more exons are alternatively spliced 
(Nilsen and Graveley, 2010). Consequences of alternative splicing are insertion/deletion 
of protein domains and alteration of transcript/protein activity/stability (Garcia et al., 
2004; Resch et al., 2004; Xing and Lee, 2007; Xing et al., 2003). Larger than a third of 
alternative splicing events in humans generate premature termination codons (PTCs) in 
mRNA isoforms (Lewis et al., 2003). Transcripts with PTCs are subjected to nonsense-
mediated decay (NMD). As a general rule, a PTCs located more than 50 nucleotides (nt) 
upstream of an exon-exon junction triggers NMD in mammalian cells. However, 
mechanism is not foolproof and variations in NMD mechanisms could be expected 
depending upon the context of the PTC. If the termination codon is downstream of or 
within the 50 nt of the final exon-junction complex, the transcript is translated normally. 
NMD-sensitive transcripts due to retention of SMN intron 3 or a point mutation within 
exon 3 have been reported (Brichta et al., 2008; Setola et al., 2007). Potential for the 
formation of an NMD-prone alternatively spliced transcript of SMN is also likely if an 
intronic Alu-like sequence is exonizationed. However, exonization of an intronic Alu-like 
sequence of SMN has not yet been reported.  
Here, we describe a SMN splice variant generated by exonization of an Alu-like 
sequence within SMN intron 6. We call this new exon and splice variant as 6B and 
SMN6B, respectively. Exon 6B appears to be conserved within primates. We demonstrate 
that SMN6B is universally expressed in all tissues of a transgenic mouse carrying SMN2. 
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We show that SMN6B is degraded by NMD. The residual SMN6B transcripts are 
translated into a stable SMN6B protein. We demonstrate that SMN6B interacts with 
Gemin2, a critical protein associated with most functions linked to SMN. Our finding 
expands the diversity of protein isoforms generated by SMN genes and reveal an 
important evolutionary event with significance to a novel function of SMN genes in 
humans.   
 
 
Results and Discussion 
To examine the tissue-specific splice variants of SMN2, we employed allele C 
model of SMA. Allele C model produces a mild phenotype in the form of the tail and ear 
necrosis (Osborne et al., 2012). Generated on a C57BL/6J background, allele C model 
harbors a full SMN2 gene along with a hybrid Smn gene at the same locus (Figure 1A) 
(Osborne et al., 2012). We used a multiple-exon-skipping detection assay (MESDA) to 
determine the relative abundance of various SMN2 transcripts generated by alternative 
splicing. Since the forward and the reverse primers used in MESDA annealed to exons 
2B and 8, respectively, assay was ideal for capturing splice variants generated by 
exonization of sequences located within introns 3, 4, 5, 6 and 7 (Seo et al., 2014; Singh et 
al., 2012). We observed Δ7 splice variant as the predominant transcript followed by the 
full-length (FL) transcript in all tissues except in testis of allele C mice (Figure 1B). 
Testis of allele C mice showed substantially higher levels of FL transcripts followed by 
Δ5 and Δ7 transcripts. These results are consistent with the reported high expression of 
FL transcripts in testis of other mouse models. During our investigation of the relative 
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abundance of various SMN2 splice variants in allele C model, we serendipitously 
discovered a noticeable expression of a large transcript (see 883-nt band in Figure 1B) in 
both non-neuronal and neuronal tissues. We cloned and sequenced this transcript that was 
found to contain a novel 109-nt long exon that we term exon 6B. We call this new 
transcript as SMN6B. Insertion of exon 6B into FL transcripts was a consequence of 
exonization of a 109 nt long sequence of intron 6 (Figure 1C). Except in testis, levels of 
SMN6B transcripts in other tissues were comparable to that of FL transcripts (Figure 1B). 
In testis, levels of SMN6B transcripts were lower than the FL transcripts.  
To validate the expression of SMN6B in human cells, we used commercially 
available and widely utilized type I SMA patient fibroblasts (Singh et al., 2012). We 
performed PCR using primers that anneal to exons 6 and 8 respectively (Figure 2A). We 
observed two major bands and one slow running faint band (Figure 2B; lane 1). The two 
major bands corresponded to FL and Δ7 transcripts, respectively. The slow migrating 
faint band corresponded to SMN6B transcripts. We also confirmed exon 6B inclusion 
using additional primer combinations (Figure 2B: lanes 2 and 3). Results of qPCR 
showed that SMN6B transcripts are ~20 times less abundant than FL transcripts (Figure 
2C).  
Alternative splicing of any of the known exons of SMN2 does not create a PTC 
because all SMN2 exons are divisible by three. However, inclusion of exon 6B inserts a 
PTC after the 16th amino acid and makes SMN6B transcript a likely substrate of NMD 
(Figure 1C). NMD is a translation dependent process and inhibition of translation has 
been known to increases the stability of the PTC-bearing transcripts (Stalder and 
Mühlemann, 2008). To confirm that SMN6B transcripts are prone to NMD, we treated 
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SMA patient cells with cycloheximde (CHX; a translation inhibitor) and determined SMN 
transcripts by RT-PCR and MESDA. We observed a small but noticeable increase in 6B-
containing transcripts in CHX-treated cells (Figures 2D and 2E). These results support 
the role of NMD in downregulation of SMN6B transcripts.  
To determine if SMN6B is translated, we overexpressed SMN6B transcripts using 
a mammalian expression vector harboring the complete coding sequence of SMN6B and 
3ʹ′ untranslated region (UTR) (Figure 3A). For detection purposes, we inserted 3XFLAG 
tag at the N-terminus of protein. As a control, we used 3XFLAG tagged SMN and 
SMNΔ7 expressing vectors. All transfection experiments were done under similar 
conditions employing identical concentrations of expression vectors as well as equal 
number of cells. The goal was to determine the relative expression of SMN isoforms with 
variable C-terminal residues. SMNΔ7 is known to have poor stability due to the presence 
of a degron signal at the C-terminus (Cho and Dreyfuss, 2010). Consistently, we 
observed low expression of SMNΔ7 compared to SMN (Figure 3B).  Expression of 
SMN6B was comparable to that of SMN, suggesting that the presence of the C-terminal 
16 amino acids coded by exon 6B has a stabilizing effect similar to that of the C-terminal 
16 amino acids coded by exon 7 (Figure 3B). Our conclusions are based on the fact that 
SMN and SMN6B transcript levels are comparable and SMN6B transcript generated by 
cDNA clone is not degraded by NMD. However, interpretations would change if a high 
expression of SMN6B is maintained despite low levels of SMN6B transcripts due to 
likely degradation by NMD. In this scenario, we would conclude that the exon 6B-coded 
polypeptide sequence has a stabilizing effect than the exon 7-coded polypeptide 
sequence.  
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To examine the expression of endogenous SMN6B, we raised mouse polyclonal 
antibodies against the peptide encoded by exon 6B  (TGFHCVSQDGLNLLTP). We refer 
this 6B-specific antibody as anti-6B-001. After tittering of anti-6B-001, we tested 
endogenous SMN6B with the lysate from SH-SY5Y cells that carry both SMN1 and 
SMN2. Non-immune mouse sera were used as a negative control for anti-6B-001 (Figure 
3C). The anti-6B-001 detected both, FLAG-SMN6B as well as endogenous SMN6B 
(Figure 3D). However, expression of endogenous SMN6B was low due to low levels of 
SMN6B transcripts. Further analysis will be needed to determine SMN6B protein levels 
in various tissues and cell types using anti-6B-001. Findings of such studies might 
provide insight into the function(s) of SMN6B. We analyzed human genome to determine 
if there are other proteins that harbor motifs similar to the 16 amino acids coded by exon 
6B. We were able to identify two genes, PRO2822 [GenBank: AAF69654.1] and 
hCH1747827 [GenBank: EAW53691.1], with potential to code for the first 15 amino acid 
residues of SMN exon 6B. However, functions of these genes are not known.  
The SMN-Gemin2 interaction has been linked to several SMN functions 
including small nuclear ribobucleoprotein (snRNP) biogenesis (Zhang et al., 2011), 
signal recognition particle biogenesis (Piazzon et al., 2013), DNA recombination (Takaku 
et al., 2011) and translation regulation (Sanchez et al., 2013). Moreover, SMN co-
localizes with Gemin2 in motor neuron axons indicating that these complexes have a role 
in motor neuron trafficking of mRNAs (Fallini et al., 2011). To test whether SMN6B 
interacts with Gemin2, we transiently transfected HeLa cells with FLAG-SMN6B. As a 
positive control, we performed a parallel experiment with FLAG-SMN. As a negative 
control, we included a side-by-side experiment with FLAG-hnRNP A1. Universally 
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expressed hnRNP A1 does not interact with either SMN or Gemin2. Total cell lysates 
were used for immunoprecipitation with anti-FLAG antibodies, and bound proteins were 
analyzed by western blotting. As shown in Figure 4, both FLAG-SMN and FLAG-
SMN6B pulled Gemin2, suggesting that SMN6B is functionally equivalent to SMN. 
Underscoring the specificity of interaction between SMN/SMN6B with Gemin2, FLAG-
hnRNP A1 did not pull Gemin2. Due to low expression of endogenous SMN6B and poor 
reactivity of antibody against SMN6B, we were unable to detect SMN6B pulled by 
FLAG-SMN. YG domain coded by exon 6 is the most conserved motif of SMN from 
yeast to humans (Figure S1). YG domain has been linked to self-association of SMN as 
well as interaction of SMN with Gemin3 and ZPR1. Considering YG domain is retained 
within SMN6B, we believe that SMN6B interacts with SMN, Gemin3 and ZPR1.  
To assess the mechanism of exon 6B insertion into SMN6B transcript, we 
analyzed repetitive DNA elements in SMN intron 6 of different species using MacVector, 
Dfam and RepeatMasker program (Figure S2). Our analysis showed that human SMN 
intron 6 has a very high content of Alu repeat sequences (12 Alu elements, which 
represents 62.13% of intron 6). Our analysis also suggested that insertion of exon 6B is 
the result of an exonization of a part of an AluSc8 like element that is present in the 
antisense orientation (Figure S2A). In order to determine the origin of exon 6B, we 
analyzed SMN intron 6 of different species including primates (Figure S2B). We 
observed the presence of exon 6B in all members of the Hominidae (Homo sapiens, Pan 
troglodytes, Pongo abelii and Macaca mulatta). Our results uncovers for the first time the 
role of an Alu-like sequence in generation of a novel splice isoform with significance to 
SMN protein stability. Previous study has shown two Alu elements in introns 4 and 6 and 
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that these Alu elements mediated deletion of intervening sequences of SMN1 in two type 
I SMA patients (Wirth et al., 1999). It has been suggested that Alu elements in 3ʹ′UTRs of 
mRNAs provide targets for microRNAs (Smalheiser and Torvik, 2006). Indeed, insertion 
of exon 6B into mRNA generates an altered 3ʹ′UTR that includes part of exon 6B, entire 
exons 7 and 8 (Figure S1B). This new 3ʹ′UTR is sufficient to change the regulation of 
expression of SMN6B compared to the regulation of SMN expression. However, 
mechanism by which microRNAs affect SMN expression through interaction with 3ʹ′UTR 
is poorly understood. Interestingly, inclusion of exon 6B combined with the skipping of 
exon 7 will generate SMN6BΔ7 transcripts with capability to produce SMN6B protein. In 
fact, we detected SMN6BΔ7 transcripts expressed in neuronal SH-SY5Y cells (Figure 
S3). It remains to be seen if different 3ʹ′UTRs of SMN6B and SMN6BΔ7 transcripts 
contribute differently to the expression of SMN6B protein.  
 
 
Conclusions 
SMA is a disease of wide spectrum ranging from infant mortality to adult onset 
(Howell et al., 2014). Severity of disease correlates with SMN2 copy number. A high 
SMN2 copy number reduces severity due to increase in the cumulative levels SMN and 
SMNΔ7 (Parsons et al., 1998; Tiziano et al., 2007; Wirth et al., 2006). Earlier finding that 
overexpression of SMNΔ7 delays disease onset and increases lifespan of a severe mouse 
model of SMA suggests that SMN stabilizes SMNΔ7 protein (Le et al., 2005). Our 
finding of SMN6B as a stable and functional protein suggests a similar stabilizing and 
disease-modifying role of SMN6B. Genetic mutations and/or expression of splicing 
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factors regulating the expression of exon 6B-containing SMN transcripts will also serve 
as the additional modulating factors of disease severity. Now that we have uncovered 
SMN6B and SMN6BΔ7 as novel transcripts capable of making a functional protein, future 
studies will determine if these transcripts have other functions unique to humans.   
 
 
Materials and Methods 
Animals 
All experiments with mice and experimental procedures were approved and monitored by 
the Institutional Animal Care and Use Committee at Iowa State University (Ames, IA, 
USA). The mice were housed in standard conditions: constant temperature (22 ± 1 °C), 
humidity (relative, 30%) and a 12 h light/dark cycle, where they were monitored daily for 
health. All mice had free access to food and water. Allele C mice with C57BL/6J 
background (SmnC/C, C is defined by a chimeric gene plus SMN2), were generated from 
breeding pairs obtained from Jackson Laboratory (Osborne et al., 2012). Mice were 
anaesthetized using isoflurane and then sacrificed by means of cervical dislocation. The 
tissues including brain, heart, kidney, liver, lung, muscle, spinal cord and testis were 
dissected out carefully, flash-frozen immediately in liquid nitrogen or dry ice and stored 
at -80°C for further analysis.   
 
Cell culture and treatment  
All tissue culture media and supplies were purchased from Life Technologies. Primary 
patient fibroblasts were obtained from Coriell Cell Repositories. Primary fibroblasts were 
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grown in MEM (catalog, #10370) supplemented with 2 mM GlutaMAX-I and 15% fetal 
bovine serum (FBS). Human neuroblastoam SH-SY5Y cells were cultured in 1:1 mixture 
of Minimum Essential Medium (MEM, catalog #11095) and F12 medium supplemented 
with 10% FBS. HeLa cells were grown in Dulbecco’s Modified Eagle’s medium 
supplemented with 10% FBS. HeLa cells were plated at a density of ~0.4x106 cells per 
one well of a 6-well plate. Next day the cells were transfected with 2 µg of each plasmid 
using X-tremeGENE following the manufacturer’s recommendations. Twenty-four hours 
post transfection, cells in each well were collected for cell lysates. 
CHX was obtained from Sigma. CHX treatment of pre-plated adherent cells was 
performed as follows: 18 h before the treatment, patient fibroblasts were plated at a 
density of 6.2x105 cells in 100 mm dish and SH-SY5Y cells were plated at a density of 
~2x105 cells per well of 6-well plates. CHX was added at the indicated final 
concentrations. Following 24 h and 6 h treatments, respectively, cells were collected for 
total RNAs preparation.  
 
RT-PCR  
Total RNAs were isolated from mouse tissues using Trizol reagent (Life Technologies) 
following the manufacturer’s recommendations. RNAs were subjected to DNase 
digestion using RQ1 RNase-free DNase (Promega). DNase-treated RNAs were then 
further purified using a QiagenRNeasy Mini RNA purification kit or phenol:chloroform 
extraction followed by ethanol precipitation. RNAs concentration was determined by a 
NanoDrop spectrophotometer (Thermo Scientific). To generate cDNA, reverse 
transcription (RT) was carried out using a SuperScript III (Life Technologies) following 
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the manufacturer’s recommendations. For cDNA synthesis gene-specific 3E8-Dde 
(anneals to exon 8) were employed. Generally, 1.6 µg of total RNA was used per 10 µl 
RT reaction for mouse tissues and 1.2 µg of total RNAs was used per 10 µl of RT 
reaction for immortalized human cells. One or two microliter of cDNA was used as a 
template in a 25 µl PCR reaction. MESDA was performed as previously described (Seo 
et al., 2014; Singh et al., 2012). In all cases PCR products were resolved on a 5.3% native 
polyacrylamide gel. Analysis and quantifications of splice products were performed using 
a FPL-5000 Image Reader and Multi Gauge software (Fuji Photo Film Inc). All primer 
sequences used in RT-PCR are given in Table 1. 
 
Quantitative real-time PCR (qPCR) 
For cDNA synthesis, 1.2 µg of total RNA was used per 10 µl of RT reaction. cDNA was 
generated using oligo(dT)12-18 primer. All PCR reactions were used FastStart Universal 
SYBR Green Master (ROX) and performed in 96-well plates using the StratageneMxPro 
3005P. Each RT reaction was then diluted 1:20 and 1.5µl was used as a template in the 
final volume of 20 µl PCR reaction that contained 300 nM concentration of each primer. 
For negative controls, cDNA was synthesized in the absence of RTase during PCR 
amplification or nuclease-free water was used instead of cDNA samples. The primer sets 
for each assay were designed to anneal to specific exon and exon-exon junctions to 
distinguish different spliced isoforms and to avoid amplification of genomic DNA. The 
amplicon sizes were below 200 bp (85-172 bp). In all cases there were 3 biological 
replicates amplified in technical triplicates. For normalization, we used Glyceraldehyde-
 183 
3-Phosphate Dehydrogenase (GAPDH) amplified using primers 5GAPDH and 3GAPDH 
(reference gene). All primer sequences used in qPCR are given in Table 1. 
 
Identification of SMN spliced isoforms  
Endogenous SMN spliced products were amplified using primers P1 and P2, which 
anneals to exons 6 and 8 respectively. PCR amplification was performed Taq DNA 
polymerase (New England Biolabs) following the manufacturer’s recommendations for 
30 cycles. PCR products were cloned in a pGEM-T easy vector following the 
manufacturer’s recommendations (Promega). Recombinant clones were identified by 
white/blue colony screening on indicator plates. Colonies were randomly selected from 
the plates and were purified using QIAprepSpin Miniprep Kit (Qiagen). Purified plasmids 
were sequenced in DNA facility in Iowa State University.  
 
Generation of polyclonal antibodies (anti-6B-001) 
A seventeen amino acid long 6B polypeptide (C-TGFHCVSQDGLNLLTP) was 
commercially synthesized at the protein core facility of Iowa State University. A cysteine 
was added toward the N-terminus of the synthetic peptide for conjugation with keyhole 
limpet haemocyanin (KLH). The 6B polypeptide was then conjugated to KLH using 
ImjectTM Maleimide-Activated mcKLH Spin Kit (Thermo Scientific). Mice were injected 
with 25 µg of KLH-linked 6B polypeptide by intraperitoneal (IP) route on days 1, 14 and 
28 days followed by a bleed on day 42. At this time the sera was tested for 
immunogenicity and found to have a low response. A fourth injection was then 
administered, followed by a second bleed 14 days later. The sera was then retested and 
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found to have a high enough response (1:500). Mice were then primed using Pristane 
(Sigma), and after 5 days administered an IP injection of SP2/O cells. After 10 days, mice 
were euthanized and polyclonal fluids were collected. 
 
Western blot analysis  
Whole-cell extracts from HeLa were prepared using ice-cold RIPA buffer (Boston 
BioProducts) supplemented with HALT Protease Inhibitor Single-Use cocktail (Thermo 
Scientific). The lysate was kept on ice for 30 min and cleared by centrifugation at 12,000 
rpm for 10 min at 4 °C. The supernatant was collected and protein concentration was 
determined using Bradford protein assay (Bio-Rad). Protein samples were resolved on an 
11% SDS-polyacrylamide gel electrophoresis. The separated proteins were transferred on 
polyvinylidene fluoride membrane (Bio Trace PVDF, Pall Life Sciences) using Transfer-
Blot fast (Bio-Rad) for 10 min at 1.3 A. The membrane was blocked with 5% nonfat 
dried milk in 0.05% Tween-20 in Tris-buffered saline (TBST) with shaking at a room 
temperature for 1 h and then probed using monoclonal anti-SMN (1:2,000, BD 
Transduction Laboratories) in the above blocking solution with agitation at 4 °C 
overnight. Membranes were rinsed in TBST for four times for 10 min with shaking at 
room temperature. The membrane was incubated with horseradish-peroxidase-conjugated 
anti-mouse antibody (1:4,000, Jackson Immuno Research) in the blocking solution with 
shaking for 1h at room temperature. After washing, the membranes was treated with 
SuperSignal West Dura Extended Duration Substrate or SuperSignal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific) at room temperature for 5 min. The 
membranes were scanned using a UVP BioSpectrum AC Imaging System (UVP) 
 185 
attached to FI-26x and Biochemi Camera. Densitometry measurements were done using 
Multi Guage software. After imaging, membranes were stripped using western blot 
Stripping Buffer (Thermo Scientific) for 15 min at room temperature with agitation. The 
membrane was washed four times with 1X TBST for 5 min each. The membrane was re-
proved with rabbit polyclonal anti-β-Actin (1:2,000, Sigma-Aldrich) followed by 
secondary anti-rabbit (1:2,000, GE Healthcare). For a novel SMN protein, SMN6B, anti-
peptide mouse polyclonal antibodies against the exon 6B (anti-6B-001) were prepared by 
Hybridoma facility in Iowa State University. The antibody was used at 1:500 dilution 
followed by secondary anti-mouse antibody as described above. 
 
Affinity purification of 3XFLAG protein complexes 
HeLa cells were reverse transfected with human mammalian expression vectors: 
3XFLAG-SMN, 3XFLAG-SMN6B or 3XFLAG-hnRNP A1, using Lipofectamine-2000. 
Plasmid-Lipofectamine-2000 complexes were prepared following the manufacturer’s 
suggestions. Each complex was then combined with HeLa cell suspension containing 
∼1.38×107 cells in a total volume of 20 ml, and the cells were plated in two 100 mm 
dishes. 20 µg of each vector was used per dish. ~6 hours later the medium was changed. 
~24 hours post transfection, HeLa cells were washed with ice-cold PBS three times and 
collected by scraping. Cell pellets were snap-frozen in liquid nitrogen and moved to -80 
°C for storage until further usage for preparation of whole-cell lysates. To prepare 
lysates, pellets were re-suspended in NP-40 buffer (20 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% NP-40) supplemented with HALT Protease Inhibitor Single-Use cocktail. The 
cells were lysed on ice for 30 min, the lysates were then centrifuged at 13,000 rpm for 20 
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min to remove cell debris. After centrifugation the supernatants were added to anti-FLAG 
beads (Sigma) equilibrated with NP-40 buffer (1 mg of total proteins was used for each 
sample) and incubated with them [beads] for 2 hour 30 with gentle mixing at 4 °C. 
Following the incubation the beads were washed three times: first time with high salt 
buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.02% NP-40) followed by two washes 
with NP-40 buffer. After the washes bound protein complexes were eluted with NP-40 
buffer containing 0.25 mg/ml FLAG peptide (Sigma) for 1 hour at 8 °C and analyzed by 
SDS-PAGE on 11% polyacrylamide gels. 
 
Statistical analysis  
Relative quantities with standard deviations were calculated by using ΔΔCT method by 
Excel (Microsoft Office 2011 edition). Data were expressed as mean ± standard error of 
the mean (SEM). Statistical analyses were performed using the unpaired Student’s t-test. 
Unless otherwise mentioned, P values were two-tailed and the level of statistical 
significance was set at P < 0.05.  
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Figure Legends 
Figure 1. Splicing of human SMN2 in various allele C tissues. (A) Diagrammatic 
representation of allele C transgene; hybrid Smn followed by 42 kb SMN2 genomic 
sequence. Exons are shown as colored boxes or circles, whereas introns are shown as 
lines (not to the scale). Sizes of exons and introns are given. (B) Detection of multiple 
exon skipping events in SMN2 from various mouse tissue. Splice products were analyzed 
by performing MESDA with trace amount of 32P. Name of tissues used are give on the 
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top of the gel. Splice variants are indicated on the left of the gel; their sizes are indicated 
on the right of the gel with names given in brackets. The identity of splice variants was 
established by sequencing. A pound sign marks a novel splice variant [GenBank: 
KJ780720]. (C) Sequencing result of SMN6B. Numbering of nt starts from the beginning 
of intron 6. Exon 6B is highlighted. Abbreviations, E, exon; FL, full-length; In, intron; 
BRN, brain; HRT, heart; KDN, kidney; LVR, liver; LNG, lung; MSL, muscle; SPC, 
spinal cord; TST, testis. 
 
Figure 2. Regulation of exon 6B transcripts. (A) Diagrammatic representation of 
exon/intron organization of human SMN2. Exonic sequences are shown as colored boxes 
and intronic sequences are shown as lines/broken lines. Sizes of exons and introns are 
given. Location of primers (P1 to P5) used for amplification of endogenous exon 6B 
transcripts are indicated. (B) Detection of endogenous exon 6B in GM03813 cell line 
(primary SMA patient fibroblasts). A combination of primers used is given on the top of 
the gel. PCR products are indicated as described in Figure 1B. The identity of PCR 
products was established by sequencing. (C) Expression levels of endogenous exon 6B-
containing transcripts determined by qPCR. (D) Detection of endogenous exon 6B-
containing transcripts in the absence (-) and presence (+) of 50 µg/ml of CHX for 24 h. 
The sizes of PCR products are indicated the right of the gel. (E) Detection of multiple 
exon skipping events in SMN2 from GM03813 cell lines in the absence (-) and presence 
(+) of CHX. We used same cDNA as in (D). MESDA products are described in Figure 
1B. A pound key refers to a novel splice variant. FL, full-length. 
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Figure 3. The expression of SMN6B. (A) Diagrammatic representation of exon 
organization of SMN6B, SMN and SMNΔ7 sequences, cloned into protein expression 
vectors. 3XFLAG tag, exonic sequences and 3ʹ′UTR are shown as colored boxes and an 
exon 7 deletion is shown as a broken line. The positions of a stop codon as well as 
protein molecular weights are shown. (B) Western blot showing translated products 
generated from protein expression vectors. HeLa cells were transfected with 2 µg of each 
plasmid: 3XFLAG-SMN6B, 3XFLAG-SMN and 3XFALG-SMNΔ7. Twenty 
micrograms of proteins were loaded per each lane. Primary antibodies used for probing 
are indicated on the right of the gel. Names of overexpressed SMN isoforms are given on 
the top of the gel. Anti β-Actin antibody was used as a loading control. (C) Western blot 
with non-immune mouse serum. Fifty micrograms of protein were loaded. We used 
overexpression of SMN6B as a positive control. The molecular weight is indicated on the 
left of the gel. The antibody dilution and exposure time are shown. (D) Detection of 
endogenous SMN6B protein. Endogenous SMN6B is detected with anti-6B-001, which 
recognizes exon 6B peptide (TGFHCVSQDGLNLLTP). 
 
Figure 4. Interaction SMN6B with Gemin2. HeLa cells were transiently transfected with 
a pCI vector encoding FLAG-SMN, FLAG-SMN6B, or FLAG-hnRNP A1 (a negative 
control). Total extracts were prepared and used for immunoprecipitation with anti-FLAG 
antibodies. Proteins bound to the FLAG constructs were analyzed by western blotting 
with antibodies indicated on the right. Total represents of 10% of the extract used for the 
immunoprecipitation. 
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Supplementary Figure Legends 
Figure S1. Description of transcripts and protein encoded SMN and SMN6B. (A) 
Diagrammatic representation of the full-length transcript and the full-length protein 
derived from SMN. Exons are presented as colored boxes with the number of amino acids 
noted within each box. Arrows indicate locations of the start codon, stop codon and 
amino acids derived from exon 7. Corresponding protein domains and their functions are 
indicated. (B) Diagrammatic representation of the SMN6B transcript and the SMN6B 
protein derived from SMN6B. Arrows indicate locations of the start and stop codons as 
well as amino acids derived from exon 6B. (C) Amino acids sequences from the start and 
stop codons. Sequences were aligned by ClustalW using MacVector software. Human 
exons are presented on the top of human sequences. GenBank accession numbers are 
shown at the end of the sequences. 
 
Figure S2. Alignment of SMN intron 6 region spanning the AluSc8 insertion of different 
species. (A) Stars and boxes annotate sequence identity and exon 6B, respectively. The 
arrow corresponds to the position of mutation that caused exonization of intron 6. AluSc8 
sequences (reverse and complement) are obtained from Dfam. (B) Boxes indicate exon 
6B. GenBank accession numbers are shown at the end of the sequences. Hyphens 
designate the positions where gaps were introduced to maximize sequence identity. The 
+1 nucleotide shown for each species corresponds to the first nt intron 6. Sequence 
alignment was done by ClustalW using MacVector software. 
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Figure S3. SMN isoform exon 6B-containing transcripts. (A) Diagrammatic 
representation of exon/intron organization of C-terminal SMN. Exonic sequences are 
shown as colored boxes and intronic sequences are shown as lines/broken lines. Sizes of 
exons and introns are given. Annealing positions of primers used for amplification of 
endogenous exon 6B-containing transcripts are shown as arrows. (B) Detection of 
endogenous 6B-containing transcripts in the absence (-) and presence (+) of 20 µg/ml 
CHX for 6 h in SH-SY5Y cells. The sizes of PCR products are indicated on the right of 
the gel. The identity of PCR products was established by sequencing. NS, non-specific.  
 
 
Table 1. List of primers used in this study. 
No. Name Type Sequence (5ʹ′ to 3ʹ′) Annealing 
site 
Primers for PCR 
1 P0 Forward GAATACTGCAGCTTCCTTACAAC
AG 
E2B, Fig.1 
2 P2 Reverse CTTCCTTTTTTCTTTCCCAACAC E8, Fig.1 
3 3E8-Dde Reverse CTACAACACCCTTCTCACAGCTC E8, RT 
4 P1 Forward CCAGATTCTCTTGATGATGCTGA
TGCTTTGGG 
E6, Fig.2 
5 P3 Reverse GATCACGGGGTCAGGAGATTGA
G 
E6B, Fig.2 
6 P4 Forward CTCAATCTCCTGACCCCGTGATC E6B, Fig.2 
7 P5 Reverse GCATAAGCTTTCCTTAATTTAAGG
AATGTGAGC 
E7-HindIII, 
Fig.2 
Primers for qPCR 
8 5E6 Forward CCTCCCATATGTCCAGATTCTC E6, Fig.2 
9 3E67 Reverse CTTTTTGATTTTGTCTAAAACCC
ATATAAT 
Jxn E6/E7, 
Fig.2 
10 3E66B Reverse CTAACACAGTGAAACCCTGTCA
TATAAT 
Jxn E6/E6B, 
Fig.2 
11 5GAPDH Forward AACAGCGACACCCACTCCTC Fig.2 
12 3GAPDH Reverse CATACCAGGAAATGAGCTTGAC
AA 
Fig.2 
Abbreviations, E, Exon; Jxn, Junction; Extra sequences are shown in Italic; junction sites 
are in bold.  
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Figure 1. Splicing of human SMN2 in various allele C tissues 
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Figure 2. Regulation of exon 6B transcripts. 
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Figure 3. The expression of SMN6B. 
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Figure 4. Interaction SMN6B with Gemin2. 
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Figure S1. Description of transcripts and protein encoded SMN and SMN6B. 
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Figure S2. Alignment of SMN intron 6 region spanning the AluSc8 insertion of different 
species. 
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Figure S3. SMN isoform exon 6B-containing transcripts. 
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CHAPTER 5. GENERAL CONCLUSIONS 
Humans carry two near identical copies of Survival Motor Neuron gene: SMN1 
and SMN2. Deletion or a mutation(s) of SMN1 coupled with the predominant skipping of 
SMN2 exon 7 causes SMA, the most frequent genetic cause of infant mortality. 
Correction of SMN2 exon 7 splicing holds the promise for cure. Hence it is crucial to 
understand the regulation of SMN2 splicing and function of SMN isoforms. After 
screening several patient cell lines derived from various diseases, including SMA, 
Alzheimer’s disease, Parkinson’s disease and Batten disease, we reported a Batten 
disease cell line that lacks SMN2. Cell lines that lack functional SMN1 (SMA patient cells) 
and SMN2 (Batten disease cells), respectively, provide a powerful tool to examine pre-
mRNA splicing of SMN (Chapter 2). In addition, we employ a healthy carrier SMA 
mouse and a mild allele C SMA mouse model for in vivo study (Chapter 3).  
In Chapter 2, we describe an improved method of detection of relative abundance 
of various transcripts generated by SMN. Employing MESDA, we observed surprising 
diversity of splice isoforms from SMN including deletion of exon 4 and co-skipping of 
three adjacent exons. We observed vulnerability of various SMN2 exons to skipping 
under conditions of OS. We also observe OS induced skipping of SMN1 exon 5 in several 
cell types, including non-neuronal cells. Moreover, we demonstrate that depletion of 
SMN2 exon 7 induced by OS is modulated by a combinatorial control including promoter 
sequence, endogenous context, and the weak splice sites. In addition, we observed that an 
8-mer antisense oligonucleotide targeting a GC-rich sequence prevents SMN2 exon 7 
skipping under the conditions of OS. 
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 In Chapter 3, we describe OS-induced splicing regulation of various SMN2 exons 
in different tissues of normal (TG) and mild SMA (allele C) mouse models. We observed 
unique tissue-specific signatures and profound differences between male and female 
reproductive organs with respect to the SMN2 splice isoforms generated under OS. We 
generated a minigene harboring SMN2 promoter, all internal exons and flanking intronic 
regions to study the effect of SMN2 promoter on regulation of alternative splicing of 
various SMN2 exons. Employing this minigene, we demonstrate transcription-coupled 
splicing regulation of various SMN2 exons under normal and OS conditions. In addition, 
we demonstrate that hnRNP H as a positive regulator of SMN levels. 
In Chapter 4, we characterize a novel splice variant SMN6B that is generated by 
incorporation of a portion of SMN intron 6. Exon 6B appears to be conserved within 
primates and is generated from the exonization of an Alu-like sequence. We demonstrate 
that SMN6B is expressed in all cell types, but its low abundance is due to NMD. 
Furthermore, we report that SMN6B protein is detected by polyclonal antibodies that we 
generated. We also demonstrate that SMN6B interacts with Gemin2, a critical SMN-
interacting partner.  
Taken together, a number of important observations from the three investigations 
described in Chapter 2, 3 and 4 expand the diversity of protein isoforms generated by 
SMN and bring new insight into our understanding of splicing regulation of SMN. 
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Abstract 
The dynamic process of pre-mRNA splicing is regulated by combinatorial control 
exerted by overlapping cis-elements that are unique to every exon and its flanking 
intronic sequences. Splicing cis-elements are usually 4–8-nucleotide-long linear motifs 
that furnish interaction sites for specific proteins. Secondary and higher-order RNA 
structures exert an additional layer of control by providing accessibility to cis-elements. 
Antisense oligonucleotides (ASOs) that block splicing cis-elements and/or affect RNA 
structure have been shown to modulate alternative splicing in vivo. Consistently, ASO-
based strategies have emerged as a powerful tool for therapeutic manipulation of aberrant 
splicing in pathological conditions. Here we describe the application of an ASO-based 
approach for the enhanced production of the full-length mRNA of SMN2 in spinal 
muscular atrophy patient cells. 
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Phosphorothioate, 2′-O-methyl modification, Transfection 
 
 
1. Introduction 
Pre-mRNA splicing is modulated by a strict code of conduct in which overlapping 
regulatory sequences that are known as exonic or intronic splicing enhancers (ESEs or 
ISEs) and silencers (ESSs or ISSs) play an important role [1-3]. While enhancer and 
silencer motifs promote or suppress splice-site (ss) selection, respectively, they do so 
under the influence of unique contexts furnished by varying sizes of introns and exons. 
RNA structure provides an additional layer of control by positioning and/or sequestering 
splicing cis-elements [4-6]. Current methods do not reliably predict the functional 
significance of every splicing cis-element in the context of endogenous gene. This is in 
part due to coupling of pre-mRNA splicing with transcription, which is in turn controlled 
by DNA modifying and chromatin remodeling factors [7]. The antisense oligonucleotide 
(ASO)-based approach is one of a few strategies that could be applied to assess the 
impact of a splicing cis-element in the context of the endogenous gene [8-11]. The ability 
of an ASO-based approach to selectively remove or incorporate a particular exon 
provides a promising means to enrich a splice variant from a specific gene. Therefore, 
manipulation of protein levels through ASO-based splicing modulation has been 
considered as potential therapy for several human diseases [12]. The ASO-based strategy 
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is also useful for uncovering the position specific role of residues associated with long-
distance RNA:RNA interactions [13]. 
Here we describe an example of ASO-mediated splicing correction in spinal 
muscular atrophy (SMA), a leading genetic cause of infant mortality [14]. SMA is caused 
by the loss of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of 
SMN1, fails to compensate for the loss of SMN1 due to predominant skipping of SMN2 
exon 7. Our earlier finding of intronic splicing silencer N1 (ISS-N1) has recently 
emerged as the leading therapeutic target for an ASO-mediated restoration of SMN2 exon 
7 inclusion in SMA [8, 15-17]. Interestingly, an 8-nucleotide (8-nt) long GC-rich 
sequence that partially overlaps with ISS-N1 has turned out to be the shortest ASO target 
for the restoration of SMN2 exon 7 inclusion (Fig 1;9). Here we focus exclusively on the 
8-nt GC-rich target for an ASO-mediated splicing correction in SMA patient cells (Fig 
1;9). We also describe how this method could be adapted for an ASO-based splicing 
modulation in HeLa cells as well as in neuronal SH-SY5Y cells. Complementing this 
method, several recent reports describe ASO-based methods of splicing correction in 
mouse models of SMA [15-17]. To maintain in vivo stability, we have used RNA ASOs 
with phosphorothioate backbone and 2′-O-methyl modifications [13]. These propriety 
free modifications remain one of the most frequently used oligonucleotide chemistries for 
in vivo applications. Of note, the methods described here can be applied to any gene, 
given that proper cis-element targets can be identified. 
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2. Materials 
2.1. Cell culture components 
1. GM03813 primary fibroblasts (Coriell Cell Repositories). 
2. SH-SY5Y neuroblastoma cells (ATCC). 
3. HeLa cells (ATCC). 
4. Minimum Essential Medium (MEM) (with Non-essential Amino Acids, without 
Glutamine). 
5. Dulbecco’s Modified Eagle’s Medium (DMEM), High Glucose. 
6. Minimum Essential Medium (MEM) (with L -Glutamine). 
7. Ham’s F12 Nutrient Mixture. 
8. GlutaMAX-I (Invitrogen) or equivalent. 
9. Fetal Bovine Serum (FBS). 
10. Opti-MEM I Reduced Serum Medium (Opti-MEM). 
11. Dulbecco’s phosphate-buffered saline (DPBS). 
12. 0.25 % Trypsin–EDTA solution. 
13. 100 mm dishes, tissue culture-treated. 
14. 6-Well tissue culture-treated plates. 
15. Hemocytometer. 
16. NAPCO Series 8000 WJ CO 2 Cell Incubator (Thermo Scientific) or equivalent. 
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2.2. Antisense transfection components 
1. RNase-free water. 
2. 2′-O-methyl modified and phosphorothioate backbone containing Antisense 
Oligonucleotides (ASOs) (Dharmacon or TriLink) (see Note 1). 
3. Lipofectamine 2000 (Invitrogen). 
4. Cell Lifter. 
5. Vortex Mixer. 
6. Microcentrifuge. 
7. 1.5 mL Microcentrifuge tubes. 
8. 15 mL Centrifuge tubes. 
 
2.3. RNA isolation components 
1. TRIzol (Invitrogen) (see Note 2). 
2. Chloroform (see Note 2). 
3. Isopropanol. 
4. Ethanol. 
5. RQ1 RNase-free DNase (Promega). 
6. Phenol:chloroform (1:1), Tris-EDTA buffer saturated premixed with Isoamyl 
Alcohol 25:24:1 (see Note 2). 
7. Mini centrifuge (PHENIX Quick Spin). 
8. Dry ice. 
9. 15 mg/mL glycogen. 
10. BioMate 3 (Thermo Scientific) for nucleic acid concentration measurement. 
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2.4. RT-PCR and imaging components 
1. 0.2 mL thin-walled tubes. 
2. SuperScript III Reverse transcriptase (Invitrogen), 5x SuperScript III RT buffer, 
0.1 M DTT, Oligo(dT)12-18 Primer, dNTP mixture (10 mM each), RNaseOUT 
(Invitrogen), Taq DNA polymerase (5 U/µl), 10x Standard Taq (Mg-free) 
Reaction buffer, 25 mM MgCl2. 
3. Primers 5′hSMN-E2b (forward, 5′-GAATACTGCAGCTTCCTTACAACAG-3′) 
and P2-2 (reverse, 5′-CTTCCTTTTTTCTTTCCCAACAC-3′) (see Note 3). 
4. [γ- 32 P]-ATP (3,000 Ci/mmol). 
5. Micro Bio-Spin Columns with Bio-Gel P-30 in Tris Buffer (Bio-Rad). 
6. 10x Tris-borate EDTA (TBE) electrophoresis buffer (see Note 4). Dilute tenfold 
to make working solution (1x TBE). 
7. 6x DNA loading buffer (see Note 5). 
8. 40% Acrylamide/bis solution (29:1), ammonium persulfate (APS) and N, N, N′, 
N′-tetramethylethylenediamine (TEMED), Sodium Dodecyl Sulfate (SDS). 
9. A 19.7 cm x 19.7 cm x 3 mm gel-casting cassette and an electrophoresis system. 
10. Native acrylamide gel with dimensions of 17.3 cm x 16 cm x 1.5 mm (see Note 
6). 
11. Chromatography Paper 3MM Chr. 
12. Saran wrap. 
13. AB15 pH meter (Fisher Scientifi c) or equivalent. 
14. Model 583 Gel Dryer (Bio-Rad) or equivalent. 
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15. FLA-5000 Image Reader (Phosphorimager) with Multi Gauge Software (Fuji 
Photo Film Inc) or similar system. 
16. Phosphorimager screen (cassette). 
 
2.5. Western blotting components 
1. RIPA buffer supplemented with Halt Protease Inhibitor Single- Use cocktail 
(Thermo Scientific) (see Note 7). 
2. BCA protein assay kit (Thermo Scientific). 
3. Microplate Reader Spectrophotometer (Spectra Max) or similar instrument for 
measuring protein concentration. 
4. 1.5 M Tris-HCl (pH 8.8), 1 M Tris-HCl (pH 7.6), 1 M Tris-HCl (pH 6.8), 5 M 
NaCl, Tween 20. 
5. 10x Tris-Glycine Sodium Dodecyl Sulfate (SDS) Running Buffer: 250 mM Tris 
base, 1.92 M glycine, 1 % SDS, pH 8.3. Dilute tenfold to make working solution 
(1x Tris-Glycine Sodium SDS). 
6. 2x Laemmli Sample Buffer (see Note 8). 
7. A 10.1 cm x 8.2 cm x 1.5 mm gel-casting cassette and an electrophoresis system. 
8. Minigel casting system. 
9. SDS-acrylamide gel with dimensions of 8 cm x 7.3 cm x 1.5 mm (see Note 9). 
10. Plastic trays. 
11. 10x Transfer buffer: 0.25 M Tris base, 1.92 M glycine, pH 8.4. Dilute tenfold to 
make 1x Transfer buffer supplemented with 10 % methanol (working solution). 
12. 10x Tris-buffered saline with Tween 20 (TBST): mix 195 mL water, 500 mL 1 M 
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Tris-HCl (pH 7.6), 300 mL 5 M NaCl, and 5 mL Tween 20. Dilute tenfold to 
make 1x TBST (working solution). 
13. Western blot blocking solution: 5 % (w/v) nonfat milk in 1x TBST (see Note 10). 
14. Polyvinylidene fluoride membrane (PVDF). 
15. Extra thick blot paper, mini blot size. 
16. Transfer-Blot SD Semi-Dry Transfer Cell (Bio-Rad). 
17. Primary antibodies: mouse monoclonal anti-SMN antibody (BD Transduction 
Laboratories), mouse monoclonal anti-Gemin2 antibody (Sigma-Aldrich), and 
rabbit polyclonal anti-actin antibody (Sigma-Aldrich). 
18. Secondary antibodies: horseradish-peroxidase (HRP)-conjugated anti-mouse goat 
antibody (Jackson Immuno Research) and HRP-conjugated anti-rabbit donkey 
antibody (GE Healthcare). 
19. Restore™ Western Blot Stripping Buffer (Thermo Scientific). 
20. SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) or 
SuperSignal west Femto Maximum Sensitivity Substrate (Thermo Scientific). 
21. UVP BioSpectrum AC imaging System (UVP). 
 
 
3. Method 
3.1. Cell culture and transfection of GM03813 cells with ASOs 
(Described for a single transfection in a 100-mm size dish) 
1. Suspend ~8 x 105 GM03813 cells in 8 mL MEM supplemented with GlutaMax-I 
and FBS (see Notes 11 and 12), and then plate in a 100-mm culture dish (see Note 
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13). Incubate cells at 37 °C in a CO2 incubator (set at 5 % CO2) until they are ~80 
% confluent. This takes ~24 h. 
2. Transfect cells (from Subheading 3.1, step 1) using the following procedure (see 
Note 14). Prepare an ASO suspension by mixing 1.1 µL of 0.5 mM ASO with 1.5 
mL of Opti-MEM I in a 15 mL tube. In a separate 15 mL tube prepare 
Lipofectamine suspension by mixing 30 µL Lipofectamine 2000 with 1.5 mL 
Opti-MEM I. Incubate Lipofectamine suspension at room temperature for 5 min. 
Make ASO-Lipofectamine complex by adding Lipofectamine suspension to ASO 
suspension. Mix gently and incubate ASO-Lipofectamine complex for 20 min at 
room temperature. Add entire ASO-Lipofectamine complex drop wise to a 100-
mm dish containing GM03813 cells and 8 mL medium (from Subheading 3.1, 
step 1). The final ASO concentration becomes 50 nM. Mix gently by rocking the 
plate back and forth. Incubate the cells at 37 °C in a CO 2 incubator for 24 h 
(similarly as in Subheading 3.1, step 1). Perform parallel transfection experiments 
with a control ASO as well as with no ASO. 
3. Remove the culture media by aspiration at 24 h post transfection and add 10 mL 
fresh MEM to the culture dish. Continue to incubate the cells at 37 °C in a CO 2 
incubator for an additional 24 h (similarly as in Subheading 3.1, step 1). 
4. At 48 h post transfection remove the culture media by aspiration and wash the 
cells three times with 10 mL ice-cold DPBS. Following washes, add 2 mL ice-
cold DPBS directly to each dish. Collect cells by scraping and make appropriate 
aliquots for immediate use in Subheadings 3.3, step 1 and/or 3.4, step 1 (see Note 
15 for later use). 
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3.2. Cell culture and transfection of HeLa and SH-SY5Y cells with ASOs 
(Described for a single transfection in a well of a 6-well plate) 
1. Suspend ~4 x 105 HeLa cells in 2 mL DMEM or ~3 x 105 SH-SY5Y cells in 2 mL 
SH-SY5Y medium (see Notes 11 and 12) and then plate in a well of a 6-well 
tissue culture plate (see Note 13). Incubate cells at 37 °C in a CO 2 incubator (set 
at 5 % CO2) until they are 70-80 % confluent (similarly as in Subheading 3.1, step 
1). This takes ~24 h. 
2. Transfect cells using following procedure (see Note 14). Prepare an ASO 
suspension by mixing 2.5 µL of 50 µM ASO (diluted 1:10 from 0.5 mM stock 
solution) with 250 µL of Opti-MEM I in a 1.5 mL tube. In a separate 1.5 mL tube 
prepare Lipofectamine suspension by mixing 5 µL Lipofectamine 2000 with 250 
µL Opti-MEM I. Incubate Lipofectamine suspension at room temperature for 5 
min. Make ASO-Lipofectamine complex by combining ASO suspension and 
Lipofectamine suspension in a 1.5 mL tube. Mix ASO-Lipofectamine complex 
gently, and incubate at room temperature for 20 min. Add entire ASO-
Lipofectamine complex drop wise to the well of 6-well plate containing HeLa or 
SH-SY5Y cells and 2 mL of medium (from Subheading 3.2, step 1). The final 
ASO concentration becomes 50 nM. Mix gently by rocking the plate back and 
forth. Incubate the cells at 37 °C in a CO2 incubator (similarly as in Subheading 
3.1, step 1). Perform parallel transfection experiments with a control ASO as well 
as without an ASO. 
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3. Remove the culture media by aspiration at 6 h post transfection and add 2 mL 
fresh medium (DMEM for HeLa and SH-SY5Y medium for SH-SY5Y cells) (see 
Note 11) to the culture dish. Incubate the cells at 37 °C in a CO2 incubator. 
4. At 48 h post transfection remove the culture media by aspiration and wash the 
cells with 2 mL of DPBS. Remove DPBS by aspiration and add 0.25 mL of 0.25 
% Trypsin-EDTA. Incubate cells at 37 °C for 3 min in a CO2 incubator. Add 1 
mL of cell growth medium and lift the cells by repeated pipetting. Total volume 
of suspension becomes 1.25 mL. Set aside 400 µL of cell suspension for RNA 
isolation (see Subheading 3.3). Transfer the remainder of the cell suspension 
(about 800 µL) to a 1.5 mL microcentrifuge tube. 
5. Centrifuge cells at 3,500 x g for 1 min at 4 °C. Aspirate supernatant without 
disturbing pellet. Resuspend cell pellet in 1 mL of ice-cold DPBS to wash. 
6. Repeat step 5 for a total of two washes in ice-cold DPBS. Proceed to Subheading 
3.4 for protein isolation. 
 
3.3. RNA isolation, RT-PCR, and imaging 
1. Take 0.5 mL cells from Subheading 3.1, step 4 or 0.4 mL cells from Subheading 
3.2, step 4 and spin at 3,500 x g for 1 min at 4 °C. Aspirate supernatant without 
disturbing cell pellet. Resuspend pellet in 1 mL TRIzol Reagent and incubate at 
room temperature for 5 min. Addition of TRIzol Reagent will lyse the cells. Add 
200 µL chloroform to the cell lysate and shake vigorously by hand for 15 s. 
Incubate cell lysate at room temperature for 3 min. Spin at 12,000 x g for 15 min 
at 4 °C. Transfer ~450 µL upper aqueous phase to a fresh 1.5 mL tube and mix 
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with 500 µL isopropanol. Incubate the mixed suspension at room temperature for 
10 min. To pellet RNA, spin the suspension at 12,000 x g for 10 min at 4 °C. 
Wash the pellet by adding 1 mL of 75 % (v/v) ethanol and spinning at maximum 
speed for 10 min at room temperature. Discard the supernatant and briefly spin 
the sample. Pipette out the residual ethanol and air dry the pellet at room 
temperature for 2-3 min. Dissolve the pellet in 20 µL of RNase-free water, 
measure concentration using spectrophotometer, and perform DNase treatment to 
remove any traces of DNA. 
2. Use entire RNA sample for DNase treatment in a 100 µL reaction volume as 
follows: combine sample with 10 µL of 10 x RQ1 DNase buffer, an appropriate 
amount of RQ1 RNase-free DNAse (see Note 16), and RNase-free water up to a 
final volume of 100 µL. Mix and incubate the reaction mixture at 37 °C for 30 
min. Add 100 µL of phenol– chloroform solution and vortex to inactivate the 
enzyme. Spin the mixture at 16,500 x g in microcentrifuge for 5 min at room 
temperature. This will partition RNA into the aqueous phase at the top. Collect 90 
µL of aqueous phase in a fresh 1.5 mL tube. 
3. Recover RNA from the aqueous phase (obtained from Subheading 3.3, step 2) by 
mixing it with 1/10th volume of 3 M sodium acetate (pH 5.2), 0.25 µL of 15 
mg/mL glycogen (GlycoBlue), and 2.5 x volume 100 % ethanol. Mixture will turn 
into a cloudy suspension. Chill the suspension on dry ice for 5 min or at −20 °C 
overnight. Spin the suspension at 16,500 x g for 30 min at 4 °C to pellet the RNA. 
Wash the pellet with 1 mL of 70 % (v/v) ethanol as described in Subheading 3.3, 
step 1. Dissolve the pellet in 10 µL RNase-free water, measure concentration. 
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4. Assemble a 10-µL reverse-transcription reaction to generate first-strand cDNA. 
First combine 1.2 µg total RNA and RNase-free water to a total volume of 5.5 µL. 
Add 0.5 µL of Oligo(dT)12-18 and 0.5 µL 10 mM dNTP. Mix and heat at 65 °C for 
5 min. Place immediately on ice to quickly chill samples. Add 2 µL of 5x first-
strand buffer, 0.5 µL of 0.1 M DTT, 0.5 µL of RNase OUT, and 0.5 µL 
SuperScript III RT, mix. The final reaction volume is 10 µL. Incubate the reaction 
at 50 °C for 1 h. Inactivate the reaction by heating at 70 °C for 15 min. Store at -
20 °C until ready to use. 
5. Radiolabel the 5′ primer for multi-exon-skipping detection assay (MESDA) to 
capture all known SMN transcripts (11, see Note 17). For radioactive labeling of 
the 5′ primer, set up a 50 µL T4 Polynucleotide Kinase (PNK) reaction. First 
combine 25.5 µL water, 5 µL 10x T4 PNK buffer, 3 µL 10 µM 5′ primer 
(5′hSMN-E2b), and 15 µL [γ- 32P]-ATP to a total volume of 48.5 µL. Incubate the 
reaction mixture at 94 °C for 2 min. Snap cool the reaction and keep it on ice for 5 
min. Add 1.5 µL PNK, mix and incubate the reaction at 37 °C for 1 h. Inactivate 
the enzyme by heating at 65 °C for 20 min. 
6. Clean up and purify the end-labeled primer by using a Micro Bio-Spin column. 
Start with spinning a column at 1,000 x g for 2 min at room temperature to 
remove the packing buffer. Add 500 µL RNase-free water and spin the column at 
1,000 x g for 1 min at room temperature. Repeat the process three times to 
completely exchange the column packing buffer with water. Add 50 µL water and 
spin the column for 4 min at 1,000 x g. Repeat this step until the volume of eluate 
is 50 µL. Place the column in a clean 1.5 mL tube. Carefully apply 50 µL of the 
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end-labeled primer (from Subheading 3.3, step 5) directly onto the top center of 
the gel bed of the column. Spin the column at 1,000 x g for 4 min at room 
temperature to collect the 5′-labeled primer in the 1.5 mL tube. 
7. Assemble a 25-µL PCR as follows. Combine water (to a total volume of 25 µL), 
2.5 µL 10x Taq reaction buffer, 1.5 µL 25 mM MgCl2, 0.5 µL 10 mM dNTPs, 0.5 
µL 10 µM P2-2, 0.16 µL 10 µM 5′hSMN-E2b, 5.6 µL 32P-labeled 5′hSMNE2b 
(from Subheading 3.3, step 6), 2 µL cDNA (from Subheading 3.3, step 4), and 
0.125 µL Taq DNA polymerase. 
8. Perform PCR using following profile: initial denaturation at 95 °C for 5 min, 20-
cycle amplification (denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s, 
and extension at 68 °C for 1 min) and a final extension at 68 °C for 7 min. 
Following PCR, add 5 µL of 6x DNA loading buffer to the PCR mixture and mix. 
Spin and analyze sample on a native polyacrylamide gel. 
9. Load 3 µL of PCR products (from Subheading 3.3, step 8) on a 6 % native 
polyacrylamide gel. Run gel electrophoresis in 1x TBE running buffer at 200 V 
for 2.5 h at room temperature. Upon electrophoresis, transfer the gel to 
chromatography paper and cover the gel with Saran wrap. 
10. Dry the gel on chromatography paper using Gel Dryer apparatus at 80 °C. Expose 
the dried gels to a phosphorimager screen. 
11. Analyze and quantify the results using an Image Reader FLA-5000 and Multi 
Gauge software. 
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3.4. Western blotting 
1. Spin 1.5 mL cells from Subheading 3.1, step 4 or 1 mL of cells from Subheading 
3.2, step 5 at 3,500 x g for 1 min to collect cells. Add RIPA buffer supplemented 
with 1x Halt Protease Inhibitor Single-Use cocktail (~2x volumes of cell pellet) 
and mix to resuspend cells. Incubate on ice for 30 min with occasional mixing. 
Spin at 15,000 x g for 10 min at 4 °C. Collect supernatant. Determine protein 
concentrations using BCA protein assay kit. 
2. Resolve protein samples on a 12 % SDS–polyacrylamide gel and equilibrate gel 
in 1x transfer buffer for 30 min (see Note 18). 
3. Transfer proteins from the gel to a PVDF membrane using Transfer-Blot SD 
Semi-Dry for 45 min at 75 mA (see Note 19). 
4. Block the PVDF membrane in 50 mL of blocking solution at room temperature 
for 1 h or at 4 °C overnight (use a plastic tray). 
5. Transfer the membrane into the primary antibody (mouse monoclonal anti-SMN, 
1:2,000 dilution). Incubate the membrane with shaking at room temperature for 1 
h. 
6. Wash the membrane three times with 1x TBST for 15 min each (see Note 20). 
7. Incubate the membrane with secondary antibody (anti-mouse horseradish-
peroxidase-conjugated, 1:4,000 dilution) with shaking at room temperature for 1 
h. Wash the membrane three times with 1x TBST for 15 min each (see Note 20). 
8. Detect the protein signal by developing the blot with SuperSignal West Dura 
Extended Duration Substrate or SuperSignal West Femto Maximum Sensitivity 
Substrate at room temperature for 5 min. 
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9. Scan the membrane using a UVP BioSpectrum AC Imaging System.  
10. For reprobing, strip the membrane at room temperature for 15 min using Western 
Blot Stripping Buffer. 
11. Wash the membrane four times with 1x TBST for 5 min each (see Note 20). 
12. Block and reprobe with mouse monoclonal anti-Gemin2 (1:400 dilution) or rabbit 
polyclonal anti-actin (1:2,000 dilution). For reprobing, follow steps 4 through 10. 
 
 
4. Notes 
1. ASOs are dissolved at 0.5 mM in RNase-free water, aliquotted, and stored at -20 
°C. We have observed batch-to-batch variations in efficiency of ASOs. Use 
HPLC purified ASOs for optimal results. ASO concentration should be confirmed 
by measuring its absorbance at 260 nm. 
2. When working with the hazardous reagents, use fume hood. Use lab coats, gloves, 
and eye protection. When using radioactive material, use proper shielding 
recommended by your institution. 
3. Primers 5′hSMN-E2b and P2-2 are used for amplifying SMN2 transcripts; the 
product size is 774 bp when exon 7 is included, or 720 bp when exon 7 is skipped 
[11]. 
4. To make 10x TBE, dissolve 108 g Trizma base, 55 g boric acid, and 9.3 g EDTA 
in water (total volume 1 L). Confirm that pH is equal to 8.3. 
5. To make 6x DNA loading buffer add 0.25 % (w/v) bromophenol blue, 0.25 % 
(w/v) xylene cyanol FF, and 30 % (v/v) glycerol in RNase-free water. 
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6. To make a 6 % native gel, prepare a 60 mL solution as follows. Combine 44.34 
mL RNase-free water, 9 mL of 40 % (w/v) acrylamide/bis solution (29:1), 6 mL 
of 10x TBE. Filter the solution to remove any solid particles. Then add 600 µL of 
10 % (w/v) APS and 60 µL TEMED to initiate polymerization. Pour the mixture 
into a gel-casting cassette, and allow the gel to polymerize for at least 30 min. 
7. Add 100 µL of 100x Halt Protease Inhibitor Single-Use cocktail to 10 mL RIPA 
buffer immediately before usage. 
8. 2x Laemmli Sample Buffer is supplemented with β-mercaptoethanol (50 µL per 
950 µL sample buffer) immediately before usage. 
9. To make a SDS-polyacrylamide gel, prepare a 10 mL resolving solution. For 12 
% resolving gel, combine 4.3 mL RNase-free water, 3 mL of 40 % (w/v) 
acrylamide/bis solution (29:1), 2.5 mL of 1.5 M Tris-HCl (pH 8.8), 100 µL of 10 
% (w/v) SDS, 100 µL of 10 % (w/v) APS, and 5 µL TEMED; mix the solution by 
swirling gently. Pour the mixture into a gel-casting cassette, and allow the gel to 
polymerize for at least 30 min. For 5 % stacking gels, combine 2.92 mL RNase-
free water, 500 µL of 40 % (w/v) acrylamide/bis solution (29:1), 500 µL of 1 M 
Tris-HCl (pH 6.8), 40 µL of 10 % (w/v) SDS, 40 µL of 10 % (w/v) APS, and 5 µL 
TEMED; mix the solution by swirling gently. Pour the mixture into the gel-
casting cassette, and allow the gel to polymerize for at least 30 min. 
10. It is best to prepare this before usage and can be stored at 4 °C for 1 week. 
11. To prepare MEM media for GM03813 fibroblasts, mix 500 mL of MEM (with 
Non-Essential Amino Acids, without Glutamine) with 75 mL of FBS and 5 mL of 
100x GlutaMAX-I. To prepare DMEM media for HeLa cells, mix 500 mL of 
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DMEM High Glucose with 50 mL of FBS. To prepare media for SH-SY5Y cells, 
mix 500 mL of MEM (with L -Glutamine) with 500 mL of Ham’s F12 nutrient 
mixture. Add 100 mL of FBS and mix. 
12. The MEM media used for GM03813 and SH-SY5Y culture are different 
formulations. Refer to the product description to ensure that the correct MEM is 
used for each cell type. 
13. Use a hemocytometer to count number of cells. 
14. Monitor transfection efficiency by simultaneously transfecting with a fluorescent-
labeled control ASO. The 5′ or 3′ end labeling of ASOs by Cy3 or Cy5 is 
commercially available. GM03813 cells have large nuclei. Therefore, cells could 
be readily identified by fluorescing nuclei several hours after transfection. 
15. For using cells later, pellet the cell suspension (from Subheading 3.1, step 4) by 
centrifuging at 3,500 x g for 1 min at room temperature. Aspirate supernatant and 
store the pellet at -80 °C. For protein isolation resuspend pellet in 2x volume of 
RIPA + Halt Protease inhibitor. For RNA isolation resuspend pellet in 1 mL 
TRIzol reagent. 
16. Adjust DNase concentration based on nucleic acid (DNA + RNA) concentration 
in the sample. We generally use 1 unit of DNase for 1 µg nucleic acid. 
17. MESDA is a new PCR-based method to capture all known splice variants of SMN 
[11]. For detection of SMN2 exon 7 skipped products only, 5′ primer annealing to 
exon 6 could be used [9]. 
18. Load ~20 µg protein per well on a 12 % SDS–polyacrylamide gel. 
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19. Refer to manufacturer’s recommendation for set up procedure on Transfer-Blot 
SD Semi-Dry apparatus. 
20. Use 200 mL 1x TBST for washing. 
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Figure Legend 
Figure 1. ASO-based modulation of pre-mRNA splicing of SMN2 exon 7. (a) 
Diagrammatic representation of ASO target within intron 7 of SMN2. Part of the SMN2 
gene is shown. Numbering starts from the first position of SMN2 intron 7. ISS-N1 
overlaps with the GC-rich sequence. 3UP8 is an ASO that targets the GC-rich sequence. 
(b) Splicing pattern of SMN2 in GM03813 cells transfected with 3UP8 or a control ASO. 
We performed MESDA to capture all known splice variants of SMN2 [11]. Bands lacking 
various exons are shown. Top band corresponds to the full-length transcript. 3UP8 
restores SMN2 exon 7 inclusion and increases the levels of the full-length transcript. (c) 
Levels of SMN and Gemin2 proteins in GM03813 cells transfected with various ASOs as 
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shown in (b). Statistical analysis was performed using the GraphPad Prism 6.0 software. 
Data are expressed as mean ± standard error of the mean. We used unpaired Student’s t-
test for analysis. P values are two-tailed and the level of statistical significance is set at 
*P < 0.05. E exon, ISS-N1 intronic splicing silencer N1, GC-rich GC-rich intronic 
splicing silencer. 
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Figure 1. ASO-based modulation of pre-mRNA splicing of SMN2 exon 7. 
